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Genome sequencing is emerging as a powerful tool to identify the molecular mechanism of 
cancer progression. However, the software tools to define genomic and post-genomic mutations 
are just in its infancy. We have used a novel software algorithm to analyse the cancer genome by 
DNAseq and expressed cancer genome arising from transcription by RNAseq to define dominant 
sources of potentially expressed tumour-specific mutations and oncogenic targets. We focus 
primarily on the rare human pleomorphic sarcoma as a disease of high unmet clinical need but 
use a range of cancer models to accelerate the development of the pipeline.  
First, we applied next generation sequencing of whole exomes of tumour tissues and two 
matched normal tissues (blood and “normal” tumour adjacent tissue) from a small set of patients 
to define parameters for use of the new software. The approaches identified significant 
mutations in tumour relative to germline DNA, but also in normal adjacent tissue, relative to 
normal germline, consistent with known field cancerization.  Thus, in setting up the larger 
sequencing screen in the subsequent set of twenty cancer pleomorphic sarcoma cancer patients, 
whole exome sequencing was performed on tumour tissue and their matched normal adjacent 
tissues, rather than germline blood derived DNA, to define truly tumour-specific mutations. This 
approach provided sets of recurrent non-synonymous mutations in tumour tissue such as a 
transmembrane protease and suggests potential therapeutic targets for future focus that are 
highly tumour specific in pleomorphic sarcoma.  
A major problem with using DNA genomics only to define drugable landscapes in cancer is that 
the tumour genome is static and the mutations do not reflect the expressed cancer landscape at 
the time of surgery. Thus, in a smaller subset of patients we also applied shotgun RNAseq to 
determine the number of expressed mutated genes. We defined within the parameters chosen, 
from 8-17% of the mutated genome is expressed as defined at the RNA level. However, to our 
surprise, there were an order of magnitude more RNA mutations that were not DNA encoded 
suggestive of RNA editing events. Each patient showed elevated RNA edits that were 
independent of each other suggesting a highly-patient, cancer-specific perturbation in the 
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specificity of the RNA editing machinery.  We thus developed a cancer cell model to validate the 
RNA-editing software and we found we could recapitulate some of the RNA edits observed in 
clinical tumour tissue, in particular the signalling kinase in the MAP kinase-kinase-kinase-kinase 
super-family. It was interesting that RNA edits can often cluster in exon-intron boundaries 
suggesting a link to splicing and allows us to begin to produce “rules” for RNA editing. These data 
provide future direction to understand the role of RNA editing, as well as DNA encoded mutations, 
as mutagenic events and possible drugable targets in cancer signalling.  
Lastly, novel or orphan mutant proteins observed in human cancers, whether from DNA encoded 
mutant proteins or from RNA-edited driven mutant protein synthesis require new tools and 
technologies to discover new oncogenic signalling mechanisms. We developed an SBP-tagged 
affinity purification method in combination with label-free SWATH mass spectrometry to identify 
a novel binding protein for the gain-of-function mutant protein in a key metastatic gene, ELMO1. 
This identified an elevated interaction with another oncogenic protein encoded by AGR2 gene 
and validates this proteomics discovery platform to further advance function of new mutated 
proteins.  
In conclusion, we have applied and validated newly emerging software to begin to interrogate 
cancer tissue from patients of unmet clinical need in order to define new mechanisms of cancer 
progression and to define possibly new or better drug targets for new therapies. The data 
identified highly recurrent genome encoded mutations in human pleomorphic sarcoma and a 
potentially novel, targetable landscape represented by RNA editing driven mutant protein 
production.  This will provide a foundation for future work on making better choices to advance 
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1.1.1 Cancer background 
Cancer is the second leading cause of death in the world, after cardiovascular diseases. It is not 
a new disease and has afflicted people throughout the world. Some of the earliest evidence of 
human bone cancer was found in mummies in ancient Egypt, and the disease is mentioned in 
ancient manuscripts dated about 1600 B.C. [1]. Cancer is a complex and heterogeneous disease 
to which all organs and tissues in our body are susceptible. It develops when normal cells in a 
particular part of the body begin to grow out of control [1, 2]. Cancer cells continue to grow, 
divide and re-divide instead of dying, and thus form colonies of new, abnormal, cells. Some types 
of cancer cells often travel to other parts of the body through blood circulation or lymph vessels, 
and this process is known as metastasis. For example, when a breast cancer cell spreads to the 
liver through blood circulation, the cancer is still called breast cancer, rather than liver cancer [1]. 
1.1.2 Cancer incidence  
The occurrence of cancer is increasing in the world because of the growth and aging of the 
population, as well as an increasing prevalence of established risk factors such as smoking, 
alcohol consumption, and being overweight and physically inactive [3]. In 2012, the worldwide 
burden of cancer involved 14 million new cases per year, a figure expected to rise to 24 million 
annually within the next two decades [4]. Lung and breast cancers are among the most frequently 
diagnosed cancers and are leading causes of cancer death in men and women, respectively, both 
overall and in the less developed world. In more developed countries, however, prostate cancer 
is the most frequently diagnosed cancer among men and lung cancer is the leading cause of 
cancer death among women. Other frequently diagnosed cancers worldwide include those of the 
liver, stomach and colorectal among males, and of the stomach, cervix, uterus, and colorectal 
among females. In more developed countries, bladder cancer among males and uterine cancer 
among females are also frequently diagnosed [3]. 
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Cancer type frequencies are different in different regions of the world. Most cancers that are 
frequently observed in one population are relatively rare in another, and these patterns vary over 
time. For example, oesophageal cancer is common among men in East Africa but rare in West 
Africa. Colorectal cancer, once rare in Japan, increased fourfold in incidence in just two decades 
[3]. 
1.1.3 Cancer genetics 
There is accumulating evidence indicating that genetic variation accounts for a proportion of 
susceptibility to common diseases such as diabetes, cardiovascular disease and cancer [5]. 
Genetic variation in the human genome is present in many forms and occurs at different 
frequencies throughout the genome. The different forms of genetic variation include base 
substitutions, insertions and deletions (indels) of bases, rearrangements caused by breakage and 
abnormal re-joining of DNA, and changes in the copy number of DNA segments [5, 6].  
A century of laboratory and clinical research has made it clear that cancer is fundamentally a 
genetic disease, driven by heritable changes in the cancer genome or chromatin, arising either in 
the germline or during the many subsequent steps required for a normal cell to become 
malignant [7]. Most common cancers are caused by acquired mutations in somatic cells. In 
contrast, specific germline mutations account for rare hereditary cancer syndromes [8]. 
1.2 A brief history of sequencing approaches in cancer 
Over the past half-century, many technologies have been deployed to characterise systematically, 
at ever-increasing levels of resolution, the state of cancer genomes across the range of cancer 
types (fig 1.1) [6]. Chromosomal abnormalities were first suggested to be causally related to 
tumorigenesis in 1914. This notion was confirmed half a century later with the arrival of 
sophisticated cytogenetic techniques, which facilitated the identification of the first specific 
translocation driving human neoplasia: the t(9;22)(q24;q11) translocation responsible for 
generating the Philadelphia chromosome, resulting in the BCR–ABL fusion oncoprotein causing 
leukemiagenesis [9].  
By the middle of the 20th century, scientists had solved the complex problems of the chemistry 
and biology behind cancer. Watson and Crick received the Nobel Prize in 1962 for the discovery 
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of the helical structure of DNA. Later, scientists learned how genes worked and how they could 
be damaged by mutations. Scientists found that cancer could be caused by chemicals 
(carcinogens), radiation, viruses, and also could be inherited from ancestors. Most carcinogens 
cause damage to the DNA which leads to abnormal growth of cells [1]. 
Cytogenetic techniques, such as fluorescence in situ hybridization (FISH) and comparative 
genome hybridization (CGH), helped identify several additional recurrent chromosomal 
aberrations, and revealed important aspects of cancer biology. In addition, early sequencing 
technologies developed during the same period by Ray Wu and Frederick Sanger allowed for the 
targeted sequencing of specific regions, and therefore helped identify recurrent mutations in 
genes of interest [10]. Technically, standard Sanger sequencing identifies linear sequences of 
nucleotides by electrophoretic separation of randomly terminated extension products [11]. 
In 1990, just five years after Sanger’s chain termination sequencing method was partially 
automated for the first time, the Human Genome Project was launched as collaboration between 
genome centres in several countries. A draft sequence was published eleven years later, and the 
project was deemed complete in 2004 [10]. 
The Human Genome Project and its accompanying need for large-scale sequencing approaches 
and data analysis inspired the creation of next generation sequencing (NGS) methods, which 






Figure 1.1. Time line showing key events in the investigation of the cancer genome [6]. 
1.3 Next generation sequencing (NGS) in cancer 
1.3.1 NGS background 
NGS refers to the high-throughput DNA sequencing technologies which are capable of 
sequencing large numbers of different DNA sequences in one reaction [11]. The advent of NGS 
technologies has stimulated rapid cataloguing of all alterations in cancer genomes, and has 
enabled researchers to look at large-scale genomic events such as chromosomal lesions and 
copy-number variations, as well as small-scale aberrations represented by point mutations, and 
small indels. This has provided enormous insight into the genomic landscape of several tumour 
types, identifying new drugable targets, and revealed the heterogeneity of many tumours [9, 12]. 
In 2008, the full human genome sequence was obtained using NGS technology. In the same year, 
the first cancer genome and the first tumour–normal genome comparison was published in a 
study that used data from acute myeloid leukaemia (AML). That study identified ten genes with 
somatic mutations, only two of which have been previously described in AML [10]. The study 
established that genome sequencing of tumours allowed the identification of cancer-associated 
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mutations, heralding a revolution in cancer research in which similar analyses across an 
expanding number of tumours have been published. 
 
1.3.2 NGS workflow 
NGS reads are produced from fragment ‘libraries’ that have not been subject to the conventional 
vector-based cloning and Escherichia coli (E. coli)-based amplification stages used in Sanger 
sequencing. This way, some of the cloning bias issues can be avoided [13]. 
The workflow to produce NGS libraries is straightforward; DNA fragments are prepared for 
sequencing by ligating specific adapter oligonucleotides to both ends of each DNA fragment (fig 
1.2, A). The adapter sequences are capable of hybridising to the oligonucleotides on the 
Sequencer’s flow cell surface. Cluster generation proceeds when denatured DNA libraries are 
allowed to randomly hybridize to the oligonucleotide lawn in the channels by their adapter ends 
(fig 1.2, B). A covalently-attached DNA fragment is created by extension of the flow cell 
oligonucleotides using the hybridized library fragment as a template. The original library strands 
are then denatured and washed away, leaving only the newly-synthesized strand. A 
complimentary copy of the covalently-bound strand is then generated through bridge 
amplification, a process by which the strand bends to hybridise to an adjacent and 
complementary oligonucleotide, thereby allowing the polymerase to extend the complementary 
strand. Bridge amplification is repeated 24 times to produce clusters of DNA clones in which half 
of the molecules represent the forward orientation and the other half the reverse orientation. 
Bases are read using a cyclic reversible termination strategy, which sequences the template 
strand one nucleotide at a time through progressive rounds of base incorporation, washing, 
imaging and cleavage. In this strategy, fluorescently-labelled 3´-O-azidomethyl-dNTPs are used 
to pause the polymerisation reaction, enabling removal of unincorporated bases and fluorescent 
imaging to determine the added nucleotide (fig 1.2, C). Depending on the instrument and library 
construction protocol used, forward and reverse reads can be paired to map both ends of linear 
DNA fragments during sequencing (paired-end sequencing). This process is repeated until the 
predetermined sequence (read) length is reached. The sequence reads obtained are then aligned 
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to a reference genome, using bioinformatics software, to analyse the differences between them 
(fig 1.2, D) [14, 15]. 
 
 






1.3.3 Applications of NGS 
NGS techniques can be broadly classified into applications for investigating the genome or 
transcriptome. Genomic assays include whole genome sequence (WGS), whole exome sequence 
(WES), and targeted re-sequencing of specific regions to discover variants associated with cell 
function or disease [15].  
The application of NGS is becoming important for both rare disorders, and for phenotypically and 
genetically heterogeneous common diseases such as epilepsy and intellectual disability. For 
example, it was reported that a patient with epilepsy, intellectual disability, and other features, 
had undergone more than 20 different genetic tests before the disease-causing mutation was 
found in the SCN2A gene by WES [16]. 
NGS has been applied to great effect in cancer. The Cancer Genome Atlas (TCGA) and 
International Cancer Genome Consortium (ICGC) have performed WGS and WES on thousands of 
tumour–normal pairs. These studies have described the mutational landscapes for over 20 cancer 
types, showing that tumours can vary in both the type and number of mutations. These global 
descriptions have been integral to the development of background mutation rates that are 
necessary for the detection of cancer driver genes [14]. 
1.3.4 WGS and WES 
WGS covers the whole genome and provides a unique window by which to investigate genetic or 
somatic variations, leading to new avenues for exploration of normal and disease phenotypes. 
However, the massive quantity of data and the requirement of significant computational 
resources make WGS cost prohibitive for routine genetic and biological studies. In contrast, WES 
focuses on capturing and sequencing protein-coding regions (exomes), which cover between 1 
and 2% of the genome, limiting the data to a more functionally informative part of the genome, 
and thus has become a popular choice for genetic studies to identify coding and splice-site 
variants from a large number of samples in a short time period [15].  
WES is currently the popular technology for sequencing cancer genomes, and has led to an 
abundance of discoveries in many cancer types [17]. 
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WES is a relatively comprehensive, inexpensive, and rapid way of identifying coding mutations, 
compared with other variant detection methods. However, there are still some limitations. None 
of the WES capture probe sets seem to target all of the exons, so some exons would be missed. 
The capture step is not uniform and tends to have a bias against high GC-rich regions. The capture 
would also skip as yet unidentified exons, and so miss variants [15].  
1.3.5 Transcriptome sequencing 
The development of cancer is a multistep process that involves the accumulation of a wide range 
of genetic and phenotypic alterations, leading to the aberrant expression of genes that regulate 
cell proliferation. Microarrays have been used to identify differential gene expression profiles in 
many cancer types, which have aided the screening, prognosis, and classification of tumours. 
However, microarrays have limitations, including low sensitivity and hybridization artefacts [18].  
The development of NGS has also revolutionized transcriptomics by enabling RNA analysis 
through the sequencing of complementary DNA (cDNA). This method, termed RNA sequencing 
(RNAseq), has eliminated many challenges posed by hybridization-based microarrays and Sanger 
sequencing-based approaches that were previously used for measuring gene expression, and it 
has revolutionized our understanding of the complex and dynamic nature of the transcriptome 
[19]. RNAseq is a mode of deep sequencing that enables evaluation of a complete set of an 
organism’s transcribed genes, or transcriptome, and noncoding RNAs such as micro-RNAs [20]. 
A typical RNAseq experiment consists of isolating RNA, converting it to cDNA, preparing the 
sequence library, and sequencing it on an NGS platform [19]. 
RNAseq is performed to measure gene expression, detect fusion transcripts, and for splicing 
analysis. It can also provide an observation of the underlying tumour DNA sequence, via 
transcription. Therefore, it can confirm the expression of the mutations detected in the genome 
[17]. 
There are many advantages of RNAseq: rapid, precise and quantitative measurement of gene 
expression; high sensitivity allows detection of low-abundance transcripts; enables identification 
of transcripts; facilitating the discovery of single nucleotide polymorphisms and rare mutations; 
and the detection of previously unrecognized genes [20]. 
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Despite its advantages in cancer studies, RNAseq has some limitations. Accurate sequence 
annotation and data interpretation can be computationally challenging, transcript quantitation 
can be affected by biases introduced during cDNA library construction and sequence alignment, 
and its cost remains prohibitive for many laboratories [20]. 
 
1.4 Cancer driver genes 
1.4.1 Oncogenes and tumour suppressor genes (TSGs) 
The advanced genomic studies of different cancer types have enhanced the accuracy and 
coverage of the identification of cancer-related genes that could drive or protect cancer 
development. The majority of gene variants found in cancer fall into two categories: gain-of-
function mutations in proto-oncogenes, which stimulate cell growth, division, and survival; and 
loss-of-function mutations in tumour suppressor genes (TSGs) that normally help prevent 
unrestrained cellular growth and promote DNA repair and cell cycle checkpoint activation [21]. 
Oncogene mutations are usually dominant; such that one mutant allele is enough to start 
switching on a cellular activity. TSG mutations tend to be recessive, so that two copies of the 
gene must be mutated to cause loss of function. However, recent studies show that even partial 
inactivation of TSGs could critically contribute to tumorigenesis [22]. The oncogenes and their 
related pathways are promising avenues for developing novel drugs, including antibodies and 
small synthetic molecules. 
Abnormal activation of proto-oncogenes can occur by chromosomal translocation resulting in 
fusion genes such as BCR–ABL in chronic myelogenous leukaemia (CML), by point mutations 
resulting in an altered protein product of the gene, and by amplification resulting in many copies 
of the oncogene, for example the amplification of the HER2 gene, which codes for a growth factor 
receptor, in many cases of breast cancer [2]. 
TP53 is one of the most interesting TSGs, which codes for a 53 KDa protein. This protein interacts 
with many cellular genes involved in cellular growth control, and its main function is to halt the 
cell division cycle in cells with DNA damage, to induce either DNA repair or programmed cell 
death. Cells in which this function of ‘cellular keeper’ for growth and division TP53 is 
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compromised can be more readily accumulate mutations and may more rapidly progress to overt 
malignancy [2]. 
1.4.2 Somatic mutations 
Somatic mutations are the variants found in the genomes of tumour cells, but not in their 
matched normal cells. They often play important roles in tumour initiation, progression and 
metastasis. They can be single nucleotide variants (SNVs) that change the amino acid sequence 
(missense mutation), or prematurely truncating encoded proteins (nonsense mutation), or indels 
that delete or insert some amino acids and disrupt the protein function. Discovering such cancer-
related variants is confounded by the presence of millions of germline mutations. To distinguish 
somatic from germline variants, it has become important to sequence matched tumour–normal 
samples from the same patient [23]. 
Somatic mutations are thought to occur in the genomes of all normal cells as they proceed 
through the rounds of cell division that take place during development in utero, and during 
replenishment of body tissues in postnatal life. Additional somatic mutations continue to 
accumulate in cancer cells as they divide. The rate and types of these mutations can be increased 
by exogenous and endogenous exposures that cause DNA damage and are mitigated by DNA 
repair processes [6]. 
1.4.2.1 Driver and passenger mutations 
Although most of the somatic mutations that steadily accumulate in our cells are harmless, 
occasionally a mutation affects a gene or regulatory element and leads to a phenotypic 
consequence. A fraction of these mutations can confer a selective advantage to the cell, leading 
to preferential growth or survival of a clone. These types of mutations are called driver mutations. 
The other types of mutation have no phenotypic or biological effect and are called passenger 
mutations [24]. 
The number of driver mutations in a cancer cell reflects the number of mutated cancer genes and 
thus the deregulation of cell biological processes required to convert a normal cell into a 
symptomatic cancer clone [6]. 
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1.4.2.2 Mutation timing 
Tumours evolve from benign to malignant lesions by acquiring a series of mutations over time. 
The first mutation provides a selective growth advantage to a normal cell, allowing it to outgrow 
the cells that surround it and become a microscopic clone. A study of colorectal cancer has shown 
that the first mutations occur in the APC gene (fig 1.3). The small adenoma that results from this 
mutation grows slowly, but another mutation in another gene, such as KRAS, unleashes a second 
round of clonal growth that allows an expansion of cell number. This process of mutation 
followed by clonal expansion continues, with mutations in genes such as PIK3CA and TP53, 
eventually generating a malignant tumour that can invade through the underlying basement 
membrane and metastasise to lymph nodes and distant organs [25]. Thus it is important to 
consider the cancer stage when analysing the cancer genome to detect somatic mutations. 
 
Figure 1.3. Genetic alterations and the progression of colorectal cancer. The major signalling pathways that drive 
tumorigenesis are shown at the transitions between each tumour stage. One of several driver genes that encode 












1.4.2.3 Mutation signature 
All cancers develop as a consequence of accumulating somatic mutations in their genomes, which 
may be a result of the intrinsic slight infidelity of the DNA replication machinery, exogenous or 
endogenous mutagen exposures, enzymatic modification of DNA, or defects in DNA repair. 
Different mutational processes often generate different combinations of mutation types, termed 
mutation signatures [26]. Thus, understanding the mutation signature of each tumour type can 
provide insights into the forces that cause somatic mutations. The impact of NGS in 
understanding cancer mutation signatures became clear in 2010 when two studies reported the 
pattern of somatic mutations in a malignant melanoma and small cell lung carcinoma. They found 
that there was a strong signature of tobacco carcinogens in the genome of the lung cancer, while 
the mutational signature of ultraviolet radiation overwhelmed the melanoma genome [27, 28]. 
In lung cancer, it was reported that tobacco smokers have an average 10-fold increase in the 
burden of somatic mutations in their cancer genomes compared to non-smokers. Consistent with 
the experimental evidence for tobacco carcinogens, this elevation is mainly due to the increase 
of the mutant of C>A transversions [27]. 
Alexandrov et al. 2013, [26] analysed 4,938,362 mutations, substitutions and indels, from 7,042 
primary cancers of 30 different classes. They extracted more than 20 distinct mutational 
signatures (fig 1.4, A), and found that some of these signatures are present in many cancer types 
(fig 1.4, B). They also found that certain signatures are associated with age of the patient at the 
time of diagnosis, such as signatures 1A and 1B, which may have been caused by an endogenous 
mutational process. Other signatures may have been caused by exposure to exogenous 
mutagenesis. Signature 4 is found in cancers associated with tobacco smoking and has the 
mutational features associated with tobacco carcinogens. Signature 7 is found in malignant 
melanoma and squamous carcinoma of the head and neck and has the known features of UV 
light-induced mutations. 
The ability to detect the mutation signature of a specific tumour would be expected to have an 
impact on cancer prevention by conclusively identifying risk factors. Furthermore, ongoing 









Figure 1.4. Validated mutational signatures found in human cancer and the presence of mutational signatures 
across human cancer types. A, each signature is displayed according to the 96 substitution classification defined by 
the substitution class and sequence context immediately 39 and 59 to the mutated base. The probability bars for the 
six types of substitutions are displayed in different colours. The mutation types are on the horizontal axes, whereas 
vertical axes depict the percentage of mutations attributed to a specific mutation type. All mutational signatures are 
displayed on the basis of the trinucleotide frequency of the human genome. Asterisk indicates mutation type 
exceeding 20%. B, Cancer types are ordered alphabetically as columns whereas mutational signatures are displayed 
as rows. Prevalence in cancer samples indicates the percentage of samples from the data set of 7,042 cancers in 
which the signature contributed significant number of somatic mutations. For most signatures, significant number of 
mutations in a sample is defined as more than 100 substitutions or more than 25% of all mutations in that sample. 





























1.5 Signalling pathways in cancer 
All of the driver genes detected in different cancers can be classified into one or more of 12 
pathways (fig 1.5). These pathways can themselves be further organized into three core cellular 
processes: cell fate, cell survival, and genome maintenance [25].  
 
Figure 1.5. Cancer cell signalling pathways and the cellular processes they regulate. All of the driver genes can be 
classified into one or more of 12 pathways (middle ring) that confer a selective growth advantage (inner circle). These 




1.6 Cancer immunotherapy 
1.6.1 Neoantigens and the immune system 
Human cancers arise through genetic changes that facilitate cellular immortality, but at the same 
time create foreign antigens, the so-called neoantigens, which should render neoplastic cells 
detectable by the immune system and target them for destruction. Nevertheless, although the 
immune system is capable of noticing differences in protein structure at the atomic level, cancer 
cells manage to escape immune recognition and subsequent destruction [29]. 
Immunotherapies that boost the ability of endogenous T cells to destroy cancer cells have 
demonstrated therapeutic efficacy in a variety of human cancers. Until recently, evidence that 
the endogenous T cell compartment could help control tumour growth was, in large part, 
restricted to preclinical mouse tumour models and to human melanoma [30].  
The field of cancer immunotherapy has recently received a significant boost, encouraged 
primarily by the approval, in 2010, of the autologous cellular immunotherapy, sipuleucel-T, for 
the treatment of prostate cancer, and the approval of the anti-cytotoxic T lymphocyte-associated 
protein 4 (CTLA-4) antibody, ipilimumab,  and also of anti-programmed cell death protein 1 (PD1) 
antibodies for the treatment of melanoma in 2011 and 2014, respectively [29]. 
The clinical success of immune checkpoint antagonists targeting the PD-1 pathway in multiple 
tumour types provides clear evidence that harnessing the immune system can lead to durable 
tumour regressions in cancer patients [31]. 
1.6.2 Tumour specific antigens  
The recent development of NGS, along with advances in bioinformatics, have enabled systemic 
analyses of the mutation load of the tumour as well as identification of the potentially 
immunogenic neoantigens [32]. 
T cells are able to reject tumours on recognition of tumour-specific antigens bound to the major 
histocompatibility complex (MHC) molecules of tumour cells. MHC is a protein complex that 
presents antigens on the cell surface. In humans, the MHC is encoded by the human leukocyte 
antigen (HLA) gene locus. Antigens with high tumour specificity, that is displayed by tumour cells 
but not by normal cells, have the potential to elicit a tumour-specific immune response, 
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minimizing the risk of adverse side effects, and are therefore of great interest for cancer 
immunotherapies such as engineered T cells and therapeutic vaccines [33].  
Neoantigens can be considered to be strictly tumour-specific because they originate from the 
expression of mutated genes that are present in malignant cells but not in the normal tissues. To 
elicit an immune response, the mutated proteins must be proteolytically processed into short 
peptides and then bound to MHC molecules, to be presented to T cells (Fig 1.6, A). When NGS 
data are available from matched tumour and normal tissues, neoantigens can be predicted in 
silico by integrating three computational tasks (fig 1.6, B): the identification of mutated proteins 
from matched tumour–normal samples, followed by HLA typing, and then prediction of 
neoantigens–MHC binding affinity [33]. 
A large fraction of the mutations in human cancers is not shared between patients at meaningful 
frequencies and may therefore be considered patient-specific. Because of this, technologies to 
interrogate T cell reactivity against putative mutation-derived neoantigens need to be based on 
the genome of an individual tumour [34] 
1.6.3 Classes of neoantigens 
There are three classes of antigens that have high tumour specificity: the first is viral antigens, 
which are derived from viral genes expressed in virus-infected tumour cells, second is cancer 
germline antigens, which are proteins that are normally expressed only by trophoblasts and 
germline cells but that have aberrant expression in tumour cells, and third is neoantigens, which 
are peptides that arise from the expression of somatically mutated genes [33]. 
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Figure 1.6. Identification of cancer neoantigens. A, neoantigens originate from mutated proteins expressed in cancer 
cells. The mutated protein is cleaved into shorter peptides by the proteasome and transported by transporter 
associated with antigen processing (TAP) to the endoplasmic reticulum, in which the peptides bind the major 
histocompatibility complex (MHC) molecule. Then, the peptide–MHC complex is displayed on the cell surface of the 
antigen-presenting cell to be recognized by the T cell receptor (TCR) of CD8
+ 
T cells. B, prediction of candidate 
neoantigens from next-generation sequencing (NGS) data requires the implementation of several computational 
tasks: prediction of mutated peptides from whole-exome sequencing (WES); whole-genome sequencing (WGS) or 
RNA sequencing (RNAseq) data from matched tumour–normal samples; selection of expressed peptides by 
integrating RNAseq data of the tumour sample; human leukocyte antigen (HLA) typing from WES, WGS or RNAseq 
data of the tumour sample; and prediction of peptide–MHC binding for specific HLA alleles [33]. 
 
1.6.4 Different strategies to activate immune cells 
Strategies to activate effector immune cells include vaccination with tumour antigens or 
augmentation of antigen presentations to increase the ability of the patient’s own immune 
system to mount an immune response against neoplastic cells [6]. Additional stimulatory 
strategies encompass adoptive cellular therapy (ACT) in an attempt to administer immune cells 
directly to patients, the administration of oncolytic viruses (OVs) for the initiation of systemic 
antitumor immunity, and the use of antibodies targeting members of the tumour necrosis factor 





1.6.4.1 Vaccines targeting individual mutations 
Mutation-based vaccination attempts represent ‘off-the-shelf’ approaches, as they target single 
or multiple frequently shared neoantigens, such as mutant RAS and mutant epidermal growth 
factor receptor (EGFR). These were used to stratify patients according to the presence or absence 
of the respective mutations in their tumour. Various attempts have been made to apply 
neoantigen-based vaccine strategies in mouse models. Vaccination studies with synthetic 
peptides and mRNA-encoding mutations identified by NGS in three different mouse tumour 
models revealed that a significant portion of non-synonymous point mutations is immunogenic. 
Developed mRNA vaccines that encoded single MHC class II neoepitopes were capable of 
controlling the growth of established mouse melanoma and colon cancer tumours [35]. 
Ongoing clinical trials have provided evidence for the feasibility of individualized vaccination of 
cancer patients with unique mutations. Once neoepitopes have been selected, the patient’s 
individualized vaccine can be manufactured. These vaccines can be in the form of synthetic 
peptides and antigen encoding DNA or RNA (fig 1.7) as formats which are able to deliver effective 






Figure 1.7. Schematic mechanism of an mRNA-based neoepitope vaccine. The mRNA vaccine-encoding parts of the 
neoantigen are translated in the cytosol. Subsequently, the mutated peptides are C-terminally truncated by the 
proteasome and transported into the endoplasmic reticulum (ER), where loading of the neoepitope on MHC class I 








1.7 Brief Aims of each Results chapter 
1.7.1 Detecting somatic mutations in undifferentiated pleomorphic sarcoma (UPS) 
Sarcomas are an intriguingly complex set of tumours, arising from mesenchymal tissue and 
representing approximately 1% of all adult cancers. One of the more perplexing features of soft 
tissue sarcomas (STS) is their heterogeneity. This fascinatingly diverse group boasts over 50 
distinct subtypes, each one unique with regard to histology and clinical management. This 
complexity has made it difficult to advance our molecular understanding of these tumours. 
Patient samples are rare, and thus researchers have been forced to combine sarcomas from 
multiple different subtypes when conducting genomic studies. Although some sarcomas, such as 
gastrointestinal stromal tumours, are defined by a simple genetic event that allows for treatment 
with rational therapeutics, other STS with less-well defined mutations are in need of a deeper 
molecular understanding to identify new drug targets. Of particular note is undifferentiated 
pleomorphic sarcoma (UPS), the most common STS diagnosed in adults. Similar to many other 
STS cases, the majority of patients with UPS are treated with surgical resection and radiotherapy. 
In the case of metastatic disease, patients with UPS receive a combination of doxorubicin and/or 
ifosfamide-based therapy, which is both toxic and demonstrates only marginal efficacy. 
Classically, UPS is a diagnosis of exclusion, defined by a lack of specific histological or molecular 
features. UPS is extremely unstable at the genomic level. The few genomic analyses of UPS 
conducted to date have identified dysregulation of cell cycle and tumour suppressor pathways. 
However, to the best of our knowledge, these studies did not report any disruptions in signal 
transduction pathways that may provide new molecular targets for UPS [36]. 
1.7.2 WES of 20 UPS tumour-normal tissues 
We aimed to use newly available software to define the mutated genomic landscape using UPS 
as the model cancer. In an attempt to find a drug target and specific biomarker in UPS, we have 
sequenced and analysed the WES of 20 UPS tumours and their matched normal adjacent tissues. 
We have detected a high number of somatic mutations in each patient using the Biomedical 
Cancer Research Workbench of the CLC-bio software. We have selected the highly mutated genes 




1.7.3 RNAseq analysis of three UPS 
RNA sequencing is emerging as being used as another landscape to identify and stratify mutated 
and expressed genes. However, the currently available RNAseq software tools do not share a 
high degree of integrity and we have used newly available software to quantify expressed 
mutated RNA landscapes.  We have also sequenced the whole RNA (transcriptome) of three UPS 
tumour tissues and their matched normal tissues. As not all the somatic mutations detected in 
the DNA would be expressed in the RNA, we have compared the tumour RNAseq to the tumour 
DNAseq to detect expressed somatic mutations at the RNA level. This step is necessary in order 
to select the mutation for further studies, but it has limitations as not all genes would be 
expressed at the time of tumour resection and we would miss some genes as mentioned above. 
The tumour RNAseq of the three UPS patients were also compared to the RNAseq of matched 
normal tissues to detect genes with differential expression in tumour and normal tissues of UPS. 
 
 1.7.4 Analysing WES from small sets of patients to define cut-off parameters in CLC-bio 
software 
Before we started the analysis of the UPS data search using the CLC-bio software, we have applied 
WES of tumour tissues and two matched normal tissues, normal adjacent tissue and germline 
blood, from a small set of patients with head and neck cancer (tongue cancer) to define cut-off 
parameters in the use of the new software. Patients were divided into two groups: the first group 
were young patients, and the second group were old patients. All patients have no history of 
smoking, alcohol consumption or viral infection, the most known risk factors for tongue tumours. 
Although the number of patients was low (three young and two old), we have analysed their WES 
using the CLC-bio software, and detected somatic mutations in the tumour tissues and compared 
them to the normal adjacent tissue/blood. This analysis has helped us to set up the parameters 
for the UPS data analysis. 
We were also provided with the RNAseq of four patients (two young and two old), and these 
were used in the analysis to get an idea of the percentage of the expressed somatic mutations 




1.8 Genetics of oesophageal adenocarcinoma (OAC) 
During the course of my studies, OAC has emerged as a progression model for genomics since 
intermediates in the disease can be collected. In this model, there are novel driver mutations 
identified of unknown function and I developed methods that can identify functions to such 
orphan, mutated proteins. Although, by the end of my thesis, I had no time to apply the method 
to UPS target proteins, the principle methodology is established by my thesis to applied to other 
cancer proteins. There are dozens of different cancer types. I will focus below on a cancer of 
unmet clinical need where genomics has shed light on mechanisms of development. OAC, 
including cancers of the gastro-oesophageal junction, represent a substantial health concern in 
Western countries due to its increasing incidence and poor prognosis. Recent genome-wide 
sequencing projects have shown that OAC is one of the most highly-mutated solid cancers, with 
a high degree of heterogeneity [37]. 
1.8.1 Epidemiology and risk factors of OAC 
In the early to mid-twentieth century, primary OAC was rare. However, the incidence of OAC has 
increased 600% over the last 30 years in Western countries. The increase in incidence of OAC 
during this time was greater than that of any other major cancer. OAC mainly affects older white 
men; it is five times more common in Caucasian than in African Americans, eight times more 
common in men than in women, and peaks in incidence during the seventh and eighth decade of 
life [38, 39]. 
The reasons behind this rapid increase in OAC incidence are not completely understood. It is 
hypothesized that the rise in the prevalence of both obesity and gastroesophageal reflux disease 
(GERD), and perhaps the simultaneous decline in the prevalence of Helicobacter pylori (H. pylori) 
infection, may help explain the rise in incidence of OAC [38].  
Previous studies have shown that the risk of OAC was almost eight times higher in patients with 
symptomatic GERD than in controls. Acid exposure in patients with GERD can damage the 
squamous epithelial lining of the distal oesophagus, and this damage can be followed by an 
aberrant healing process that results in the replacement of normal squamous mucosa by 
specialized, metaplastic columnar intestinal epithelium, a condition commonly known as 
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Barrett’s oesophagus. It is thought that most OAC develop from an area of Barrett’s metaplasia 
[38]. However, only few patients with Barrett’s oesophagus develop OAC. 
Infection with H. pylori appears to have an inverse association with OAC, with a reported 41% 
decrease in the risk of OAC in individuals infected with H. pylori. Whether this relationship is truly 
causal, however, remains a matter of debate. It is thought that H. pylori protects against Barrett’s 
oesophagus and OAC by leading to atrophic gastritis and reduced gastric acid secretion, which in 
turn decreases acid exposure in the oesophagus [38].  
Tobacco use has been reported to increase the risk of OAC by about twofold, and this risk is 
directly associated with the amount and duration of cigarette smoking [38].  
1.8.2 Genetic variations of OAC 
Recent efforts have been directed towards understanding the genetic landscape of OAC with a 
view to the identification of potentially targetable driver mutations. These studies have revealed 
the complexity of the genomic aberrations in OAC. The progression from Barrett’s oesophagus 
to invasive cancer is characterized by early chromosomal instability, maybe due to p53 loss, often 
including genome doubling and high frequency of chromothripsis events resulting in considerable 
genetic diversity, followed by a later acquisition of driver mutations at sub-clonal frequencies 
[40]. 
Dulak et al [41] was the first genome-wide association study to investigate gene variations 
together with pathway abnormalities in OAC. In this study, 149 OAC tumour–normal pairs were 
subjected to WES, 15 of which had also been subjected to WGS. The study detected the highest 
mutation signature A>C in OAC in non-coding areas, and within coding areas they were 
overrepresented in less expressed genes. The study also identified 26 significantly mutated genes, 
the most significant of which were two known OAC tumour suppressors, TP53 and CDKN2A. 
Many signal transduction pathways were affected by these mutations (fig 1.8). The novel 
significantly mutated genes included chromatin-modifying factors and regulators of invasion and 
motility: SPG20, TLR4, ELMO1, and DOCK2. Functional analysis of ELMO1 detected mutations 
revealed an increased cellular invasion. Given that OAC is a highly invasive tumour prone to early 
metastasis, alterations in the RAC1 pathway may be a contributor to OAC tumorigenesis [39]. 
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Figure 1.8. Overlap of protein coding modifications in known cancer signal transduction pathways. A, RAC1 
activators. B, Chromatin-remodelling enzymes. C, TGFB1(TGF-β)/SMAD4. D, KRAS/PI3K/RTK. E, WNT/CTNNB1 (β-




1.8.2.1 Mutation spectrum in Barrett’s oesophagus and OAC 
The identification of causative mutations occurring early in the OAC pathogenesis is important in 
order to develop clinically useful biomarkers. The mutations occurring at disease stage 
boundaries would be the most informative. A previous study has performed WES on 11 OAC 
samples and 2 samples of Barrett’s oesophagus adjacent to the cancer. They reported that the 
majority of mutations were detected in apparently normal Barrett’s oesophagus [39]. 
Weaver et al. [42] has analysed WGS and amplicon resequencing of 112 OAC cases, and screened 
their panel for the most recurrently mutated genes in samples from different stages of 
carcinogenesis: 90 OAC; 66 never-dysplastic Barrett’s oesophagus; and 43 high-grade dysplasia 
(HGD) cases. They found that the most prevalent mutations in OAC were also present at a similar 
frequency in HGD and never-dysplastic Barrett’s oesophagus samples, including mutations within 
cancer-associated genes, such as: ARID1A and SMARCA4. Only mutations in TP53 and SMAD4 
were confined to HGD and OAC cases, making them good markers for malignant progression risk 
(fig 1.9) [39, 42]. The frequency of SMAD4 mutation is low in OAC cases (13%) and these 
mutations were specific to OAC but not HGD samples, so the study has focused on TP53 in clinical 






Figure 1.9. TP53 and SMAD4 mutations accurately define the boundaries in the progression towards cancer whilst 
other mutations appear to occur independent of disease stage. A proposed model for the boundary-defining 
mutations in Barrett’s oesophagus carcinogenesis. The hashed box depicts multiple other mutations that may occur 
and provide selective advantage at any stage of disease [42]. 
 
1.8.3 Genome sequencing and mutation spectrum in OAC cell lines 
The number of OAC cell lines available for research is limited and their genome has been only 
partially characterized. The availability of an accurate annotation of their mutational landscape 
is necessary for accurate experimental design and correct interpretation of genotype-phenotype 
findings. Contino et al. [37] has performed high coverage, paired and WGS on nine OAC cell 
lines:ESO26; ESO51; FLO-1; JH-EsoAd1; OACM5.1 C; OACP4 C; OE33; SK-GT-4 and CP-D. They have 
identified SNVs and indels in these cell lines by comparison with the human reference genome 
and known single nucleotide polymorphisms.  
In order to investigate how closely these cell lines reflect the spectrum of mutations observed in 
human specimens, they analysed the mutational landscape of known cancer and putative OAC 
driver genes and compared them to the OAC mutations previously reported by Dulak et al.[41], 
and Weaver et al. [42]. These studies showed that 69% of OAC cases have TP53 mutations, while 
all the cell lines carried at least one deleterious TP53 mutation (fig 1.10 A, B). Two cell lines out 
of nine, ESO26 and JH-EsoAd1, have mutations in SMAD4 gene, which is consistent with 13% 
observed in OAC (fig 1.10 A, B). ELMO1 was also mutated in two cell lines: ESO51 and SK-GT-4. 
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There is no mutation detected in some genes such as ARID1A and DOCK2, which were reportedly 
mutated in OAC cases. 
In another study, Garcia et al. [40] performed WGS on OAC tumour and leucocytes, and RNAseq 
on three OAC cell lines: MFD-1, FLO-1 and OE33. They have reported that the parental tumour 
and MFD-1 cell line carried four somatically acquired mutations in three recurrent mutated genes 
in OAC: TP53, ABCB1 and SEMA5A, not present in FLO-1 and OE33. FLO-1 and OE33 had no 
expression of ABCB1 and SEMA5A genes. The detection of TP53 mutation in MFD-1 suggests that 
this cell line is representative of primary OAC tumours. The study has suggested that the MFD-1 







Figure 1.10. Analysis SNV of putative OAC genes identified in Dulak et al. (2013) and Weaver et al. (2014). A, SNVs 
identified and annotated by Variant Effect Predictor analysis (Ensembl). When more than one variant was present in 
a single gene, the most deleterious was annotated according to the colour-coded legend reported at the bottom of 
the figure. B, Blue and red bars indicate the mutation rate of OAC genes reported in Dulak et al., 2013; and Weaver 
et al., 2014, respectively [37]. 
 
1.8.4 Study of the effects of mutations detected in ELMO1 
ELMO1 and DOCK2 form the highest frequency, gain-of-function mutation “target (A protein-
protein interaction pair) in OAC.  As such one of these (ELMO1 became the focus for identifying 
functional models). Thus, at the same time of analysing the WES data of UPS, we also studied the 
effects of wild type ELMO1, and ELMO1 with the F59L mutation detected in the OAC cases by 
WES by Dulak et al. [41]. We studied the effects of wild type and mutant ELMO1 on OAC cell lines 
FLO-1 and OE19 growth by clonogenic assay. We have also developed a Streptavidin-Binding 
Peptide (SBP)-tagged affinity purification method in combination with label-free Sequential 
window acquisition of all theoretical mass spectra (SWATH) mass spectrometry (MS) to identify 
novel binding proteins for the gain-of-function mutant ELMO1. This identified an elevated 
interaction with another oncogenic protein encoded by the AGR2 gene and validates this 

















Aims and Objectives 
2.1 Head and Neck 
The main aims of analysing the DNA and RNA sequences of head and neck cancer patients is to 
set the parameters of the CLC-bio software to detect specific somatic mutations to the tumour 
tissues, and to detect the list of genes with somatic mutations in these patients. 
We were provided with the whole exomes DNA from the tumour, normal adjacent tissue and 
germline blood of each of the five patients (two old and three young) of head and neck cancer. 
We will import these sequences files into the CLC-bio software and analyse them by comparing 
the sequence of the tumour to the blood and normal adjacent tissue to detect somatic mutations 
that are specific to the tumour tissues. We will use CLC-bio to detect areas with CNV in the 
tumour compared to the normal adjacent tissue and blood sequences. 
We were also provided with the total RNA sequences of the tumour tissues from four of the five 
patients. We will compare the tumour DNA sequence with the RNA sequence to look for the 
expressed detected somatic mutations at the RNA level. 
The questions to be solved: 
1- What are the best CLC-bio parameters with the best sensitivity and specificity? 
2- What is the best tissue to be used as a control to define somatic mutations, blood or 
normal adjacent tissue? 
3- Are there any differences/similarities between the young and old patients in the genes 
with somatic mutations? 
4- What is the percentage of detected somatic mutations being expressed in the RNAseq? 




2.2 Undifferentiated pleomorphic sarcoma (UPS) 
We have been provided with the fresh frozen tissues of the tumour and normal adjacent tissues 
of 20 UPS. We will extract the DNA from both tissues of all patients and send the DNA for whole 
exomes sequence by illumine. The sequences files will be imported and analysed in the CLC-bio 
software to detect specific somatic mutations to the tumours using the parameters set for the 
head and neck patients. Then we will look for common mutated genes or pathways in the UPS 
which can serve as therapeutic targets or biomarkers. 
At the time of analysing, these sequences are analysed by another mutation calling method: 
MuTect. Thus, we will compare the results of each software and see which one is better in 
detecting real somatic mutations. 
We will also extract DNA from two different parts of one of the tumours and compare their DNA 
sequences to the sequence of the normal adjacent tissue to see if there is any difference in the 
detected mutations in the two regions. 
We will purify the total RNA from three UPS patients (tumours and normal adjacent tissues) and 
send them for sequences to compare them to the tumour DNA sequence to look for the 
expressed somatic mutations at the RNA level. We will also use the CLC-bio to study the different 
expression of genes based on the number of reads of the RNA in the tumour and normal adjacent 
tissues to detect genes that are overexpressed or suppressed in the tumour and study the 
pathways of these genes. 
Protein lysate from one tumour was processed using MS to identify total proteins present in the 
tumour (performed as a collaboration between the Hupp laboratory and Dr Borek Vojtesek’s 
laboratory, Brno, Czech Republic). So we will see which of the mutations detected at the genomic 






The questions to be solved: 
1- What is the number and type of somatic mutations detected in UPS? 
2- Are there any common mutated genes or pathways? 
3- Is there any difference between CLC-bio software and MuTect in detecting somatic 
mutations? 
4- Is there any difference in mutated genes between the two different regions of the same 
UPS tumour? 
5- What is the percentage of expressed somatic mutations which we can define by RNAseq?  
6- What are the genes and pathways that have different expression profile between the 
normal and tumour tissues? 
7- Are there any detected mutations at the genomic level translated to protein? 
 
2.3 Investigating the effects of mutations detected in ELMO1 gene in OAC 
We would like to study the effects of wt type and mutant (F59L) ELMO1 gene on the growth of 
OAC cell lines. We will study the expression of ELMO1 in some OAC cell lines such as OE19 and 
FLO1, and study the effects of the expression of wt and mutant ELMO1 on the growth and 
number of colonies of these cell lines by clonogenic assay. 
We will also develop a strep-tag binding pull down method to find out wt and mutant ELMO1 
binding proteins in OAC cell lines using SWATH-MS. We will then validate some of the important 
ELMO1 binding proteins by PLA. 
Depending on time allowing, I will study some of ELMO1 interactions to other proteins and their 
effects on cell growth and mobility. 
If time permits, these methods will be applied to investigate the effects of the detected mutated 





The questions to be solved: 
1- What OAC cell lines express ELMO1? 
2- Are there any growth differences between cells with no ELMO1 expression, with wt 
ELMO1 or with F59L ELMO1 expression? 
3- What are ELMO1 binding proteins in OAC cell lines? 
4- Are there any differences in the fold-change in the wt and mutant ELMO1-binding 
proteins? 






















Materials and Methods 
3.1 Head and Neck cancer patients’ DNA and RNA sequence 
The DNA and RNA sequences of the five patients of head and neck cancer were provided to us by 
Prof. Karin Nylander (department of medical bioscience, Umea University, Sweden). For all 
patients, the DNA sequence was provided from the tumour, normal adjacent tissue (which is 7–
10 cm distant from the tumour), and blood (except in patient 82 the sequence was derived from 
the tumour and blood only). From blood (buffy coat) they extracted DNA with illustra nucleon 
genomic DNA extraction kit according to the manufacturer manual. From tumours and normal 
adjacent tissues, fresh biopsies were homogenized in lysis buffer from Allprep DNA/RNA/miRNA 
Universal kit from Qiagen. After homogenization, extraction was continued according to the 
protocol in the kit. RNA sequence was provided from the tumour tissues only for all patients 
except 82. DNA and RNA concentrations were measured using Nanodrop. They were sent to 
Otogenetics for sequencing. For the tumour samples the HiSeq2500 PE100-125 kit was used to 
sequence the whole exomes from gDNA, paired-end 2x100-125 or PE100-125 (read length). The 
estimated average on-target coverage is 100x. For the normal adjacent tissues and blood, the 
HiSeq2000/2500 PE100 kit was used, paired-end 2x100 or PE100 (read length). The estimated 
average on-target coverage is 30x. HiSeq2500 PE100 sequencing used to sequence the whole 
RNA. 
 
3.2 Sarcoma DNA and RNA sequences to detect somatic mutations 
3.2.1 Purification of DNA and RNA 
DNA was extracted from the 20 sarcoma tumours and their matched normal tissues using the 
ChargeSwitch gDNA Mini Tissue kit from Invitrogen following the manufacturer’s protocol. 
RNA were extracted from normal and tumour tissues of patients 55, 66 and 73 using RNeasy RNA 
extraction kit from Qiagen following the manufacturer’s protocol. 
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3.2.2 Sequencing of DNA 
Exome Sequencing was performed using Agilent V5+UTR Exome Capture Kit (75Mb); Illumina, 
100bp paired-end reads using a coverage of Tumour: Normal pairs (100X/30X). Paired de-
multiplexed fastq files were generated using CASAVA software (Illumina) and initial quality 
control was performed using FastQC.  
3.2.3 Sequencing of RNA 
RNA sequencing was performed using Illumina HiSeq2500 100bp paired-end reads. 
3.2.4 Read mapping of DNA reads and variant detection 
Paired de-multiplexed fastq files from DNA-exome libraries were imported into the CLC 
Biomedical Genomics Workbench (version 2.5). Adaptor sequences and bases with low quality 
were trimmed and reads were mapped to human genome 19 (HG19). The remove duplicate 
mapped reads tool was used to remove paired reads that have the same start and end 
coordinates and are, thus, probably PCR duplicates. Variants were detected in the exome data 
with the CLC Bio Probabilistic Variant Caller using the following parameters: Minimum coverage 
(number of reads) = 5; Minimum frequency = 5%; Minimum number of variants = 2; Variants in 
normal germline DNA=0, and the coverage in the germline DNA should be at least 5 reads at the 
variant site. The CLC workflow of variants detection in the tumour is shown in figure 3.1. 
3.2.5 Read mapping of RNAseq 
Paired de-multiplexed fastq files from RNAseq libraries were trimmed for stretches of adapter 
sequences, joined into a single read followed by quality trimming using commands from the CLC 
Assembly Cell. This resulted in three different fastq files: paired-end data, single-end data after 
joining of paired reads, and single-end data after elimination of one of the paired reads due to 
e.g. low quality. All three types of fastq files were then imported batchwise into the CLC 







3.2.6 Detection of expressed somatic mutations in the RNAseq 
In order to detect the expressed somatic mutations in the RNA, the tumour RNAseq was 
compared to the tumour DNAseq of each patient (55, 66 and 73). The minimum coverage and 
number of variants were set to 1 in the RNA reads, while in the DNA the parameters were not 
changed and left as 5 for minimum coverage and 2 for the minimum number of variants. The 
workflow for detection of variants in both RNA and DNA is shown in figure 3.2.  
In order to get expressed somatic mutations; The tool remove germline variants was used to 




Figure 3.1. Workflow of the identification of somatic mutations in the tumour DNA sequence by comparing the tumour sequences to the sequence of the 




Figure 3.2. The workflow of identification of variants found in the tumour DNA and tumour RNA in CLC Biomedical Genomic workbench.
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3.3 General microbiological techniques  
All the microbiological techniques were carried out using sterile glass, plastic apparatus and 
under strict aseptic conditions. Different techniques used in the lab have been described 
below:  
3.3.1 Transformation of bacterial competent cells  
Between 50 to 200 ng of plasmid DNA or 5 μl of ligation product was added to a 50 μl cell 
aliquot of E.coli DH5α cells for plasmid propagation. The cell aliquots containing DNA were 
incubated on ice for 30 mins, placed in a water bath at 42⁰C for 45 seconds and back on ice 
for 2 mins. Under sterile conditions, 500 μl of fresh LB medium was added to the cell aliquot 
and incubated shaking at 37⁰C for 60 mins. LB agar 10 cm dishes were prepared (LB containing 
1.5% (w/v) agar) with 100 μg/ml Ampicillin (#A9618, Sigma) or 25 μg/ml Kanamycin 
(#11815032, Invitrogen), depending on the appropriate antibiotic resistance encoded by 
plasmid. All the unused plates were stored at 4⁰C upside down, sealed in parafilm and pre-
warmed in 37⁰C incubator before use. In a sterilized area, 50-200 μl of the culture was plated 
out onto the pre warmed LB plate using the glass spreader. Plates were incubated overnight 
upside down in 37⁰C incubator. 
3.3.2 Purification of plasmid DNA  
Under sterile conditions, a single colony was picked from the transformed plate using a sterile 
tip. The colony was dropped into a 5 ml LB medium (100 μg/ml Ampicillin or 25 μg/ml 
Kanamycin) in a 15 ml falcon tube (for small scale purification). The tube was incubated 
overnight at 37⁰C, 220 rpm and the following day the tube was centrifuged at 4000 rpm for 
10 mins at 40C. Following centrifugation, the tip and supernatant was discarded carefully. 
QIAprep Spin Miniprep Kit (#27106, Qiagen) instructions were followed to extract and purify 
plasmid DNA which was then further eluted in 30-50 μl of elusion buffer. The concentration 
of the DNA was measured on a Nanodrop and stored at -20⁰C.  
For a larger scale purification of plasmid DNA, colony was dropped in a similar way but the 
volume of LB containing appropriate antibiotic was increased to 150-200 mL and grown 
overnight at 37⁰C. HiSpeed Plasmid Kit (#12663, Qiagen) was used for extraction and 




3.4 Molecular biology techniques  
All primers were designed and ordered from Sigma Genosys, whereas all enzymes and buffers 
were ordered from New England Biolabs unless stated otherwise.  
The plasmids used and their sources were: pEGFP-C1 and pEXPR-IBA105 (Addgene)  
3.4.1 DNA quantification  
The concentration of DNA was measured using Nanodrop spectrophotometer (absorbance at 
260 nm). 
3.4.2 Polymerase chain reaction  
A suitable template as cDNA or plasmid DNA is used to amplify the desired gene by 
Polymerase chain reaction (PCR). The primers were designed in such a way that forward 
primer contains a restriction site which cuts at the 5’end of the gene and a reverse primer 
which has a site attached at the 3’ end of the primer.  
While designing the primers, it was ensured that the gene was in frame with the N-terminal 
of the vector sequence. Few base pairs were added to the 5’end of the primers before the 
restriction sites in order to allow efficient binding of the restriction sites to the primer and 
allow significant digestion of the insert. Also, primer length was manipulated to get a suitable 
melting temperature and presence of GC at the primer extremities was favoured. PCR 
reactions were carried out on ice in nuclease free tubes with 2 X high Fidelity Phusion Master 
mix (#M2075 NEB), 100ng of plasmid DNA, 0.5 μM of each primer, nuclease free H2O made 
up to 50 μl. 
The PCR program was as the following: 
- incubate at 95 C for 2 minutes 
 - incubate at 95C for 20 seconds 
 - incubate at 58C for 40 seconds 
 - incubate at 72C for 1 minutes 
 - cycle to step 2 for 35 cycles 
 - incubate at 72C for 5 minutes 
 - 4C forever 
 
5-10 μl of PCR reaction was run on a 1.5% (w/v) agarose gel to check if the desired band for 
the amplification of the gene was obtained. Multiple PCR reactions were run on 1.5% (w/v) 
agarose gel until maximum separation of the desired and non-specific bands was achieved. 
The desired band was cut using a sterile scalpel and this excised gel was purified by using Gel 
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extraction kit (#28704, Qiagen) manufacturer’s protocol. The DNA was eluted in 30-50 μl of 
elusion buffer (Buffer EB) and the concentration of the DNA was determined using Nanodrop 
(OD600nm). 
3.4.3 ELMO1 primers 
The primers used to amplify ELMO1 cDNA are shown in table 3.1. 
 Forward 5’to 3’ primer with 
EcoR1 restriction site  
Reverse 3’ to 5’ primer with 
BamH1 restriction site 












Table 3.1. primers to amplify whole ELMO1 cDNA. Primers were designed using primer 3 website. Forward and 
reverse primers have EcoR1 and BamH1 restriction sites (underlined) respectively to be ligated in Pexpr-iba105 
and EGFP-C1 vectors. Additional one base (green) was added to each of the forward primer to make the 
expression of ELMO1 inframe  
 
3.4.4 Restriction digestion of the purified PCR product and destination Vector DNA  
For these above purified PCR products, double digestion was performed using two different 
enzymes and compatible buffers recommended by supplier. The destination vector along 
with the insert was digested using these two enzymes and incubated for 1-2 hours depending 
upon the amount of the vector and insert. To ensure efficient digestion has taken place, 
controls were set up such as single digestion using enzyme 1 and enzyme 2 individually as well 
as no enzymes. 
Restriction Enzyme Recognition sequence 5’-3’ (/ indicates cut site): 
- BamH1 G/GATCC 








3.4.5 Ligation of vector and insert 
Ligation of vector and insert was carried out using T4 DNA ligase (Promega), following 
manufacturer’s instructions. A standard amount of vector (100 ng) was used and the amount 
of insert required was calculated using the following formula: 
Insert ng = Vector ng x Insert size kb x Molar ratio of insert 
                                    Vector size kb vector 
 
A 1:1 and 3:1 molar ratio of insert to vector was always tested. 
Ligation reactions were as follows: 
- 1 μl ligase buffer (10x) 
- 100 ng vector 
- X ng insert 
- 1 μl T4 DNA ligase 
- Nuclease free water to 10 μl water 
Ligation reactions were carried out at room temperature for 1 hour. Following which 2.5 μl of 
the mix was transformed into DH5α competent cells and plated onto Ampicillin or Kanamycin 



















3.4.6 Site directed mutagenesis 
Site directed mutagenesis was carried out using methods from Stratagene. The primers used 
to make F59L mutation (TTC > TTA) in ELMO1 were TGCCGATAGTTCAAACTTATATATCACAGA 
and its reverse complement TCTGTGATATATAAGTTTGAACTATCGGCA. 
The PCR reaction was set up in nuclease free tubes using 2 x Pfu master mix (Rovalab) as 
follows: 
- 25 μl 2x Pfu master mix 
- 5 μl Band doctor (Rovalab) 
- 20 ng template DNA 
- 1 μl forward primer (20 μM stock) 
- 1 μl reverse primer (20 μM stock) 
- Nuclease free water up to 50 μl 
Thermal cycling conditions: 
- Incubate at 95°C for 2 minutes 
- Incubate at 95°C for 1 minute 
- Incubate at 60°C for 1 minute 
- Incubate at 72°C for 5 minutes 
- Cycle to step 2 for 16 cycles 
- Incubate at 72°C for 5 minutes 
- Hold at 4°C forever 
 
 
Post PCR 1 μl DpnI (20000 U/ml, NEB) was added directly to each reaction tube and 
incubated at 37°C for 1 hour. Dpn1 was inactivated after this time by incubating at 65°C for 
10 minutes. 
PCR reactions (2.5 μl) were transformed into DH5α competent cells and plated onto 
Ampicillin or Kanamycin containing LB agar plates. Colonies were selected and plasmid DNA 








3.4.7 Agarose gel electrophoresis of DNA 
Agarose gel electrophoresis was used to separate, identify and purify DNA fragments. 
Agarose gels (1 %) were prepared by dissolving agarose in 1xTAE. To detect the DNA the 
SYBR®Safe (Invitrogen) was added to the gel prior to pouring the gel. Loading dye (6x) was 
added to the DNA samples prior to loading onto the agarose gel; the gel was run in 1x TAE 
buffer at 100 V for~1 hour. 
            1x TAE buffer                                                   6x DNA loading dye 
- 40 mM Tris                                                      0.25 % (w/v) bromophenol blue 
- 1 mM EDTA                                                     0.25 % (w/v) xylene cyanol 
- pH 8                                                                  15 % (v/v) glycerol 
 
 
3.4.8 Reverse transcription of total RNA to cDNA  
Omniscript Reverse transcription kit (Qiagen) was used in order to make cDNA from RNA. The 
preparation of reaction mixture is shown in table 3.2. 
Component Volume/ reaction Final concentration 
Master mix 
10X Buffer RT 
2 μl 1 x 
dNTP mix (5 mM each dNTP) 2 μl 0.5 mM each dNTP 
Oligo –dT primer (10 μM) 2 μl 1 μM 
RNAse inhibitor (10 units/ μl) 1 μl 10 units (per 20 μl) 
Omniscript Reverse transcription 1 μl 4 units (per 20 μl) 
RNAse free water variable  
Template RNA 
Template RNA, added at step 5 
variable Up to 2 μg (per 20 μl reaction) 
Total volume 20 μl Total volume 20 μl  









3.4.9 DNA sequencing 
Sequencing was carried out by Source Bioscience (LifeSciences). Plasmid DNA was obtained 
from clones by using the Qiagen Mini-prep kit, following manufacturer’s instructions. 
Plasmids were sequenced using stock primers from source bioscience. 
 
3.5 Validation of detected mutations 
3.5.1 Validation of variants detected in DMKN gene in head and neck cancer patients 
The primers to amplify the region of DMKN gene with the variants were designed using primer 
3 website. The primers are 5’ GCCCGTCTTGGTGCTCTGTCT and 3’ 
CCCGGCAGGGACCACTAGGGCC. The gene was amplified and tested for the variants in the 
department of medical bioscience, Umea University, Sweden. 
 
3.5.2 Validation of variants detected in sarcoma patients 
In order to validate some of the detected variants; primers have been designed to amplify the 
regions around the variant (table 3.3) and sent for Sanger sequence. 
Gene name Patient 5’primer 3’primer 
FAT3 73 CCAGAGACAAAGACTTAGGTTCT TGACAGAGAGACAGGCCGCCCTT 
IL11RA 55 AGGAGGAGTCCATCCACAGG ATGCTGTACGAGTCAGTGCC 
SEMA6A 55 CAAGCCGTGGATTACGGAGATTA AGCGGGTGCGTCTTGATGAAGTT 
MTCH2 55 TGACCACGTTATCAAGGAG AGAAGGCGAGGAACAAGAC 
Table 3.3. primers designed to amplify regions around the detected variants in FAT3, IL11RA, SEMA6A and 
MTCH2 genes. 
 
3.5.3 RNA editing variants in sarcoma patient 55 
Primers were designed around the variant in each of the 10 genes selected for RNA editing 
validation in patient 55 (table 3.4). The black bases are the primers which are complementary 
to the gene sequence to be amplified, and the red bases are the adapter sequence linked to 
the primer. The primers were used to amplify the genes directly from the RNA of patient 55 
using the superscript one-step RT-PCR (Invitrogen 12574018) according to the manufacturer 
manual. The amplified amplicons were sent for deep sequencing which was performed by 











5' to 3' primer 3’ to 5’ primer 
6 33289
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Table 3.4. primers designed to amplify regions around RNA edits in 10 genes of sarcoma patient 55. Adapter 
sequence (red) was attached to the primer sequence. 
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3.5.3.1 Validating the edit in MAP3K5 gene 
The primers were designed to amplify and validate the RNA edit in MAP4K5 gene transcripts 
as shown in fig 3.3 below. 
Figure 3.3. the primers locations and sequences for the MAP4K5 gene transcripts to validate the RNA edit A>T. 
 
 
3.6 Cell lines  
3.6.1 Maintenance of cell lines  
Cell lines were maintained in the appropriate medium supplemented with 10% (v/v) foetal 
bovine serum (FBS; Autogen Bioclear). Cells were incubated at 37°C in a humidified 5% CO2 
incubator or 10% CO2 for specific cell lines (table 3.5). 
Cell line Cell Line Origin Culture medium Origin 




Prof. Ted Hupp 
OE19 Human Caucasian 
oesophageal carcinoma 
RPMI 1640 (Gibco, 
Invitrogen) 
Prof. Ted Hupp 
OE33 Human Caucasian 
oesophageal carcinoma 
RPMI 1640 (Gibco, 
Invitrogen) 
Prof. Ted Hupp 
Table 3.5. oesophageal adenocarcinoma cell lines.  
 
Cells were maintained in 10 cm tissue culture dishes and were sub-cultured 2-3 times a week 
once the confluency rate reached ~90%. The appropriate media needed for the cell line was 








washed with 7-8 ml of sterile PBS. The PBS was poured off and cells were trypsinized using 2 
ml of trypsin –EDTA 0.5% (#25300, Gibco, Invitrogen) with an incubation period of 5 minutes 
at 37°C. Following 5 minutes of trypsinisation, 8 ml of pre-warmed fresh media was added 
and 2 ml was transferred to a new 10 cm dish containing 8 ml of fresh relevant media. The 
dishes were then incubated at 37°C overnight. 
3.6.2 Transfection of mammalian cells  
Cells were seeded in such a way that they reached a confluency of 50-70% in order to transfect. 
Transfection was carried out under laminar air flow in tissue culture room. For transfection, 
sterile eppendorfs as well as filter sterile tips were used after spraying with 70% ethanol. For 
preparing transfection reaction mix, 100 μl of respective serum free media (based on the cell 
line) was taken in a sterile eppendorf. To this media, appropriate amount of DNA was added 
(0.5, 1 and 5 μg) along with 5 μl of transfection reagent. The transfection reagent used was 
attractine (Qiagen). The reactions were then incubated for 15 minutes. Subsequently, the 
transfection reactions were added to the cells that were seeded before 12-14 hours 
previously. The plates were incubated for 18- 24 hours in a 37°C with 5% CO2. 
3.6.3 Harvesting of cells  
The cells were washed once within the 10cm plate with PBS and 1ml of PBS was added in 
order to harvest the cells. The cells were harvested by using a plastic scraper and harvested 
cells were then transferred into a fresh sterile eppendorf. The cells were centrifuged at 5,000 
rpm for 5 minutes and the pellet was snap frozen and stored in -80⁰C. 
3.6.4 Lysis of cells  
Lysis buffers:  
- Urea lysis buffer                                               - 0.5% NP-40 lysis buffer 
6.24M urea                                                              25mM Tris-HCl, pH 7.4 
0.1M DTT                                                                 150mM NaCl 
0.05% Triton X-100                                                 1mM EDTA 
25mM NaCl                                                               0.5% NP-40 
20mM HEPES-KOH, pH 7.6                                     5% glycerol 
1X Protease Inhibitor mix                                      1X Protease Inhibitor mix 
 
The cells were incubated on ice for 30 minutes for lysis and centrifuged at 10000 rpm and the 
supernatant were transferred to a sterile eppendorf. The protein concentration within the 
lysate was determined by Bradford assay (Bio-Rad) after reading the plate at wavelength of 
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595 nm. The samples were then prepared using 2X sample buffer containing 1 M DTT and 
normalized with water. The prepared samples were heated at 85⁰C for 5 minutes and loaded 
onto an appropriate percentage SDS gel. 
3.7 SDS gel preparation and Immunoblotting 
3.7.1 2X Sample buffer preparation 
- 2 ml Tris (1 M, pH 6.8)  
- 4.6 ml glycerol (50%)  
- 1.6 ml SDS (10%)  
- 0.4 ml bromophenol blue (0.5%)  
- 0.4 ml β- mercaptoethanol  
 
The samples after normalizing were made up to a certain amount with 2X sample buffer. 
Based on the size of protein, the lysate/ protein was run on an appropriate percentage of SDS 
polyacrylamide gel. The samples were loaded onto the gel along with a pre-stained ladder 
and the gel was run in 1X running buffer at 150 V for 1 hour at RT. Solutions needed for Tris 
glycine SDS - polyacrylamide gel electrophoresis- three different size of combs: 0.75 mm, 1.0 
mm and 1.5 mm (10, 15 wells), the appropriate percentage of SDS gel was made based on the 




Table 3.6. SDS gel ingredients: different percentage of gel based on thickness to run higher and lower molecular 
weight proteins.  
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Stacking gel:  
30 % acrylamide mix 5 % (v/v) 
1 M TRIS (pH 6.8) 0.13 M 
10 % (w/v) SDS 0.1 % (v/v) 
10 % (w/v) APS 0.1 % (v/v) 
TEMED 0.1 % (v//v) 
H2O to final volume 
3.7.2 Western blot  
Once the gel was run, it was transferred onto nitrocellulose membrane in such a way: Black 
side of cassette – sponge - blotting paper – gel - membrane – blotting paper –sponge. 10 X 
transfer buffer was diluted down to 1 X with an addition of 200 ml of methanol to enhance 
transfer of small proteins. The western blot was performed at 100 V for 1 hour with an ice 
block. Subsequently, the membrane was ink stained and blocked with 5% (w/v) skimmed milk 
in PBS-T (0.1%) for 1 hour. Following on, primary antibody was diluted in 5% milk (in PBS-T) 
and added to the blocked membrane and incubated for 1 hour at RT or overnight at 4°C. A list 
of the primary antibodies used is shown in table 3.7. The blot was then washed three times 
with PBS - T (0.1% (v/v)) and HRP conjugated appropriate secondary antibody was diluted in 
blocking buffer and added to the blot and again incubated for hour. The blots were then 
washed three times again with PBS-T 0.1% (v/v) and the results were analysed by overlaying 
the blots with ECL (1+2) for 2 minutes. 
ECL I  ECL II  
100 mM Tris HCL pH 8.5  100 mM Tris HCL pH 8.5  
2.5 mM Luminol  0.02% (v/v) H2O2  
0.4 mM p- Coumaric acid  -  
Make up with H2O upto 100 ml  Make up with H2O upto 100 ml  
 
Protein Primary used Company Approximate molecular 
weight of the band 
KDa 
ELMO1 Goat polyclonal Abcam ab2239 ~ 80 
GFP Rabbit polyclonal Abcam ab6556 27 
AGR2 Rabbit polyclonal K47 Moravian Biotechnology 18-21 
B-actin Rabbit polyclonal Abcam ab8227 47 
Table 3.7. A list of primary antibodies used to detect ELMO1, GFP, AGR2 and B-actin proteins. 
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3.7.3 Silver staining 
Silver staining was carried out according to instruction in Pierce™ Silver Stain Kit (Thermo 
Scientific 24612). 
 
3.8 SBP-tagged pull down experiment 
FLO-1 and OE19 cells were cultured in 10 cm plates and transfected with 5 µg of the Strep-
tag vector (pEXPR-IBA105), empty, wt ELMO1 and F59L ELMO1 using attractine. After 24h of 
incubation in 37°C incubator, cells were lysed with 500 µl of 0.5NP40 lysis buffer. Then 15 µl 
of Streptavidin agarose beads were added to the lysate and incubated in the shaker at 4°C for 
2 hours. The beads were then washed 3X with 0.5NP40 buffer and ran on SDS-PAGE. Silver 
staining, and immunoblotting with ELMO1 specific antibodies were carried out. The beads 
were then sent to Borek Vojtesek laboratory, Brno, Czech Republic, to identify ELMO1 binding 
proteins by SWATH-MS. 
3.9 SWATH-MS 
SWATH method for label-free quantification of proteins in complex mixtures was set-up 
according to previously published methods [43]. TripleTOF 5600+ (AB-SCIEX, Toronto, Canada) 
operated in high sensitivity positive mode. Random precursor ion peaks were extracted from 
TOF-MS and the approximate chromatographic peak width was defined to correctly establish 
SWATH method so that at least ten data points were acquired across a peak. Four randomly 
extracted precursor peaks from TOF-MS were evaluated and the peak width at FWHM was in 
average 1.5 min, so the cycle time of SWATH was set to 3.5 s. With the defined cycle time an 
optimal SWATH width of 20 Da with 1 Da overlap was calculated, with accumulation time 98 
ms per SWATH. Precursor range was selected from 400 amu up to 1100 amu. Product ion 
range was scanned from 300 amu up to 1600 amu and rolling collision energy was used with 
collision energy spread (CES) of 10 mV. Spectral library for SWATH data mining was measured 
from 1 _L pool of cell lysates (approx. 1 _g/_L protein concentration). Mass spectrometer 
TripleTOF 5600+ (AB-SCIEX, Toronto, Canada) operated in data-dependent mode. During each 
cycle, mass spectrometer fragmented the top 20 intense precursor ions with exclusion time 
set to 12 s. Minimum precursor ion intensity was set to 50 cps, 100 ms accumulation time was 
used and 150 ms accumulation time for TOF-MS scan. For building up of spectral library 1632 
proteins FDR 1% were used after Protein Pilot 4.5 (AB-SCIEX, Toronto, Canada) search using 
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Uniprot 2013_12 database. Spectral library was built in Peakview software 1.2.0.3 (AB-SCIEX, 
Toronto, Canada), only the identifications below FDR of 1% were indexed. Quantitative data 
(peak areas) corresponding to each protein included in spectral library were extracted from 
SWATH data using manual analysis in Peak view 1.2.0.3 (AB-SCIEX, Toronto, Canada). 
Data were extracted using retention time window of 3.5 min, which was determined by 
extracting random peaks across LC gradient. Retention time window describes the LC 
retention time shifts between SWATH technical replicates and data dependent acquisition 
(DDA) measurement and specifies in which scope of retention times software should look for 
peaks included in spectral library (DDA measurement result). Eight peptides per protein and 
five product ions per each peptide were used. Extracted quantitative data were further 
analysed in Marker view where T-testing was done on quantitative data from all replicates 
originating from compared sample pair. As a result, for all proteins in spectral library protein 
fold changes and p values between chosen sample pair were calculated and are valid only for 
the concrete pair comparison. 
 
 3.10 Proximity ligation assay (PLA)  
As means of developing new assay to demonstrate the binding between ELMO1 and AGR2, 
we performed PLA onto FLO-1 cells. FLO-1 cells were grown on a 19 mm cover slip for 24 
hours, then they were transfected with ELMO1 (wt and mutant) with and without AGR2. In 
the following day coverslips were made ready for PLA to be carried out.  
The cells were fixed onto slides with 4% paraformaldehyde in PBS for 20 min at RT, 
permeabilized for 10min in 0.25% Triton x-100 in PBS and blocked with 3% BSA in PBS for 30 
min. Antibodies from different species were then incubated on the slides, goat polyclonal 
ELMO1 antibody (Abcam ab2239) and rabbit polyclonal AGR2 K47 antibody (Moravian 
Biotechnology), at a 1:250 dilution for 1 hour at RT. Following PBS washes IF coverslips were 
incubated with donkey anti-goat and donkey anti-rabbit antibodies for 1 hour at RT. IF 
coverslips were further washed in PBS stained with DAPI and mounted onto slides with 
fluorescent mounting medium. Proximity ligation assay (PLA) was carried out with the OLIGO 
duolink. 
Designated protocol using anti-goat and anti-rabbit probes (Sigma; The duolink probe product 
numbers are 92002 (rabbit plus), 92006 (goat minus), and the duolink green detection is 
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92014.) The PLA coverslips were stained with DAPI and mounted in the same fashion as the 
IF coverslips. Images were taken at 20X using an Olympus BX51 microscope. 
 
3.11 Clonogenic assay 
FLO-1 cells were cultured in 6-well plates, and when they were 70-80% confluent they were 
transfected with 1 µg of pEGFP-C1 and pEXPR-IBA105 plasmids; empty, with wt ELMO1, with 
F59L ELMO1 using Attractine as a tranfection reagent. After 24 h, cells were trypsinized and 
recultured in 10 cm plates with DMEM media containing G418 (Geneticin) drug at 
concentration of 400 µg/ml. Cells were incubated at 37°C incubator for around one month, 
changing media with drug selection every week. After the one month, media were discarded 
and cells were washed with PBS and then stained with Leishman stain (sigma Aldrich) for 
around 15 minutes and then washed with water and allowed to dry at room temperature. 


















Analysing somatic mutations in the whole 
exome sequence and RNA sequence of 
five patients with Head and Neck cancer 
 
4.1 Introduction 
4.1.1 Developing a cancer tissue model for applying novel genomic DNA variant-calling 
software to identify mutations in human cancers 
The vast majority of studies that have been published for identifying mutations in DNA 
sequencing files from NGS use a version of MuTect, usually modified by bespoke code. This is 
not accessible to the vast majority of scientists. In parallel, and similar to next generation DNA 
sequencing technologies which have largely been commercialized, software applications with 
browser interfaces have also been developed by commercial groups. Thus, in a similar way to 
Illumina being the first to develop protocols for DNA sequencing, CLCbio have generated 
applications for interrogating DNA and RNAseq files. My lab has had access to beta versions 
of these programs and was one of the first to use them for both DNAseq and RNAseq analysis. 
This thesis presents how we developed and used this software and what we have learned 
from our analyses.  
Upon starting to develop our analysis of novel software for defining cancer-specific mutations, 
we focused on a selected set of cancer samples that are relatively homogeneous clinically, 
and from which we can obtain normal adjacent tissue as well as blood for defining truly “non-
tumour” DNA sequences. In addition, collaborators in the pathology field can guarantee 
follow-on validation. Most NGS studies use either only germline (blood) or normal adjacent 
tissue as the source of “non-tumour DNA”. This approach is relatively controversial; as normal 
adjacent tissue might have “field” mutations. Thus, these papers do not address true 
mutations that are different from germline (if normal adjacent tissue is used), or they do not 
define true tumour mutations (if normal blood is used) as normal adjacent tissue might have 
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seed mutations not linked to the cancer itself. This is especially important due to the concept 
of cancer field cancerization. Head and neck cancer (HNC) was our chosen tissue to begin our 
analysis. The clinical group chosen is also emerging as a new focus area, so the clinical 
questions are novel.  
4.1.2 Head and Neck Cancer (HNC) 
HNC is a heterogeneous disease that can involve multiple sites within the head and neck 
region, such as the paranasal sinuses, nasal cavity, oral cavity, pharynx, salivary glands and 
the thyroid [44]. HNC remains a major medical problem with high morbidity, mortality and 
quality of life issues with a 5-year survival of less than 50%. Patients are often diagnosed at 
advanced stages with serious lymph node metastasis. The HNC is the fifth most common 
cancer type in the world, with approximately 550,000 new cases of HNC diagnosed annually 
worldwide [45]. Tumours of the head and neck have different incidences, mortalities and 
prognoses in different parts of the world; for example, in India, it is the most common cancer, 
accounting for 40% of all malignancies [46]. Head and neck squamous cell carcinoma (HNSCC) 
comprises the great majority of HNC cases. With more than half a million cases diagnosed 
every year, HNSCC is the sixth most common cancer in the world [47].  
4.1.3 HNC Risk Factors 
Environmental risk factors, namely tobacco use and alcohol consumption, are the most 
common causes of HNC, which work synergistically, and are responsible for 70–75% of cases 
[48]. Recently, infection with the human papilloma virus (HPV) has been shown to promote 
HNSCC and causes cancer. In some parts of Asia, betel-quid chewing has been shown to play 
a role in the development of HNC [48]. On the molecular level, HNCs often have p53 
mutations and many display chromosomal instability. The average age of patients affected 
with HNC is 63 years; two thirds of these patients are men [49]. 
4.1.4 HNC in young patients 
HNC is traditionally considered to arise in older members of the population; however, during 
recent years, an increasing incidence of HNC among young adults has been reported. Reports 
indicate an increase in tumours affecting the tongue and oropharynx among young adults in 
India, Europe, the USA and China [45]. The growing incidence of HNC in younger patients 
could be partially explained by a shift in social behaviours and the role of genetics contributing 
to the development of these tumours. Some authors have proposed that HNC in young 
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patients might be more related genetic predisposition or HPV infection, compared to HNC in 
older patients who have had longer exposure to the major risk factors, mainly tobacco and 
alcohol consumption[45]. 
4.1.5 Symptoms of HNC 
Symptoms of the HNC vary, depending on the site of origin. The five most frequently reported 
symptoms are: weight loss, pain, feeding difficulties, dysphagia, and cough. It has also been 
reported that more than one third of HNC patients develop psychological problems [49]. 
4.1.6 Treatment Options 
Treatment of HNC is challenging because of the diversity of the anatomic sites in the head 
and neck and the critical normal structures around the tumour site, which can result in 
impairment of vital functions including; breathing, hearing, swallowing, taste and smell [4]. 
Treatment options for HNC can be definitive surgical resection, chemotherapy, or a 
combination of both procedures, and radiation therapy. Progress in molecular targeting of 
HNC has found that cetuximab, an anti-EGFR monoclonal antibody, can benefit patients when 
it is combined with chemotherapy or radiation [50]. Only a small number of patients have 
benefitted from the current targeted treatments due to development of drug resistance 
causing decreased efficacy with long-term treatment. Despite the availability of these 
aggressive treatments, the 5-year survival rate of for HNC remains relatively poor at 65%, and 
many patients still develop recurrent tumours and distant metastasis [48]. Therefore, the 
identification of new therapeutic targets is necessary. 
4.1.7 Genetics of HNC 
An understanding of the molecular and genetic abnormalities that play roles in oncogenesis 
of HNC has increased in the past few years due to the development of new methods that 
allow researchers to study the genome. The development of microarray technology has 
enabled classification of HNC into distinct types based on gene expression. More recently, the 
development of NGS has enabled researchers to sequence the whole genome, or whole 
exome, of a large number of tumours, leading to identification of novel mutations in tumour 
suppressor genes and oncogenes which can guide to the development of new therapeutics 
[48]. 
The studies performed by Stransky et al.[51] and Agrawal et al. [4] in 2011 were the first to 
sequence the whole exome of HNSCC using NGS. Stransky et al. analysed the whole-exome 
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sequence from 74 tumours and their matched normal tissues, and Agrawal et al performed 
the analysis from 34 tumour–normal pairs. Both studies reported that the number of 
mutations was higher in tumours from patients who smoked than from those who did not 
smoke. They also found that HPV-negative tumours had higher mutation rate than did HPV-
positive tumours, and the difference was independent of patients’ smoking status. Both 
studies reported that the TP53 gene had the highest number of mutations in HPV-negative 
tumours, and frequent mutations in cyclin-dependent kinase inhibitor 2A (CDKN2A), 
phosphatidylinositol-4.5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA), and Notch 
homolog 1 translocation-associated (Notch1). 
There is a type of HNC emerging in which very young people who have no apparent exposure 
to alcohol, smoking, or HPV are developing the disease. We thus focused on this group and 
we were provided with whole exome sequences of genomic DNA derived from the tumours, 
normal adjacent tissue, and blood, as well as whole tumour RNA, from five HNC patients 
(clinical features shown in table 4.1). We analysed them using the novel software (CLC-bio), 
which allows us to assemble fastq files containing next generation DNA or RNA sequencing 
data to detect tumour specific somatic variants. 
No. Gender Age at 
diagnosis 
Localisation Status Follow-up 
time 







< 2 years 















> 2 years 







< 2 years 







< 1 year 
                   Table 4.1. Clinical information of the five head and neck cancer patients.                                       








In our research we have analysed the whole exome DNA sequencing of tumours, normal 
adjacent tissues, and germline blood from five HNC patients (82, 98, 111, 119, 137) using the 
CLC Biomedical Genomic Workbench 2.5. Two patients (119 and 137) were old, and the other 
three are young patients with no smoking or alcohol history, and were negative for HPV 
infection. Four patients (no RNA for 82) have had their tumours RNA sequenced and 
compared to the tumour DNA sequence to look for expressed mutations in the tumours.  It is 
appreciated that with such small numbers, the results will not be necessarily clinically robust 
on predicting risk factors for why young people are acquiring HNC, but the dataset allows us 
to (i) apply novel software and (ii) determine whether blood (germline) or normal adjacent 
tissue (not necessarily germline) provides the best source of a “normal” reference genome.  
4.2.1 DNAseq analysis 
For all patients, the DNA sequence was provided from the tumour, normal adjacent tissue 
(which is 7–10 cm distant from the tumour), and blood (except in patient 82 the sequence 
was derived from the tumour and blood only). The total RNA sequences from the tumour 
samples of four patients (98, 111, 119 and 137) were provided. Clinical samples were lysed 
using commercially available kits to acquire DNA and RNA. These samples were used by a 
commercial sequencing facility and processed using an Illumina sequencing platform. For the 
tumour samples the HiSeq2500 PE100-125 kit was used to sequence the whole exomes from 
gDNA, paired-end 2x100-125 or PE100-125 (read length). The estimated average on-target 
coverage is 100x. For the normal adjacent tissues and blood, the HiSeq2000/2500 PE100 kit 
was used, paired-end 2x100 or PE100 (read length). The estimated average on-target 
coverage is 30x. The HiSeq2500 system uses sequencing by synthesis (SBS) technology. The 
SBS technology supports massively parallel sequencing using a proprietary fluorescently 
labelled reversible terminator method that enables detection of single bases as they are 
incorporated into growing DNA strands. A fluorescently-labelled terminator is imaged as each 
dNTP is added and then cleaved to allow incorporation of the next base. Since all four 
reversible terminator-bound dNTPs are present during each sequencing cycle, natural 
competition minimizes incorporation bias. SBS technology supports both single read and 
paired-end libraries. 
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The DNA and RNA sequences of these patients were imported as fastq files and analysed in 
the CLC biomedical workbench 2.5. Below I will review the general workflow of this 
application, since it is the first robust software tool that does not require coding to generate 
outputs. The tool ‘identify somatic variants from tumour normal pair (whole exome sequence) 
ready to use workflow’ was used to identify potential somatic variants in tumour samples by 
using the blood as a control sample. The analysis steps in the software options were 












STEP1; The Identify Somatic Variants from Tumour Normal Pair (WES) ready-to-use workflow is used to identify potential somatic variants in 
the tumour sample when we have a normal/control sample from the same patient (fig 4.1). 
 
 
Figure 4.1. Identification of somatic mutations from tumour-normal pair. From the toolbox options; the ready to use workflow was chosen; then from the five options; 
whole exome sequencing was chosen; then somatic cancer; then identify somatic variants from tumour normal pair. Identify Somatic Variants from Tumour Normal Pair: 
Removes germline variants by referring to the control sample read mapping, removes variants outside the target region (outside exomes), and annotates the output files 







STEP 2; The paired-end tumour sequencing reads (previously imported from fastq files, 
named below as “index26” were selected from the navigation area as shown in figure 4.2. 
Figure 4.2. The tumour reads from each paired-end read were selected. Samples are in patient 111 file (as in 
folder in the left column). The index26 represents the tumour WES. On the right side of the table, it highlights the 
selected DNAseq files from the paired-end sequencing (R1 and R2). This information is then transferred to the 











STEP 3; the paired-end normal sequencing reads (previously imported from fastq files, 
named below as “index22…”); the normal sequencing reads were selected as in figure 4.3. 
Figure 4.3. The normal reads were selected. Samples are in patient 111 file (as in folder in the left column). The 
index22 represents the normal WES. On the right side of the table, it highlights the selected DNAseq files from 
the paired-end sequencing (R1 and R2). This information is then transferred to the next step of the work flow: 











STEP 4; The targeted region file was added (figure 4.4), which is the file that specifies which 
regions have been sequenced using the Illumina exome sequencing primers, when working 
with whole exome sequencing data.  
Figure 4.4. Addition of a target region. A file with the genomic regions targeted by hybridization kit is available 













STEP 5; The parameters for minimum coverage, minimum count and minimum frequency for 
the detected mutation, could be changed as shown in figure 4.5. These are the parameters 
that are usually altered if computer coding is used in standard open source software. The CLC-
bio software provides an interface that allows manual alterations in these parameters 
without knowledge of computer code. We had chosen the minimum coverage to be 5, so only 
variants in this region covered by at least 5 reads were called. We set the minimum count to 
2, so only variants that were present in at least 2 reads were called. The minimum frequency 
(count/coverage) was set to 5, so only variants that were present in at least 5% frequency 
were called.  
 
Figure 4.5. Set the parameters for the analysis. The parameters for the variant detected are adjustable. The 
minimum coverage of any variant detected will be 5 reads in the tumour, and the minimum counts are 2, and the 




STEP 6 – The aim of this step is to define only tumour-specific variants (mutations) only, so 
the parameter selected is ‘keep variants with control reads below’ 1, (figure 4.6). This means 
any variant that presents in at least one read in the control would not be called. 
Figure 4.6. Adjust the settings for removal of germline variants step. Keep variants with control read count 












STEP 7- In the next step of the work-flow, the same target region for the normal sequencing 
is chosen as in the tumour; to make sure there are enough sequencing reads in the normal 
sample at the mutation site, we set the minimum coverage to be 5 in the normal reads (figure 
4.7). 













STEP 8- Save the file (fig 4.8) and the computational analysis has initiated. 
Figure 4.8. Check the parameters and save the results. 
 
4.2.2 Analysis summary 
When the workflow was run, the DNA sequencing reads were mapped and the variants 
(mutants) identified. An internal workflow removed germline variants that were found in the 
mapped reads of the control sample, and variants outside the target region were removed as 
they were likely to be false positives due to non-specific mapping of sequencing reads. The 
remaining variants were then annotated with gene names, amino acid changes, and 
information from clinically relevant databases like ClinVar (variants with clinically relevant 
association). 
 The analysis results in an output table with all the detected variants and their details, and 
genome browser as shown in figure 4.9. If any variant were selected from the table, it would 
appear on the browser, which shows the tumour reads with the mutation, and the normal 
reads, and the amino acid change. The sequencing reads are shown in different colours 
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depending on their orientation, whether they are single reads or paired reads, as explained 
below: 
- The colour of the consensus and reference sequence. Black per default.  
- Forward: The colour of forward reads (single reads). Green per default.  
- Reverse: The colour of reverse reads (single reads). Red per default.  
- Paired: The colour of paired reads. Blue per default, in this case, because the original 
fastq files were not imported together as paired-end reads, then only individual 
strands are analysed and there is no fusion to produce paired-end reads (blue).  The 
choice to not use pair-end read import allows visual analysis of each read (forward or 
reverse) for examination.  
Figure 4.9. The results of the analysis. The table shows all the variants detected with many details of each variant 
such as the chromosome number, the region and type of the variant, the count, coverage, frequency, control 
coverage, gene name and amino acid change. The file above the table shows the normal and the tumour reads. 
When any variant is selected, it will appear on the reads above. The selected variant shows that there is a 
mutation from A to G, which changed the amino acid from Q to R. 
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4.2.3 Defining the number of non-synonymous mutations and types of mutations by 
comparing tumour to blood (germline) 
We were interested primarily in defining in non-synonymous mutations only the variants 
detected towards identifying functional mutated protein drivers. Table 4.2 shows the number 
of the somatic non-synonymous mutations detected in each patient, and the type of these 
mutations. Young patients have less than half the number of mutations detected in older 
patients, except for patient 98, who had a high number of mutations, similar to that seen in 
the older patients. These mutations were in a very large number of genes. For each variant 
detected, the table produced by analysis gives all the information, including the count, the 
coverage, frequency, chromosome number, region, gene name, and amino acid change. By 
using the chromosome number and the variant region, the variant could be viewed in the 
browser as shown in figure 4.10, highlighting some mutations in patient 82. 
 
 
Sample No. of Non-
synonymous 
mutations 
No. of SNV No. of MNV No. of Indel No. of 
replacement 
82 3460 3110 57 288 5 
98 7467 6829 71 559 8 
111 3302 2943 71 286 2 
119 10853 9765 107 975 6 
137 8273 7522 63 682 6 
Table 4.2. Number of non-synonymous mutations in each patient, and their types. SNV: single nucleotide 
variant. MNV: multiple nucleotides variant. Indel: insertion and deletion. Replacement when a number of bases 




Figure 4.10. A genome browser view of the sequencing reads in the indicated genes. CDKN2A, TP53, and CASP9 
mutations in patient 82. The above reads are the normal reads (from blood) and the lower reads are the tumour 
reads. The amino acid sequence of the protein is shown above, with the amino acid changed at the mutation site 


















4.2.4 Defining the mutation signature by comparing tumour to blood (germline) 
Somatic mutations are a major cause of cancer development. Each of these mutations was 
caused by the activity of endogenous and/or exogenous mutational processes with different 
strengths. Understanding the mutational mechanisms in cancer can yield further insights both 
into the biology of cancer cells, and of cellular processes in general regulating DNA damage 
and repair. 
In lung cancer, tobacco smokers have on average a 10-fold increase in the burden of somatic 
mutations in their genomes compared to non-smokers. This is mainly due to the increase in 
the number of C>A transversions, which is consistent with the experimental evidence for 
tobacco carcinogens [27]. In glioblastoma, it was demonstrated that treatment with an 
alkylating agent, such as temozolomide, significantly elevates the number of somatic 
mutations and results in a distinct mutational pattern of C>T transitions [27]. We wished to 
define mutation spectra in our head and neck samples to see what type of mutation signature 
they have, and whether there are any differences between the old and young patients. When 
we looked at the types of mutations of the SNVs, all five patients have the same type of 
mutations, with C>A or G>T being the highest number, then C>T or G>A, as shown in figure 





Figure 4.11. The number of each mutation type of single nucleotide variants (SNVs) in all the five patients. All 













4.2.5 Defining the commonly mutated genes 
The number of genes detected in each patient is very high. In order to lower this number; we 
have applied some cut-offs to increase stringency. Genes that were detected in at least two 
patients and had mutations with ≥ 15% frequency (count/coverage) have been chosen for 
discussion (table 4.3).  
Number  Young patients Old patients 
1 Gene name 82 98 111 119 137 
2 RARRES1, MFSD1, RP11-
379F4.4 
√ √    
3 SRRD √ √ √  √ 
4 SHROOM4 √ √ √ √  
5 TNRC18 √ √ √  √ 
6 ANKLE1 √ √ √  √ 
7 EP400 √ √  √ √ 
8 MUC5B √ √ √ √  
9 MMP23B √ √  √  
10 MUC4 √ √ √ √ √ 
11 NBPF1 √ √ √   
12 PKD1 √ √    
13 MACROD1 √ √    
14 ENTPD1 √ √   √ 
15 RP11-1055B8.7 √ √    
16 LOR √ √    
17 GOLGA6L2 √ √ √ √ √ 
18 KRTAP4-7 √  √  √ 
19 RP11-458D21.5, NBPF10 √  √ √  
20 MESP2 √  √  √ 
21 FXN √  √ √  
22 NBPF20 √  √   
23 KRTAP4-11 √  √ √ √ 
24 MAML2  √ √  √ 
25 TPRXL  √ √   
26 CRIPAK  √ √ √ √ 
27 KRTAP10-10  √ √ √  
28 KIAA0430  √ √   
29 ADAM12  √ √   
30 POLRMT  √ √   
31 PCDHB2  √ √   
32 TPRX2P  √ √  √ 
33 GSPT1    √ √ 
34 DHFR, MSH3    √ √ 
35 SELO    √ √ 
36 ENAH    √ √ 
37 GOLGA8B  √  √ √ 
38 UGT2A1    √ √ 
39 FAM194B √   √ √ 
40 DSPP  √  √ √ 
41 LRP2    √ √ 
42 HERC2    √ √ 
43 MUC12 √   √ √ 
44 BRWD1    √ √ 
45 MCC    √ √ 
46 KRTAP4-11 √   √ √ 
47 RP11-683L23.1 √   √ √ 
48 SPINT2, CTB-102L5.4    √ √ 
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49 TP53 √   √ √ 
50 RAB36 √   √  
51 KRT10 √   √  
52 DACT3 √   √  
53 COMTD1 √   √  
54 CD163L1 √   √  
55 GAREML √   √  
56 KRTAP4-5 √   √  
57 FOXC2 √   √  
58 KRTAP10-4 √   √  
59 EVI5L √   √  
60 COMMD1 √   √  
61 C2CD4A √   √  
62 ZFPM1 √   √  
63 CASP9 √    √ 
64 KRTAP4-8 √    √ 
65 CDKN2A √    √ 
66 TNRC6A √    √ 
67 C10orf71 √    √ 
68 KIF11 √    √ 
69 WDR7 √    √ 
70 MICALL1 √    √ 
71 ATXN2 √    √ 
72 TUBB8P7 √    √ 
73 HCN2 √    √ 
74 KCNN3  √  √  
75 RP11-108K14.8, PAOX  √  √  
76 KBTBD11  √  √  
77 KRTAP9-4  √  √  
78 BARX1  √  √  
79 GLTSCR1  √  √  
80 KRTAP5-AS1, KRTAP5-2  √  √  
81 VPS37D  √  √  
82 C9orf172  √  √  
83 TRIO  √  √  
84 GAS1  √  √  
85 RPL14  √  √  
86 PRB4  √  √  
87 RP1L1  √   √ 
88 KRTAP10-2  √   √ 
89 FAM46A  √   √ 
90 FLG  √   √ 
91 CNTNAP3  √   √ 
92 SCAF1  √   √ 
93 PPP2R3B  √   √ 
94 EMILIN3  √   √ 
95 SSUH2  √   √ 
96 CACNA1I  √   √ 
97 GP1BA  √   √ 
98 KRT1   √ √  
99 AGAP5, RP11-464F9.1   √ √  
100 CTBP2   √ √  
101 C20orf194   √ √  
102 GPLD1, ALDH5A1   √ √  
103 AC090616.2   √ √  
104 TPSB2   √ √  
105 CDC42EP1   √  √ 
106 NUTM2F   √  √ 
107 CROCC   √  √ 
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108 SPANXD   √  √ 
109 KIAA0040   √  √ 
110 TMEM52   √  √ 
Table 4.3. A list of genes detected with somatic mutations in at least two patients and ≥ 15% 
mutation frequency (count / coverage). 
 
4.2.6 Identifying expressed mutations by comparing the tumour RNA to the tumour 
DNA 
One problem with using genetic maps to identify drug targets is that there is no guarantee 
that the mutant gene is expressed at the time of disease presentation. DNA sequencing can 
identify thousands of genomic variants in a single cancer genome, and even more if the 
sample is highly heterogeneous. Therefore distinguishing a genomic variant that causes a 
selective growth or survival advantage to the tumour is a challenging task [52]. The detected 
somatic variant frequently occurs on a single allele. The impact of a heterozygous mutation 
will depend on whether the mutation-containing allele is transcribed to RNA. The mutation 
detected in the genomic DNA may not be transcribed into RNA if the wild-type allele is 
selectively transcribed. Furthermore, the mutation-containing transcript could activate RNA 
surveillance mechanisms and cause rapid degradation of the mutation-containing transcript. 
Nonsense-mediated decay (NMD) surveillance, for example, scans transcripts for the 
presence of a premature termination codons before the last exon and, when found, initiates 
degradation of such transcripts [53]. Therefore, defining “active” somatic genome mutations 
using RNAseq is very important for judging if the DNA mutation is expressed and/or 
advantageous to tumour development, or not, at the time of disease presentation.  
To define for the expressed genomic mutations, we have compared the variants between the 
tumour DNA and the RNA. The tumour RNA sequence was compared to the tumour DNA 
sequence in each patient (98, 111, 119, and 137) to detect the common mutations in DNA 
and RNA (expressed mutations). In order to detect all the expressed somatic mutations, we 
have set the parameters of coverage and count of the mutation in the RNAseq to 1. A large 
number of mutations were detected. Then, we removed all the germline variants found in 
normal control (blood), as we only interested in the expressed somatic mutations. The steps 
in comparing the variants in DNA and RNA and detection of expressed somatic mutations are 
shown below in figures 4.12 to 4.16. 
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Step 1; the icon was chosen that runs “Compare variants in DNA and RNA” ready-to-use 
workflow to start the analysis as shown in figure 4.12. 
Figure 4.12. Defining variants in DNA and RNA. The following steps were taken; Toolbox →Ready to use 
workflows →Whole Transcriptome Sequencing →Human →Compare variants in DNA and RNA. The Compare 
variants in DNA and RNA ready-to-use workflow identifies variants in DNA and RNA and studies the relationship 






STEP 2; After selection of the tumour DNA reads and tumour RNA reads, the parameters were 
set as shown in figure 4.13. We have set the minimum coverage, count and frequency to 1, 
because RNA read coverage is not necessarily very high, as shown in figure 4.13 below. 
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Figure 4.13. Set the parameters for the Low Frequency Variant Detection step for the RNA sample. Minimum 






















STEP 3- The samples were filtered against sequencing files that subtract known germline 
variants in certain populations (fig 4.14).  
Figure 4.14. Specify the relevant 1000 Genomes population for the RNA sample. Choose the population that 
best matches the population the samples are derived from. The European samples have been chosen, as all our 










STEP 4; The analysis has detected many common mutations in tumour DNA and tumour RNA. 
Many of these mutations were germline (found in blood). So, in order to get the somatic 
variants only, we removed all the germline variants that were found in blood as shown in 
figures 4.15 and 4.16 below: 
Figure 4.15. Removing germline variants from the expressed mutations which were common in tumour DNA 
and tumour RNA. Toolbox → Remove Variants →Remove Germline Variants. 
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Figure 4.16. Select the normal reads (blood) for each patient to remove the germline variants found in them. 
Keep variants with control read count below 1, so any variant in at least one read in germline reads would be 













In this workflow, we have removed all the germline variants found in blood, and we are left 
with expressed somatic mutations specific to the tumour. The number of the expressed 
somatic mutations in each patient is very low compared to the number of somatic mutations 
detected in the tumour DNA. This could be due to the low quality of the RNA reads and/or 
very low coverage compared to the DNA reads as shown in figure 4.17 below, which shows 
variants with high coverage in tumour DNA but very low coverage in the tumour RNA. 
Previous studies [54] have shown that only 36% of validated somatic SNVs were observed in 
the transcriptome sequence when RNAseq data compared with the genomes/exomes data in 
breast cancer. Similar proportions were also observed in a lymphoma study in which 137 
somatic mutations were expressed in RNAseq, out of 329 total somatic mutations [54]. Many 
variants had been missed because there were no reads in the RNA at the position of the 
variants. Alternatively, these mutant genes might not be expressed at the time of surgery and 
resection.  
Detected expressed somatic non-synonymous mutations are listed in table 4.4 below with a 




















No. Patient 98 Patient 111 Patient 119 Patient 137 
 Gene name Mutation Gene name Mutation Gene name Mutation Gene 
name 
Mutation 
1 COL4A1 19G>C XAF1 396C>G HADHB 3_4insACT TAF1B 187delA 
2 USP36 2874_2879delGAAAAA UBXN11 1114G>A IMMT 883C>A IGKV1-17 97C>A 
3 SRRD 106G>C TRBV10-2 136_137delTGinsGA NOP58 1562A>G TXNDC9 *293-1370C>A 
4 NBPF1 3145G>A TRBV10-2 140G>A TMEM39A *753G>T TTC29 1232T>C 
5 HLA-DQA2 45_46delTGinsCA CTBP2 20A>G HLA-DRB1 730G>A MEF2C 410C>A 
6 POTEF 2392C>A CTBP2 22A>T HLA-DRB1 629_630delCAinsTG ALDH7A1 895G>T 
7 HLA-B 363C>G HLA-C 621A>C CCL26 61G>T HLA-DRB1 317C>A 
8 MAN2B2 1330A>G TRBV10-2 145A>C KMT2E 1299A>G TRAF3IP2 1613delA 
9 HLA-C 176G>A HLA-DQB1 755G>A DDHD2 1982A>T CALU 298G>A 
10 HLA-DRB5 74C>G MMS19 262+651G>A TATDN1 70G>T KCTD9 866C>A 
11 EGFL6 143C>A PTHLH 524+1383delA NRAP 445G>A WHSC1L1 1626G>T 
12 HLA-DRB5 84G>C ABCF1 218delA SLC2A3 272G>A CDKN2A 215C>T 
13 PIGT 1037delC TRBV10-2 155T>A LDHB 830T>A CARD17 7+2028A>G 
14 ASCC2 541+332G>A FRG1 3_4insAGA LRP1 4219G>A CARD17 7+2014C>A 
15 CEP95 1225G>T MYD88 473C>A OASL 615G>T B4GALNT1 672_675delTTAC 
16 TBC1D2B 485C>A TMEM43, 
RP11-
434D12.1 
797G>A IGHG4 704A>G FGD6 522A>C 
17 LARP7 1770delA FAM104A 431_433delGCA RPL13 398delC OAS1 902C>A 
18 TAF1B 186_187insA SLC30A5 206G>T YWHAE 562C>A POSTN 278delC 
19 ZRANB1 2126_2127insA RPN2 *84delA ZNF257 266G>A PNN 91G>A 
20   CAMKK2 *174_*175insA LTN1 952C>T IGHV4-61 104A>G 
21   HLA-C 299T>A IGLV6-57 398G>T UACA 93G>C 
22   IGHV4OR15-8 232A>T PDZD11 65C>A ZNF720 *5136_*5137insA 
23   HMGXB4 *999delA FHL1 226G>T TP53 535C>T 
24   ARHGEF37 1810A>G FGF13 704G>T CCL13 58C>T 
25   PTK2B 2983G>A   SOCS7 110C>A 
26       GAREM 1373T>C 
27       KIF16B 481C>G 
28       APOBEC3A 443delC 
Table 4.4. Expressed somatic non-synonymous mutations in patients 98, 111, 119, and 137, with the gene names. Coding region change shown above is in the longest 






Figure 4.17. Examples of expressed somatic mutations in TP53 and CDKN2A in patient 137 and COL17A1 in patient 111. The variants had high coverage in the tumour 
DNA reads, but very low coverage in the tumour RNA reads. The reference human genome Hg19 is shown at the top of the image.
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4.2.7 Comparing normal adjacent tissue to blood 
4.2.7.1 Number of mutations in normal adjacent tissue compared to tumour tissue 
We next compared the DNA mutation landscape in normal tissue versus blood (germline) to 
determine whether field mutations are dominating. The field cancerization is defined as ‘the 
presence of one or more areas consisting of epithelial cells that have genetic alterations and 
does not show invasive growth and metastatic behaviour, the hallmark criteria of cancer’[55]. 
The reads from the normal adjacent tissue have been compared to the blood reads (in the 
same way as tumour to blood). The number of non-synonymous mutations detected in the 
normal adjacent tissue is very much higher than that detected in the tumour from each 





Sample No. of Non-
synonymous 
mutations in 





tissue v Blood 
98 7467 34558 
111 3302 19879 
119 10853 24115 
137 8273 25652 
Table 4.5. The number of non-synonymous mutations detected in the tumour and normal adjacent 

















4.2.7.2 Mutation signature in the normal adjacent tissue 
The mutation type of SNVs in the normal adjacent tissue is similar between the four patients 
and is exactly the same as in the tumour from each patient, as shown in figure 4.18 below, 
with the C>A or G>T the highest number. 























4.2.7.3 Common mutations in tumour and normal adjacent tissue 
In order to define ‘true’ cancer mutations, we need to make sure that the mutations detected 
in the tumour tissue are specific to tumour tissue only. Since we have a high number of field 
mutations, if we compare tumour vs blood we do not define “true” cancer-specific mutations. 
As such, we next compared cancer vs “normal” adjacent tissue. This “normal” tissue has a 
large number of mutations vs germline. This could be due to evolution of a pre-tumour, or it 
could be that, as we age, “all” of our normal tissue accumulates mutations. As we do not have 
any other “normal” squamous tissue (from oral mucosa or skin) for comparison we cannot 
say why the “normal” adjacent tissue has a high number of mutations. However, we believe 
that a better definition of “true” tumour mutations is a comparison of tumour with “normal” 
tissue, not “tumour” with blood (germline)”. The tumour in each patient shares some 
mutations with the normal adjacent tissue as shown in figure 4.19 below. These common 
mutations are listed in the supplementary file. There were some genes in common between 
the four samples (98,111, 119 and 137) in this list. Table 4.6 below shows genes that were 
detected in at least two patients, which had same mutation in the tumour and normal 
adjacent tissue in a patient. 
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Figure 4.19. Venn diagram showing the numbers of non-synonymous mutations detected in the tumour and 




















Sample Mutation Amino acid change 





119 205_206delCG Arg69fs 
137 487G>C Asp163His 






























































































8 FAM86C1 98 385T>C Cys129Arg 
119 411+49A>G Thr120Ala 
9 MUC3A 98 799A>T Asn267Tyr 





10 ANKLE1 111 *96_*109delGTGTGTGTG
TGTGT 
Cys586fs 
119 *139_*140delTT Leu591fs 






119 1045delG Gly349fs 

















137 1680T>A Ser560Arg 





































16 MUC5B 111 9569G>A Arg3190Gln 
119 6059C>T Ala2020Val 
17 NBPF1 111 2037C>A Asp679Glu 
119 2077G>T Gly693Trp 
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18 CT47B1 111 319G>T Asp107Tyr 
119 306G>T Glu102Asp 




20 USP15 98 454delG Glu152fs 
137 450G>T Arg150Ser 
21 SRRD 111 106G>C Gly36Arg 
137 106G>C Gly36Arg 
























24 KIR2DL4 119 35-4404_35-
4403delGCinsCG 
Ala236Arg 
137 35-12466A>G Met118Val 
25 AHNAK2 119 6014G>A Arg2005Lys 
137 4105G>T Gly1369Trp 
26 KIF25 119 778C>A Gln260Lys 
137 83A>T Lys28Met 
 
Table 4.6. Genes detected in more than one patient that had the same variant in tumour and normal adjacent 




4.2.8 Copy number variation detection 
SNVs are the most widely studied form of genetic variation in cancers, and there are many 
reports of SNVs associated with risk of developing a variety of cancers, though their 
contributions to modification of cancer risk are generally small [56]. Besides SNVs, copy 
number variations (CNVs) are now considered an important form of genetic variation, and it 
has been reported that certain CNVs affect cancer susceptibility in individuals [56]. Recent 
genome-wide studies have shed light on CNVs: an unexpectedly frequent, dynamic and 
complex form of genetic diversity [57]. CNVs are generally identified as being inherited or de 
novo deletions or duplications of the genome ranging in size from 100bp to 3Mb, which may 
lead to changes in gene dosage and/or expression [58]. The CLC Biomedical Cancer 
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workbench allows us to detect CNVs in tumour sample by comparing the tumour reads to the 
normal tissue reads of the same patient. We have compared each of the HNC tumours to the 
blood reads of each patient in order to detect CNVs and study genome stability in the five 
patients. 
The copy number variant detection tool in the CLC workbench is designed to detect CNVs 
from targeted re-sequencing experiments. The tool takes read mappings and target regions 
as input, and produces amplification and deletion annotations. The annotations are 
generated by a ‘depth-of-coverage’ method, where the target-level coverages of the case and 





























4.2.8.1 Running the Copy Number Variant Detection tool 
To start the CNV detection tool, re-sequencing analysis was chosen from the toolbox and then 
the copy number variant detection was selected as shown in figure 4.20. 
 
Figure 4.20. Running the Copy Number Variant Detection tool. From the Toolbox; the Resequencing Analysis 












Then the case read mapping, which is the tumour read in our experiment, has been selected 
as shown in figure 4.21.  
 
Figure 4.21. Selection of Read mappings. In this example; the index 24 reads were selected which is the tumour 
reads of the patient 82. 
At the next step another browser, as shown in figure 4.22, enables us to choose the input and 
reference parameters. Target regions track, which is an annotation track containing the 
regions targeted in the experiment, was chosen. This track must not contain overlapping 
regions, or regions made up of several intervals, because the algorithm is designed to operate 
on simple genomic regions. Control mapping read was selected, which will be used to create 
a baseline by the algorithm. For the best results, the controls should be matched with respect 
to the most important experimental parameters, such as gender and technology. In our case, 
we have selected the normal blood reads as control read mapping. Gene track, which will be 
used to produce gene-level output as well as CNV-level output, was selected. Ignore non-
specific matches: If checked, the algorithm will ignore any non-specifically mapped reads 
when counting the coverage in the targeted positions. Ignore broken pairs: If checked, the 






Figure 4.22. Input and reference parameters. Target regions track, which is an annotation track containing the 
regions targeted in the experiment, was chosen. Control mapping read, index 19 is the normal blood reads for 
patient 82, and Gene track were selected. 
 
Click Next to set the parameters related to the target-level and region-level CNV detection, 
as shown in figure 4.23. P-values lower than the threshold for significance will be considered 
"significant". The higher this value, the more CNVs will be predicted. In the Minimum fold 
change, absolute value, we had to specify the minimum fold change for a CNV call. If the 
absolute value of the fold change of a CNV is less than the value specified in this parameter, 
then the CNV will be filtered from the results. For example, if a minimum fold-change of 1.4 
is chosen, then the adjusted coverage of the CNV in the case sample must be either 1.4 times 
higher or 1.4 times lower than the coverage in the baseline for it to pass the filtering step. For 
the Low coverage cut-off: if the average coverage of a target is below this value, it will be 
considered "low coverage" and it will not be used to set up the statistical models, and p-values 
will not be calculated for it in the target-level CNV prediction. 
The graining level is used for the region-level CNV prediction. Coarser graining levels produce 
longer CNV calls and less noise, and the algorithm will run faster. However, smaller CNVs 
consisting of only a few targets may be missed at a coarser graining level. Intermediate: 
prefers CNVs consisting of an intermediate number of targets. The algorithm is most sensitive 
to CNVs spanning 5 or more targets. This is the recommended setting if you expect CNVs of 
intermediate size. Fine: prefers CNVs consisting of fewer targets. The algorithm is most 
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sensitive to CNVs spanning 3 or more targets. This is the recommended setting if you want to 
detect CNVs that span just a few targets, but the false positive rate may be increased. When 
finished with the settings, click Next to start the algorithm. 
 
Figure 4.23. The parameters related to the target-level and region-level CNV detection. The threshold for 
significance was set to 0.05, so any P-value lower than the threshold for significance will be considered 
"significant". The minimum fold change, absolute value was set 1.4, so the adjusted coverage of the CNV in the 
case sample must be either 1.4 times higher or 1.4 times lower than the coverage in the baseline, for it to pass 
the filtering step. The low coverage cut-off was set to 30, so if the average coverage of a target is below 30 it will 
be considered "low coverage" and it will not be used to set up the statistical models. From the Graining level: 








4.2.8.2 CNV results 
The CNV detection analysis detected small number of losses (deletions) in the young patients 
98 and 111, with 11 and 7 deletions respectively. There is no gain detected in both patients 
(fig 4.24). There is no common CNV in the two patients. 
There are more CNVs detected in the young patient 82 and the old patients 119 and 137 than 
the young patients 98 and 111. There are 27 losses and 27 gains in patient 82; 33 losses and 
5 gains in patient 119; and 13 losses and 11 gains in patient 137 (fig 4.25). There is no common 
CNV (exact gain or loss region) in these three patients. However, there are some overlapping 
regions of gains or losses between them: patient 82 shares an amplified region on 
chromosome 9 with patient 119, as shown in figure 4.25. Table 4.7 shows genes that are in 
these overlapping regions. 
The young patient 82 and the old patients, 119 and 137, all have p53 mutations, whereas in 
the young patients 98 and 111 there are no mutations detected in p53. This may explain why 
the old patients and patient 82 have more genomic instability and more CNVs than patients 















Number Chromosome Gene Patients Consequence 
1 9 RCL1 82, 119 Gain 
2 9 MIR101-2 82, 119 Gain 
3 9 RP11-125K10.5 82, 119 Gain 
4 9 JAK2 82, 119 Gain 
5 9 AL161450.1 82, 119 Gain 
6 9 INSL6 82, 119 Gain 
7 9 INSL4 82, 119 Gain 
8 9 RLN2 82, 119 Gain 
9 9 RLN1 82, 119 Gain 
10 9 PLGRKT 82, 119 Gain 
11 9 CD274 82, 119 Gain 
12 9 PDCD1LG2 82, 119 Gain 
13 9 KIAA1432 82, 119 Gain 
14 6 DEFB114 82, 137 Gain 
15 6 DEFB113 82, 137 Gain 
16 8 EFCAB1 82, 137 Gain 
17 8 SNAI2 82, 137 Gain 
18 8 C8orf22 82, 137 Gain 
19 8 RP11-738G5.2 82, 137 Gain 
20 8 SNTG1 82, 137 Gain 
21 18 CCDC178 119, 137 Loss 
Table 4.7. List of genes in the shared CNVs regions in patients 82, 119 and 137.
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Figure 4.24. A graph showing the mean adjusted log-ratios of coverages in the report produced by the Copy Number Variant Detection tool for patients 98 and 111 by 
comparing tumour reads of each patient to the normal blood reads of the same patient. A table beside the graph shows the number of CNVs detected in each patient. The 
CNVs are detected when the log-ratios of coverages of targets on the chromosomes are significantly higher or lower than for targets on other chromosomes. The black line 
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Figure 4.25. A graph showing the mean adjusted log-ratios of coverages in the report produced by the Copy Number Variant Detection tool for patients 82, 119, and 137 
by comparing tumour reads of each patient to the normal blood reads of the same patient. A table beside the graph shows the number of CNVs detected in each patient. 
The CNVs are detected when the log-ratios of coverages of targets on the chromosomes are significantly higher or lower than for targets on other chromosomes. The black 





4.3.1 Setting the parameters of the variant 
I have learned to set the parameters to detect variants that appear in at least two DNA 
sequencing reads in the tumour files, and at least 5 DNA sequencing reads (coverage) at the 
mutation site, to make sure it is a real variant and not a sequencing error variant. For the 
normal reads we have chosen 1 read at the beginning of the analysis, which resulted in many 
detected variants. DMKN gene was one of the genes detected in all five patients. It has a 51 
base deletion in the tumours of patients 98 and 111, and a 12 base insertion in patient 137, 
with the same deletion seen in the control (blood), but with a very low coverage of 4, 1, and 
2 respectively. We have designed primers to amplify the region that has the deletion and 
insertion to validate these indels. The PCR results (Fig 4.26) showed that the deletion found 
in tumours from patients 98 and 111 is also found in blood and in tumour adjacent tissue, as 
shown in figure 3.26 below, which means that it is a false positive variant, although it is 
reported in COSMIC as a somatic mutation (COSM69118), along with the insertion in patient 








Figure 4.26. Validation of detected mutations in DMKN gene by PCR. A, CLC browser shows the 
deletion in patient 111. B, PCR result shows the deletion in 98 and 111 patients in tumour (T), normal 
adjacent tissue (TF) and blood (B). The detected insertion in patient 137 is also in T, TF, and B. 
 
4.3.2 Factors affecting the number of mutations and mutation signature 
In young patients, the number of non-synonymous mutations is similar in the female patients 
82 and 111, whereas the male patient 98 has more than double the number found in each of 
the female patients. The older male patient 119 has a higher number of mutations than the 
female patient 137. As all of the patients in this study have no history of smoking or alcohol 
consumption and are negative for HPV infection the reason for men to have higher number 
of mutations than women is unknown. The old patients have a higher number of mutations 
than the young patients; this is not surprising, as the number of accumulated mutations is 
known to increase with age [59]. 
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All patients have the same types of mutation. They all show the highest frequency of C>A with 
C>T is the second highest. The C>A signature is observed in lung adenocarcinoma, squamous 
and small cell carcinoma, head and neck squamous, and liver cancer, most of which are 
believed to be caused by tobacco smoking [26]. All the patients in this study have no smoking 
history, so there must be another environmental or biological carcinogen causing this type of 
mutation in both young and old patients. Pickering, C. R., et al. 2014, found that the types of 
base changes observed in squamous cell carcinoma of the oral tongue (SCCOT) in young 
patients were similar to those observed in old patients despite the difference between the 
two groups in smoking history. They also found that smoking has a minor impact on the types 
of mutations in SCCOT. It was shown that the C>A type is common in hepatocellular cancers 
and this is believed to be associated with aflatoxin, a known carcinogen commonly found in 
food from South Africa and Asia [27]. 
All patients in this study were negative for HPV infection. The young age of the patients with 
no carcinogen exposure raises the possibility that a virus, either known or novel, could be the 
reason for cancer development [60]. However, Li, R., et al. (2015) failed to identify any 
potentially causative viruses, including HPV, in 19 tongue tumour samples through 
transcriptomic analysis using 3 separate approaches. They therefore suggested the “hit and 
run” hypothesis, which states that the oncogenic viruses can either integrate into the host 
cell genome or remain episomal at a particular point in the progression to cancer. The viral 
genome may be subsequently lost and become undetectable at the time of diagnosis. 
There is a diverse population of microorganisms in the oral cavity. Some of these 
microorganisms could also play a role in carcinogenesis. A number of microorganisms have 
already been associated with the development of oral cancer including species of 









4.3.3 Common mutated genes detected 
The CLC biomedical workbench analysis detected a very large number of genes with non-
synonymous mutations in each patient. This number was lowered to 109 genes after the cut-
off of 15% frequency (count/coverage) applied and specification that the gene must be 
detected in at least two patients. It is challenging to find out which of these mutated genes 
are driver genes. A driver gene is a gene which, when mutated, is responsible for the initiation 
or progression of a cancer, or a gene with a mutation that occurs more often than expected 
by chance [61]. Many of the mutations detected in the cancer genome, called passenger 
mutations, have no effect on the development of the cancer. These are attributed to the 
inherent instability of the cancer genome [61]. Beyond statistical significance, there are other 
factors to be considered when selecting driver mutations. These factors include whether the 
mutation is at a specific functional position of the gene, and whether the gene has been 
reported in any other cancer.  
Four genes out the 109 genes listed above; have been reported before as commonly mutated 
genes in HNC. TP53, CDKN2A and FLG were reported in head and neck squamous cell 
carcinoma [61]. HERC2 was reported in carcinoma of the oral tongue (OTSCC) [62]. 
When the genes in table 4.3 (109 genes with ≥ 15% frequency) were examined using the 
DAVID gene functional classification tool to see which genes were affected in different cancer 
pathways, five genes appeared in the chart as shown in figure 4.27. These genes were TP53, 
CASP9, CTBP2, MSH3, and p14 ARF and p16 INK4a that are encoded by CDKN2A gene. 
4.3.3.1 TP53 gene 
TP53 has been detected in three patients: 82 with three mutations, 119 with one mutation 
and 137 with two mutations (see additional file). TP53 is the most commonly mutated gene 
in head and neck cancers and is detected in approximately 50% of cases; this rate increases 
in HPV-negative cases to 70–80% [63]. HNC appears to be the most common p53 mutation-
carrying cancer type after ovarian cancer and lung squamous carcinoma [64]. TP53 mutations 
can occur throughout the entire gene but the majority of these mutations are missense 
mutations, causing single amino-acid substitutions in the DNA binding domain encoded by 
exons 5 to 9 [44, 63]. The gene codes for a tumour suppressor protein (p53) which plays a key 
role in the regulation of genes involved in the cell cycle and growth arrest, DNA repair and 
apoptosis (programmed cell death), thereby maintaining genomic stability [64]. When the 
 
107 
function of p53 is lost, these protective mechanisms are disabled, which leads to a higher 
propensity for the cell to accumulate and propagate genomic insults [63]. The p53 level is 
regulated by mouse double minute 2 (MDM2), an E3 ubiquitin protein ligase that binds to p53 
and causes its degradation [64]. MDM2 is inhibited by p14ARF, which is encoded by the 
CDKN2A gene, protecting p53 from degradation [64]. There is no therapeutic strategy being 
used to target tumours with p53 mutations because p53 is a tumour suppressor protein. 
However, some studies have examined delivery of functional p53 via gene therapy using an 
adenoviral vector [63]. 
4.3.3.2 CDKN2A gene 
The CDKN2A gene was detected in three patients: 82 and 137 with high frequency (41.63% 
and 32.29% respectively), and in 98 with low frequency (5.26%). CDKN2A encodes the 
proteins p14 ARF and p16 INK4a, which are generated by alternative splicing. The role of p14 
ARF is the protection of p53 as mentioned above. The p16 INK4a antagonises cyclin 
dependent kinases 4 and 6 (CDK4/6), resulting in blocking phosphorylation of the 
retinoblastoma protein pRb and, consequently, cell cycle progression [65]. Consistent with 
the CDKN2A role in the regulation of the p53 and pRb signalling pathways, which are required 
for the induction of apoptosis in response to a number of cellular stressors such as DNA 
damage, mutations in this gene are prevalent in cancers and play an important role in 
oncogenesis and tumour progression [65].  
4.3.3.3 CASP9 gene 
CASP9 was detected in two patients; 82 and 137. CASP9 has never been reported in HNC 
before, but other caspases have been reported, such as CASP8 [61]. Caspases are crucial for 
apoptosis, so their inactivation can lead to the persistence of mutated cells and promotion of 
tumorigenesis [66]. The reduced expression of proapoptotic caspases has been reported in 
different cancers, and specific mutations have been linked to various tumour types and stages 
of transformation [66]. It has been reported by [67] that the use of a specific inhibitor of 
CASP9 almost completely blocked apoptosis induced by cisplatin – one of the most effective 





4.3.3.4 MSH3 gene 
The MSH3 gene was detected in the two old patients: 119 and 137. It belongs to the DNA 
mismatch repair system family of proteins whose function is to correct base-base mispairs, 
introduced into the DNA during DNA synthesis, to maintain genomic stability [68]. It has been 
reported that MSH3-dificient mice develop late onset microsatellite instability-positive 
gastrointestinal cancer, suggesting that this deficiency can contribute to tumour initiation [68]. 
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Figure 4.27. A chart of the different genes involved in different cancer pathways made by the DAVID gene functional classification tool. The genes from our study 
involved in these pathways are marked by a red star.
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4.3.3.5 CTBP2 gene 
The mammalian C-terminal binding protein 2 (CTBP2) gene has been detected here in HNC for 
the first time. CTBP2 promotes cancer migration, invasion, and survival by acting as a 
transcriptional co-repressor of multiple tumour suppressor genes involved in pathways 
associated with tumourigenesis, including TGF-β and Wnt signalling pathways, and cell cycle 
regulators such as RB and MDM2 [69, 70]. Increased expression of CTBP2 was reported in 
tumours from patients with head and neck squamous cell cancers [71]. CTBP2 was also found 
overexpressed in tumours of colon, breast, and prostate, and this high expression was found to 
be associated with a poor prognosis in these patients [69, 72]. 
CTBP2 plays an important role in stimulation of cell migration by the RAC pathway via regulation 
of T-cell lymphoma invasion and metastasis 1 (Tiam1) protein, which is a guanine nucleotide 
exchanger factor (GEF) for RAC GTPase that plays a critical role in regulating cell adhesion, 
invasion, and migration, and has been directly implicated in the promotion of cancer progression 
and metastasis [69]. Tiam1 was detected as a transcriptional activation target of CTBP2 and the 
overexpression of CTBP2 increased Tiam1 expression, leading to increase cell migration [69]. 
It was reported by [73] that MDM2 represses p53 activity through the recruitment of CTBP2. They 
showed that this interaction between the MDM2 and CTBP2 has much greater effect on p53 
repression. 
CTBP2 appears also in the Notch signalling pathway as shown in figure 4.28 below. The Notch1 
gene was reported to be mutated in 12%–15% of tumours of HNSCC, and mutations were 
detected in other Notch family members in 3%–5% cases [74]. It was reported that reduced 
activity of the Notch signalling pathway is associated with the development of chronic 











Figure 4.28. A chart of genes involved in the NOTCH signalling pathway by the DAVID gene functional 
classification tool. Genes from our study are marked by red star. 
 
 
4.3.4 Field cancerization 
The normal adjacent tissue had many more mutations than the tumour in all patients, and there 
were small number of common mutations between the tumour and the normal adjacent tissue, 
which is compatible with the field cancerization theory. The process of carcinogenesis begins with 
a stem cell, which develops one or more genetic alterations. Subsequently a clone of genetically 
altered cells forms a patch. Figure 4.29 below shows the steps of the field development. The 
presence of a field with genetically altered cells appears to be a continuous risk factor for cancer 
as cancer can develop from such a field that is left behind in the patient after surgery [75]. The 
oral cavity was proven to be most susceptible to field formation, as it is exposed to a wide range 
of environmental carcinogens which affect the entire mucosa and result into the simultaneous 
occurrence of premalignant states [76]. A field size of over 7 cm has been reported in HNC, and 
about 62.5% of HNSCC second primary tumour recurrences are from similar clonal fields left 
behind after resection [77]. Therefore, a frequent oral examination with histological studies and 





Figure 4.29. The steps of field cancerization formation. 
 
 
4.3.5 Copy number variation detection 
The genomes of the old patients and the young patient 82 are more unstable, as they harbour 
more CNVs than the young patients 98 and 111. This may be explained by the presence of p53 
mutations in patient 82 and old patients, which increases genome instability. Some mutations in 
p53 have been shown to promote aneuploidy and tumorigenesis in the mammary gland in 
transgenic mice and to affect genomic stability, in part, by causing centrosome abnormalities [78]. 
The high number of detected CNVs in patient 82 could explain the highly aggressive tumour in 







4.4 Conclusion  
The SNV and CNV analysis showed that there were two different genetic groups in the five 
patients, independent of the age of the patients. The first group has mutations in the p53 and 
have more CNVs, which is seen in the old patients 119 and 137, and in the young patient 82. The 
other group does not have mutations in p53 and has very few CNVs. 
In order to detect a specific tumour mutation that can be used as a tumour target, it is necessary 
to compare the tumour sequences with the normal adjacent tissue rather than with blood to 
avoid selecting shared mutations between tumour and the adjacent tissue. This has important 
implications for identifying truly tumour specific mutations, since the vast majority of cancer 
genomics studies uses normal blood as the source of germline mutations, but does not usually 
use normal adjacent tissue as the source of “normal” DNA.  Ideally, all three samples types would 
be taken, but this is sometimes limited by clinical practise (such as in my study on UPS). 
Nevertheless, the high mutation rate in normal tissue, some of which mutations are shared with 
the tumour, highlight the concept that mutations are not necessarily cancer causing, but that 














Analysis of somatic mutations in 20 
undifferentiated pleomorphic sarcoma 
5.1 Introduction 
5.1.1 Sarcoma Epidemiology 
Sarcomas are uncommon, diverse mesenchymal malignancies that arise in, or from, bone, 
cartilage or connective tissues, such as muscle, fat, peripheral nerves and fibres [79]. They 
represent approximately 1% of cancers diagnosed in adults and 15% of childhood tumours [80]. 
Regardless of their tissue of origin, sarcomas share an overall poor prognosis. Because they are 
frequently discovered at more advanced stages and there is limited understanding of their 
pathogenesis, there is little guidance available for developing targeted therapies [81]. 
Sarcomas show remarkable histological diversity, with more than 50 recognized subtypes [82]. 
Because of the heterogeneity of sarcoma tumours, their true incidence has generally been 
underreported. Recent estimates from the cancer networks suggest that about 3000 patients are 
diagnosed each year in the UK [83]. Approximately half of all sarcoma patients with intermediate 
or high-grade tumours develop metastatic disease. The overall survival rate is about 50% at 5 
years [83]. 
From a molecular perspective, sarcomas are classified into two categories. The first category 
comprises sarcomas with near-diploid karyotypes and simple genetic alterations, including 
translocations or specific activating mutations. The second category includes tumours with 
complex and unbalanced karyotypes, such as the undifferentiated high-grade pleomorphic 
sarcoma (UPS) [79, 80]. UPS is the most common form of adult sarcoma, forming aggressive 





5.1.2 Sarcoma aetiology 
The aetiology of most sarcomas is unknown, but in a minority of sarcoma patients an association 
exists with irradiation, chronic lymph angioedema, viral infections and known genetic 
susceptibility [84]. There is an increased risk of sarcomas, both bone and soft tissue, in patients 
who have had a familial retinoblastoma caused by inherited mutations in the RB gene. Also, there 
is an increased risk of sarcomas, and other cancers, in families with Li–Fraumeni syndrome who 
have inherited mutations in the TP53 gene [83]. 
5.1.3 Sarcoma management 
Sarcoma tumours have traditionally been managed by wide excisional surgery with or without 
radiotherapy. The use of chemotherapy or targeted therapy has mostly been reserved for 
advanced disease, aiming to achieve disease palliation and control [84]. 
Due to the availability of increasing amounts of molecular data from expression profiling and 
other molecular techniques, differential diagnosis and subgrouping of sarcomas has been 
facilitated. Novel targeted treatment regimens should be developed on the basis of these results. 
High-throughput sequencing is of great help in identifying novel targets and is further supported 
by new applications such as RNA sequencing [85]. 
5.1.4 Molecular mechanisms of sarcoma 
The mechanisms that drive human sarcomagenesis fall into three broad categories: 
transcriptional dysregulation owing to aberrant fusion proteins that result from genomic 
rearrangements, somatic mutations in key genes and signalling pathways, and DNA copy-number 
abnormalities [79]. 
The improvements in molecular techniques and the expanded use of NGS have allowed 
identification of targetable genetic alterations in specific cancer types.  
Gastrointestinal stromal tumour (GIST), one of the more common types of human sarcoma, is 
characterized by oncogenic mutations in KIT, and in platelet-derived growth factor receptor-α 
(PDGFRA). The dependence of GIST on constitutively activated KIT and PDGFRA has led to 
treatment with the selective kinase inhibitor imatinib, which achieves a partial response or 
stabilises the disease in about 80% of patients with advanced or metastatic GIST [79]. 
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5.1.5 Exome sequencing studies to identify mutations in sarcoma 
New research has analysed targeted exon sequencing, which was done for 72 genes (selected 
because of their associations with increased cancer risk) of 1162 patients with sarcoma and 6545 
Caucasian controls, in order to investigate the genetic basis of sarcoma [86]. The study reported 
that 638 (55%) of the probands bore an excess of pathogenic germline variants. Therefore, about 
half of sarcoma patients have putatively pathogenic variations in known and novel cancer genes. 
This may explain the development of sarcoma in children and young-age patients. This study 
focused on 72 genes, and focused on detection of germline mutations. There might be other 
genes with mutations specific to sarcoma. In order to develop a drug target, a somatic mutation 
that is specific to a tumour must be detected. Therefore, we have analysed whole exome 
sequencing of tumour–normal pairs of 20 UPS patients, in order to identify tumour specific 
mutations. 
5.1.6 Analysis of 20 UPS whole exome sequences to identify somatic mutations 
The widespread use of NGS has uncovered the genomic landscape in many tumour types. Given 
the disease rarity and histologic diversity, much less is known about the somatic mutational 
landscape in sarcoma. 
UPS is defined as a sarcoma with no identifiable line of differentiation, excluding dedifferentiated 
types of specific sarcomas [87]. Biomarkers that can distinguish UPS from other types of sarcoma, 
as well as improve treatment stratification, are needed. Previous genetic analysis studies have 
failed to reveal any consistent or tumour specific aberrations [87]. 
We have used the CLC Biomedical Genomic Workbench to analyse the NGS of 20 UPS exomes 
and their matched normal exomes to define somatic mutations, including single nucleotide 
variants (SNV), small insertions or deletions (INDELS) and copy number variants (CNVs), which 







5.2 Results and Discussion 
Tumours were sequenced to an average depth of 100x coverage and matched DNA samples from 
morphologically normal tissue adjacent to the tumour were sequenced to 30x. Exome 
sequencing was performed using Agilent V5+UTR Exome Capture Kit (75Mb); Illumina, 100bp 
paired-end reads using a coverage of tumour–normal pairs (100X/30X). Paired de-multiplexed 
fastq files were generated using CASAVA software (Illumina). Somatic mutations were identified 
using the CLCbio Genomics Workbench. 
5.2.1 Identification of somatic variants from UPS tumour–normal pairs 
We have used the CLC Biomedical Workbench 2.5 to analyse the NGS of 20 UPS exomes and their 
matched normal exomes to define somatic mutations including SNVs, Indels and CNVs. The 
parameters chosen for the minimum coverage, minimum count and minimum frequency of the 
detected variant were 5, 2 and 5 respectively in the tumour reads. We selected to remove any 
variant that presents at least once in the normal reads, so that all the detected variants are 
tumour specific. The minimum coverage for the variant site has been set to 5 in the normal reads, 
so any variant with less than 5 reads in its site in the normal reads would not be called out.  
As described in the previous chapter, the ‘identify somatic variants from tumour–normal pair’ 
(WES) ready-to-use workflow was used to identify potential somatic variants in a tumour sample, 











5.2.2 Number of non-synonymous variants detected 
There were many variants detected in each patient, but we were interested in non-synonymous 
variants only. The number of non-synonymous variants ranges from 235 to 612, as shown in table 
5.1 below, with SNVs being the most detectable type of variants in each patient. 
 
No. Patient No. of Variants 
detected by CLC 
No. of SNVs 
detected by CLC 
1 52 526 412 
2 55 516 399 
3 59 346 242 
4 60 476 359 
5 66 434 293 
6 73 399 274 
7 74 574 506 
8 84 539 364 
9 90 490 312 
10 94 612 434 
11 97A 379 281 
12 97B 472 346 
13 197 316 207 
14 244 318 237 
15 258 284 195 
16 297 402 297 
17 343 449 311 
18 364 334 233 
19 378 349 239 
20 430 602 423 
21 496 235 152 
Table 5.1. Summary of the non-synonymous mutations detected in UPS. The data summarise the number of total 
variants (including in-frame deletions or insertions, as well as single nucleotide variants (SNVs)) and the subset that 
are only SNVs. Numbers 11 and 12 represent a tumour from patient 97, in which the tumour was divided into two 
parts to establish intra-tumour heterogeneity. For example, the number of variants or SNVs in 97a vs 97 b was 379 
vs 472 and 281 vs 336, respectively.  
 
5.2.3 Validation of some of the detected mutations by Sanger sequencing 
We have picked up three mutations (table 5.2) to validate by Sanger sequencing. Two of these 
mutations are in patient 55; both have high frequency. One of them has high control coverage 
and one has low control coverage. The third mutation is in patient 73, and has with relatively low 
frequency and high control coverage. As shown in figure 5.1 below, the Sanger sequence has 
confirmed the presence of the detected mutations in all of the three genes. However, the 
mutation in the Sema6a gene, which has low control coverage, is a false positive as the normal 
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sequence shows that the normal tissue is heterozygous for this variant. This germline mutation 
failed to be detected in the normal genome, most probably due to the low coverage at the 
mutation site in the normal genome. At the same time, it was successfully detected in the tumour 
genome by the analysis software which misrepresented the mutation as a tumour-specific 
mutation. Coverage at any given place in the genome is variable however, and low coverage 
regions may still lead to false-positives when coverage is not high enough to identify germline 
variants [88]. 
The effect of tumour–normal coverage ratios on variant calling was investigated to assess 
whether increasing coverage of the tumour alone is sufficient to increase mutation detection 
sensitivity [89]. The 250 coverage tumour genome was compared with control genomes at 250, 
200, 150, 100, 50 and 30 coverages. Down to 150 coverage, few differences were seen in the 
mutations called when compared with 250–250 tumour control coverage. At lower control 
coverage levels, a notable increase is observed in the overall number of mutations reported, 
because of a sharp rise in those called with a low allele fraction which appeared to be somatic 
when the control coverage is insufficient to show the same phenomenon [89]. Thus, keeping the 
tumour: normal ratio of coverage closer to one appears to play a role in maintaining the accuracy 
of mutation calling. 
 
 
Number Patient Gene 
Name 
Mutation Count Coverage Frequency Control 
Coverage 
1 55 Il11ra 649C>T 143 158 90.51% 55 
2 55 Sema6a 947G>T 55 60 91.67% 14 
3 73 Fat3 2855G>A 70 260 26.92% 61 
Table 5.2. Three mutations were chosen for Sanger sequence validation. The table highlights the patient number, 
gene name, mutation site, mutation count, tumour mutation site coverage, and frequency of mutant reads/normal 




Figure 5.1. Validation of the three detected mutations by Sanger sequences. The browser highlights the hg19 
reference sequence, the reads in normal DNA, the reads in tumour DNA (highlighting mutation in colour), and the 
Sanger sequencing validation. As an example of positive validation, Il11ra (C>T) and Fat3 (G>A) have been validated 
as somatic mutations by Sanger sequencing. As an example of negative validation, the mutation in Sema6a (G>T) 
was detected in the normal adjacent tissue, although it is possible that tumour cells contaminated the normal 
adjacent tissue. Nevertheless, we find that when the normal tissue coverage is low (as in SEMA6a which has only 14 
reads in normal tissue) that the false positive rate is high. 
 
5.2.4 Common mutated genes in UPS patients and their pathways 
To our knowledge, this is the first study to detect somatic mutations in UPS (and sarcoma in 
general) using analysis of whole exome sequences. 
To look for common mutated genes in the 20 sarcoma patients, we have selected genes with 
mutations of ≥ 15% frequency. There were many genes with somatic mutations detected in ≥ 4 
patients as shown in figure 5.2. These genes have different mutations of SNVs and Indels.  
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TP53 is one of the detected genes, which is mutated in 20% of samples, with SNV and a 15-base 
deletion in patient 52, SNV in patients 55 and 74, and a one-base deletion in patient 94. 
TMPRSS13 (Transmembrane Protease, Serine 13) gene is another example, which was detected 
in 9 patients. Table 5.3 below shows the types of mutations detected in this gene in the different 
patients, with the count, coverage and frequency of these mutations in the tumours, and the 
control tissue coverage. All the mutations have high frequency and high control coverage. There 
are five patients that share the same in-frame deletion of 15 (194–208) bases. There is another 
in-frame deletion of 15 (248–262) bases detected in three other patients.  
TMPRSS13 is a member of the hepsin/TMPRSS subfamily of type II transmembrane serine-
proteases (TTSP) [90]. The TMPRSS13 encodes a typical TTSP structure with a transmembrane 
domain near the N-terminus and a trypsin-like serine protease in the extracellular domain at the 
C-terminal side. The role of numerous proteins is controlled by proteases, and altered expression 
and activity of proteases is a key event in cancer, particularly in relation to invasion, modification 
of the extracellular matrix and metastasis [91]. 
The detected mutations still need to be validated and their effects on cell growth and metastasis 
studied. 
We have studied the pathways of these genes using the PANTHER gene ontology website: 









Number Patients Mutation Count Coverage Frequency Control 
Coverage 
1 66 233A>G 110 111 99.1 50 
230C>G 103 109 94.5 48 
194_208delCTCCAGGCCGGGCAT 76 117 64.96 41 
2 73 248_262delAGGCATCTCCAGCCC 77 115 66.96 41 
3 84 194_208delCTCCAGGCCGGGCAT 116 170 68.24 16 
4 90 230C>G 87 89 97.75 25 
194_208delCTCCAGGCCGGGCAT 57 80 71.25 24 
5 97A 248_262delAGGCATCTCCAGCCC 21 78 26.92 45 
6 297 248A>G 22 49 44.9 54 
233A>G 17 51 33.33 54 
230C>G 15 52 28.85 52 
263G>T 14 57 24.56 54 
7 364 233A>G 103 104 99.04 47 
230C>G 101 107 94.39 48 
194_208delCTCCAGGCCGGGCAT 75 106 70.75 37 
8 378 233A>G 102 106 96.23 42 
230C>G 96 100 96 43 
194_208delCTCCAGGCCGGGCAT 71 111 63.96 33 
9 430 248_262delAGGCATCTCCAGCCC 50 81 61.73 46 
Table 5.3. Types of somatic mutations detected in TMPRSS13 gene in 9 UPS patients. The table shows the 
count, coverage, frequency and the control coverage of each mutation 
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Figure 5.2. List of genes which were mutated in ≥  4 UPS patients with mutations ≥  15% frequency 
(count/coverage) in the tumour sequences. Each non-synonymous SNV mutation is represented by a green square. 
The SNV that changing the amino acid to a stop codon is represented by a red square. The gold squares represent 
the Indels. When the patient has two types of mutations the square is divided into two colours according to the 
mutation type. 
 
Figure 5.3. PANTHER pathways of the common mutated genes in UPS patients. Genes which were mutated in ≥ 4 
UPS patients with mutations ≥  15% frequency, were listed in PANTHER gene ontology website 
(http://www.pantherdb.org/) to investigate their pathways. 
 
5.2.5 The common type of mutation in each sarcoma tumour 
We have counted the number of each mutation type (mutation signature) of the SNVs in each 
tumour to see which is most frequent type of mutation in each tumour and if there is any 
similarity in mutation types between the 20 UPS patients. As shown in figure 5.4 below, all the 
sarcoma tumours (except tumour 74) have C>T mutation type with the highest frequency, and 
A>G with the second highest frequency. Tumour 74 is the only tumour that has a different 
mutation signature frequency, with C>A as the highest signature and C>T as the second highest. 
 
125 
The C>T mutation type is consistent with the deaminase activity of the apolipoprotein B mRNA 
editing enzyme catalytic polypeptide like (APOBEC) family. The APOBEC family is comprised of a 
series of molecules with conserved cytidine deaminase domains, including APOBEC1, APOBEC2, 
APOBEC3A to H and APOBEC4 [92]. Initially, this family of enzymes was identified as mutators of 
viral DNA. Most members are involved in the hypermutation state of viral genomes including 
retroviruses, hepatitis B virus (HBV) and human papilloma virus [93]. It was reported that the 
deletion of APOBEC3B (A3B) gene leads to susceptibility to HBV infection and hepatocellular 
carcinoma [93].  
Recent studies have shown that A3B is overexpressed in multiple kinds of cancers, including 
breast, head and neck, lung, bladder and cervical cancers [93]. Genomic sequencing showed that 
C to T mutations in designated regions, regarded as a hallmark of A3B activity, is commonly found 
in many kinds of human cancers [93]. Knockdown of A3B showed that the cytosine deamination 
mutation is consistent and dependent upon A3B level in breast cancer, providing evidence that 
A3B is responsible for tumour mutagenesis [94]. 
It was demonstrated that expression of A3B was higher in chondrosarcoma cancer tissues, 
compared to that in normal tissues [92].  




Figure 5.4. The percentages of mutation types in each UPS sample. All of the samples (except 74) have the highest 













5.2.6 Cancer heterogeneity  
5.2.6.1 Mutations detected in two different regions of tumour 97 
We extracted DNA from two different regions of the tumour 97 (A and B) and sent them for whole 
exome sequencing. We compared the two sequences with sequences of normal adjacent tissue. 
Tumour 97A has a smaller number of mutations detected as shown in table 5.1 above. From 
figure 5.2 the differences in genes detected in the two regions are obvious. The mutation 
signature frequency is almost the same between the two regions. When we compared the 
mutations detected in both regions, we found only a very small number of mutations that are 
common between the two regions, as shown in the Venn diagram in figure 5.5, and most of the 
mutations are specific to one region of the tumour; this is known as tumour heterogeneity. These 
two regions of the tumour may represent different grades of the tumour stage such as primary 
and metastatic. The common mutations (listed in table 5.4) may have arisen in the primary 
tumour and selection has maintained them because they may be advantageous to the tumour 
growth and metastasis. 
 
 























Deletion 1199_1228del 104 134 77.61 32 L1TD1 




26 44 59.09 23 RPL14 
3 1 158261122 SNV 62T>C 78 165 47.27 53 CD1C 
4 6 45390504 SNV 191C>A 16 35 45.71 23 RUNX2 
5 12 109017651..
109017680 
Deletion 452_481del 40 118 33.9 55 SELPLG 
6 11 17553007 SNV 187C>T 16 48 33.33 21 USH1C 
7 2 75115073 SNV 2263C>T 13 47 27.66 22 HK2 
8 5 45262297 SNV 2399T>C 40 145 27.59 91 HCN1 
9 8 3855495 SNV 748T>G 20 78 25.64 29 CSMD1 
10 3 10280462 SNV 1504C>T 26 103 25.24 76 IRAK2 
11 8 97621679..9
7621705 
Deletion 422_448del 26 137 18.98 61 SDC2 
12 9 90501486 SNV 2084G>C 25 133 18.8 46 SPATA31
E1 
13 3 65342333 SNV 418G>A 24 131 18.32 72 MAGI1 





8 51 15.69 16 C10orf71 




Deletion 145-55_163del 14 104 13.46 11 C16orf91 
18 7 139281691 SNV 2489G>A 16 165 9.7 39 HIPK2 
19 7 142224264 SNV 4A>G 3 37 8.11 24 TRBV11-
1 
20 7 119915308 SNV 622C>G 25 309 8.09 78 KCND2 
21 3 195511918 SNV 6533C>T 2 25 8 8 MUC4 












Deletion 1247_1248-2del 17 252 6.75 17 TYRO3 







281_282delGTinsC 2 37 5.41 18 KRT2 
27 7 142224256 SNV 12G>C 2 40 5 27 TRBV11-
1 
    Table 5.4. The common somatic mutations in regions A and B of tumour 97 
 
5.2.6.2 Pathways of the mutated genes in the two regions of tumour 97 
We have investigated the pathways of the genes with somatic mutations in regions A and B of 
the tumour 97 by using PANTHER gene ontology website: (http://www.pantherdb.org/).  The 
pathways of mutated genes detected in region A and region B are shown in figure 5.6 and 5.7 
respectively. Although most of the mutated genes are different between the two regions, the 
two regions share many pathways of their mutated genes, as shown in figures 5.6 and 5.7. The 
two highest pathways are the same in the two regions: Cadherin signalling pathway and Wnt 
signalling pathway.  There are other common pathways such as: T cell activation, Ras Pathway, 
FGF signalling pathway, Inflammation mediated by chemokine and cytokine signalling pathway 
and Ubiquitin proteasome pathway. 
There are some pathways that are specific to each region; for example: p53 pathway and B cell 
activation in region A, and Apoptosis signalling pathway and Cytoskeletal regulation by Rho 






Figure 5.6. PANTHER pathways of the list of genes with somatic mutations in the tumour 97A. The PANTHER gene ontology website (http://www.pantherdb.org/) 
was used to investigate the pathways of the genes with somatic mutations detected when the sequence of the region A of the tumour 97 compared to the 







Figure 5.7. PANTHER pathways of the list of genes with somatic mutations in the tumour 97B. The PANTHER gene ontology website (http://www.pantherdb.org/) 
was used to investigate the pathways of the genes with somatic mutations detected when the sequence of the region B of the tumour 97 compared to the 




Tumour heterogeneity refers to the existence of subpopulations of cells with distinct genotypes 
and phenotypes, that may harbour divergent biological behaviours, within a primary tumour and 
its metastases, or between tumours of the same histopathological subtype (intra- and inter-
tumour, respectively) [95]. 
Cancers of all types are now recognised to consist of highly diverse populations of cells, where 
intra-tumour heterogeneity is detectable at the genetic, epigenetic, and phenotypic levels [96]. 
A study has assessed the mutational spectrum in a patient with metastatic lobular breast cancer 
and identified that out of 32 coding mutations, 19 were specific to metastasis [23]. In this context, 
it was shown that performing single biopsies of primary tumours or metastatic deposits is unlikely 
to reveal the complete profile of genomic alterations in any tumour [97]. This multiregional 
separation of molecular aberrations can lead to sampling bias, potentially impairing the 
interpretation of the molecular characterization of tumours and having an impact on the 
selection of treatment [97]. For drug target development, clonal heterogeneity must be taken 
into account, as subclones can compete and synergize for growth in a symbiotic manner [98]. 
 
5.2.7 Comparison of the somatic mutations detected by CLC and MuTect 
We have compared the variants detected by the CLC analysis and the variants detected by 
another point mutation caller; MuTect (MuTect analysis was performed by Graeme Grimes, MRC 
Human Genetics Unit). MuTect is a method developed at the Broad Institute, for the reliable and 
accurate identification of somatic point mutations in NGS data of cancer genomes. MuTect takes 
as input sequence data from matched tumour and normal DNA, after alignment of reads to a 
reference genome and standard pre-processing steps that include marking of duplicate reads, 
recalibration of base quality scores and local realignment. The method operates on each genomic 
locus independently and consists of four key steps (Fig 5.8): (i) Removal of low-quality sequence 
data; (ii) variant detection in the tumour using a Bayesian classifier; (iii) filtering to remove false 
positives resulting from correlated sequencing artefacts that are not captured by the error model; 





Figure 5.8. Overview of the detection of a somatic point mutation using MuTect. MuTect takes as input NGS data 
from tumour and normal samples and, after removing low-quality reads, determines whether there is evidence for a 
variant beyond the expected random sequencing errors. Candidate variant sites are then passed through six filters to 
remove artefacts. Next, a panel of normal samples filter is used to screen out remaining false positives caused by rare 
error modes only detectable in additional samples. Finally, the somatic or germline status of passing variants is 
determined using the matched normal sample [99]. 
 
 
The CLC Workbench detects SNVs and Indels, but MuTect detects only SNVs, which makes CLC 
advantageous over MuTect. The number of SNVs detected by CLC is much greater than the 
number of SNVs detected by MuTect in each patient as shown in table 5.5 below. This is may be 









No. Patient No. of SNVs 
detected by CLC 
No. of variants 
detected by 
MuTect 
No. of variants 
detected by 
both callers 
1 52 412 305 126 
2 55 399 169 148 
3 59 242 48 25 
4 60 359 67 41 
5 66 293 56 31 
6 73 274 47 30 
7 74 506 148 49 
8 84 364 58 24 
9 90 312 140 80 
10 94 434 215 182 
11 97A 281 21 12 
12 97B 346 22 20 
13 197 207 44 20 
14 244 237 48 37 
15 258 195 62 32 
16 297 297 60 44 
17 343 311 55 43 
18 364 233 59 32 
19 378 239 79 29 
20 430 423 31 22 
21 496 152 21 7 
Table 5.5. The number of somatic mutations detected by the CLC software and MuTect in UPS patients.  
 
 
The number of shared variants detected by both methods is low in each patient as shown in table 
5.5 above, which means that each caller method detects a high number of variants which are not 
detected by the other method.  
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Mutations detected in Tp53 gene by the two methods are examples, as shown in table 5.6 below. 
CLC detected five mutations in Tp53, a deletion of 15 bases and a 1-base deletion in patients 52 
and 94 respectively, leading to frameshift mutations; and three SNVs in patients 52, 55 and 74. 
The deletions were not detected by MuTect because it does not detect Indels, as mentioned 
above. The three SNVs detected by CLC were also detected by MuTect. In contrast, MuTect 
detected another SNV in patient 90 with high frequency and high coverage in the tumour and 
normal samples, but this SNV was not detected by the CLC.  
When we looked at this mutation site in the CLC genome browser of patient 90, we could see 
that the mutation was there, as shown in figure 5.9, but the count is much less than the count 
that was detected by MuTect, which is only 4 out of 82 reads in the tumour which makes the 
frequency less than 5%; that is why this mutation was not called out by the CLC. 
 
Mutations detected in Tp53 by CLC method: 












- 34 82 41.46 22 Gly226f
s 
52 7577536 SNV T C 22 81 27.16 23 Arg249
Gly 
55 7577538 SNV C T 72 75 96 23 Arg248
Gln 
74 7578265 SNV A G 42 136 30.88 82 Ile195T
hr 
94 7579508 Deletion G - 40 82 48.78 22 Pro60fs 
Mutations detected in Tp53 by MuTect method: 
52 7577536 SNV T C 49 70 70 20 Arg249
Gly 
55 7577538 SNV C T 66 69 95.6 21 Arg248
Gln 
74 7578265 SNV A G 84 127 66.1 78 Ile195T
hr 
90 7577121 SNV G A 117 127 92 35 Arg273
Cys 






Figure 5.9. The CLC genomic browser of the G>A mutation in TP53 gene in patient 90. The mutation 





In patient 55, The CLC detected 148 variants out of the 169 variants detected by MuTect, as 
shown in the Venn diagram in figure 5.10. In other words, 87.5% of the somatic variants detected 
by MuTect have been detected by the CLC. Table 5.7 lists the rest of the variants (21 variants) 
that have not been detected by the CLC, with the reasons for their not being detected. Nine of 
them have the variant in the normal reads, which is why the CLC did not detect them. 
There are many SNVs detected by the CLC (251) but not detected by MuTect. Most of these 
variants have high frequency and high coverage in the tumour and normal samples, as in the 
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mutation in KIAA1958 gene, shown in figure 5.11, which has a frequency of 87.6% and coverage 






Figure 5.10. A Venn diagram showing the number of mutations detected by the CLC and MuTect in 


































1 AMY1C 1 104297162 C T c.920C>T Ala307Val False negative 
2 RETSAT 2 85570849 C T c.1606G>
A 
Gly536Arg Detected in 
normal 
3 RETSAT 2 85570857 G A c.1598C>T Ala533Val Detected in 
normal 
4 POTEJ 2 131414975 A T c.2642A>T Tyr881Phe Detected in 
normal 
5 MAATS1 3 119463011 C T c.1870C>T Arg624Cys False negative 
6 TACC3 4 1732978 G A c.1541G>
A 
Gly514Glu Low frequency 
7 PCLO 7 82784471 A G c.1486T>C Ser496Pro Detected in 
normal 
8 OR2AE1 7 99473692 C T c.965G>A Arg322Gln Low frequency 
9 PRSS1 7 142459626 C T c.202C>T Arg68Cys Detected in 
normal 
10 FAM115C 7 143400205 G A c.118G>A Val40Met Detected in 
normal 
11 PABPC1 8 101724606 G A c.956C>T Thr319Ile Detected in 
normal 
12 GLIS3 9 3828360 C T c.2705G>
A 
Arg902His False negative 
13 FAM154A 9 18928669 C T c.806G>A Cys269Tyr Low frequency 
14 IFNA14 9 21239468 T C c.467A>G Glu156Gly No variant 
detected 
15 IFNA14 9 21239504 T C c.431A>G Lys144Arg False negative 




17 OR8G5 11 124135536 G A c.814G>A Ala272Thr Detected in 
normal 
18 GOLGA8T 15 30433598 A T c.844A>T Arg282Trp False negative 
19 ODF3L2 19 464067 C T c.647G>A Arg216His False negative 
20 EDEM2 20 33722572 C T c.671G>A Arg224His False negative 
21 FAM83C 20 33880040 A C c.68T>G Val23Gly Bad sequence 
Table 5.7. Variants detected by MuTect only; 21 variants were detected by MuTect and not by CLC. 
Includes their details and possible reasons for not being detected by the CLC. 
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Figure 5.11. CLC genome browser of a G>A mutation in KIAA1958. The mutation presents with high frequency in 









A previous study has used whole genome sequencing of a melanoma sample and matched blood, 
whole exome sequencing of 18 lung tumour–normal pairs and seven lung cancer cell lines to 
evaluate MuTect and other mutation caller methods such as VarScan 2 [100]. Out of 119 true 
positive SNVs in melanoma, MuTect detected 115 SNVs and missed four SNVs for reasons of 
nearby gap events and an alternate allele in normal tissue. 
For the 43 WES samples, 118 putative SNVs were validated as true positives. Of these, 92 SNVs 
had high coverage in the tumour and normal samples (high quality), while 26 of them had less 
than 8 coverage in the normal sample (low quality). MuTect identified 77 SNVs of the 92 high 
quality SNVs, missing 15 variants. All the other methods in the have detected more high quality 
variants than did MuTect. Of the 26 low quality variants, MuTect detected the largest number: 
19 out of the 26 SNVs (missing 7 variants) compared to other methods, which makes MuTect the 
best for detection of low quality variants.  
From the analysis of the 18 lung tumours, MuTect detected a total of 11 false positive SNVs, the 















5.2.8 Copy number variation (CNV) in UPS 
As described in the head and neck chapter, the same tools in the CLC Biomedical Genomics 
Workbench have been used to detect the CNVs in the UPS samples. Many CNVs were detected, 
of both amplifications and deletions, in each sample (data in additional file). The tumour of 
patient 55, for example, has 52 CNVs detected, 19 of them are amplifications and 33 are deletions. 
The amplifications were in chromosomes 3, 7, 15, 19 and 21, as shown in figure 5.12 below. The 
33 deletions were distributed through different chromosomes and they are in small regions, 
except for the two large deletions in chromosome 10.  
 
 
Figure 5.12. A graph showing the mean adjusted log-ratios of coverages in the report produced by the CNV 
detection in patient 55. In this report, regions of the 3rd, 7th, 15th, 19th, and 21st chromosomes are amplified (red X), 
and regions of chromosome 10 are deleted (blue X). The log-ratios of coverages of targets on these chromosomes 
are significantly higher or lower than for targets on other chromosomes. The black line in these regions is outside the 










5.2.8.1 Shared CNVs in UPS samples 
There are regions of 52 CNVs that are shared between two or three samples of UPS, as shown in 
table 4.8. Of these, 11 CNVs are deletions and 41 are amplifications. There are three CNVs 
detected in three UPS samples, two gains and one loss. The first gain is on chromosome 3, at 
location 3q13.33, detected in patients 90, 94 and 97A, with the minimum CNV length of 145928 
bases; the other gain is on chromosome 5 (5q11.2) detected in patients 84, 94 and 197, with 
minimum length of 209501. The loss is on chromosome 11 (11p15.4) and found in patients 73, 
94 and 197, with a minimum length of 944. All the other shared CNVs are only seen in two 
samples. Patients 90 and 97A share the highest number of CNVs with 16. Patients 84 and 94 share 
the second highest number, with 14 CNVs, and finally patients 94 and 97A have 9 CNVs. A study 
was carried out by [80] to detect CNVs in 20 UPS untreated patients using array-based 
comparative genome hybridization. They reported that the most frequently observed significant 
alterations involved gains at: 20q13.33 in 75% of samples; 1q21.3-q23.1 in 60%; 7q22.1 in 60%; 
9q34.11 and 20p11.21 in 45%; and 1q21.1-1q21.2, 8p11.21, 11q13.1 and 16p13.3 in 40% of 
samples. They have validated the amplifications of some of the genes located in some of these 
regions by quantitative real-time PCR. Most of these CNVs were also detected in our analysis. 
There are gains detected at: 20q13.13 in patients 94 and 97A; 1q22 in patients 90 and 97A; 7q22.1 
in patients 90 and 97A; 11q13.1 in patients 90 and 97A; and 16p13.3 in patients 84 and 94.There 
is a large difference in the number of CNVs detected in samples 97A and 97B. There are 431 CNVs 
detected in 97A and only 90 CNVs in 97B, and they share only four CNVs as shown in table 5.8. 
This means that the number and type of CNVs are also different between different sites of the 
same tumour. 
In conclusion; the newly available software was able to identify genomic mutations in UPS and 







Number Samples Chromosome 
location 
Region Minimum CNV 
length 
Consequences 
1 60, 84 4p16.1 7043045..10509695 3466651 Gain 
2 84, 94 2p22.3 33824206..36583843 2759638 Gain 
3 84, 94, 97A 5q11.2 53606160..53815660 209501 Gain 
4 84, 94 5q31.2 137771222..137804146 32925 Gain 
5 84, 94 7p15.2 26903889..27497459 593571 Gain 
6 84, 94 8q22.1 96281271..97172921 891651 Gain 
7 84, 94 10p11.21 35896547..35930313 33767 Gain 
8 84, 94 10q25.2 112837732..112838496 765 Gain 
9 84, 94 13q14.3 53419925..53422629 2705 Gain 
10 84, 94 14q13.2 35871605..36005206 133602 Gain 
11 84, 94 16p13.3 1756292..1877945 121654 Gain 
12 90, 97A 1q22 155531872..155533272 1401 Gain 
13 90, 94 3q13.2 111697898..111698138 241 Gain 
14 90, 94, 97A 3q13.33 120169505..120315432 145928 Gain 
15 90, 97A 4p15.2 26321381..26322455 1075 Gain 
16 90, 97A 4q23 100867620..100871448 3829 Gain 
17 90, 97A 5q11.2 54603174..54604070 897 Gain 
18 90, 97A 6p21.33 31783494..31803251 19758 Gain 
19 90, 97A 6p21.33 31939130..31940828 1699 Gain 
20 90, 97A 7q22.1 100859979..100861570 1592 Gain 
21 90, 97A 8q23.1 109260724..109455990 195267 Gain 
22 90, 97A 10q23.31 91087672..91087912 241 Gain 
23 90, 97A 10q24.32 104180746..104181231 486 Gain 
24 90, 97A 11q13.1 63919711..63953790 34080 Gain 
25 90, 97A 12p13.2 10765962..10766206 245 Gain 
26 90, 97A 12q14.3 66562928..66563792 865 Gain 
27 90, 94 13q14.13 45914264..45915312 1049 Gain 
28 90, 94 16q21 66583885..66586779 2895 Gain 
29 90, 97A 17p13.3 1303230..1303474 245 Gain 
30 90, 94 17q23.3 62500715..62503327 2613 Gain 
31 90, 97A 22q11.21 19466543..19467764 1222 Gain 
32 94, 97A 1p36.33 861267..1565994 704728 Gain 
33 94, 97A 1q31.2 193070213..193091479 21267 Gain 
34 94, 97A 4q28.1 128703073..128703863 791 Gain 
35 94, 97A 7q21.13 90747375..90896159 148785 Gain 
36 94, 97A 8q24.13 125384090..125487563 103474 Gain 
37 94, 97A 9p13.2 37784632..37800695 16064 Gain 
38 94, 97A 10q23.33 94333589..94333829 241 Gain 
39 94, 97A 10q24.32 104262278..104264144 1867 Gain 
40 94, 97A 20q13.13 48769952..48808616 38665 Gain 
41 97A, 97B 17p13.1 8192047..16252058 8060012 Gain 
42 55, 364 4q13.2 69416379..69433917 17539 Loss 
43 66, 84 18p11.21 12095417..12127862 32446 Loss 
44 73, 94, 197 11p15.4 4976026..4976969 944 Loss 
45 84, 94 4q24 107114760..107183372 68613 Loss 
46 84, 94 16q12.2 55559422..55585020 25599 Loss 
47 84, 94 17p11.2 16455128..16676861 221734 Loss 
48 84, 94 17q12 33255059..33285772 30714 Loss 
49 97A, 97B 1p36.33 721382..792446 71065 Loss 
50 97A, 97B 1p13.2 112991586..113269425 277840 Loss 
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51 97A, 97B Xp22.13 19008966..19037888 28923 Loss 
52 244, 378 10p12.33 17756495..17891625 135131 Loss 





















Identifying expressed somatic mutations 
and RNA editing events in the whole 
transcriptome sequence of three UPS 
patients 
6.1 Introduction 
6.1.1 The principle of RNA sequencing 
The major limitation of human cancer genome sequencing is that the information does not reflect 
the expressed state of the cancer at the time of surgery. For example, we could consider the 
cancer genome as a “fossil record” that reflects the natural history of how the cancer evolved. A 
better exploitation of DNA sequencing would be the use of RNA sequencing to identify which 
mutated genes are expressed. The advent of NGS has revolutionized transcriptomics and quickly 
established RNAseq as the preferred methodology for the study of gene expression [101]. 
RNAseq can also aid in the discovery of novel and unannotated transcripts and identification of 
SNVs [102]. However, it has been noted that RNAseq is in its infancy and a recent report 
highlighted that different methodologies do not show high concordance [103].  
The standard RNA sequencing method is described as follows: The RNAs in the sample of interest 
were initially fragmented and reverse transcribed into cDNAs. The cDNAs obtained are then 
amplified and subjected to NGS. In principle, all NGS technologies can be used for RNAseq such 
as the Illumina sequencer, which is now the most commonly used platform. The millions of short 
reads generated can then be mapped onto a reference genome, and the number of reads aligned 
to each gene gives a digital measure of gene expression levels in the sample under investigation. 





6.1.2 Measuring gene expression in cancer 
Gene expression is considered to be a key molecular marker for diagnostic and prognostic 
assessment of cancer [102]. The study of differential gene expression enables the comparison of 
gene expression profiles from tumour and normal tissues to identify genes that play a major role 
in the development of the tumour. Here we have used the CLC software to compare the RNAseq 
from tumour tissues of patients 55, 66 and 73 to the RNAseq of matched normal tissues, to 
identify differential gene expression profile in these patients. The software used at the time of 
inception was a ‘beta” version, not yet commercially available. As noted above, there is no high 
quality software that can capture accurately the complete RNAseq landscape (reference). The 
CLCbio software might have its own limitations, nevertheless, here I describe, for the first time, 
its use applied to human cancer samples.  
6.1.3 Expression of somatic mutation 
Somatic mutation calling is traditionally performed on patient matched pairs of tumour and 
normal genomes/exomes. For a somatic mutation to drive cancer, it must manifest a phenotypic 
effect. Transcription is the primary conduit by which changes in the genomic code are translated 
into cellular phenotype [104]. Therefore, the analysis of somatic mutation is better 
complemented by allelic expression studies, which show whether a mutated allele is expressed. 
Mutated alleles that are not expressed are unlikely to have any impact on tumour progression 
[105]. We have analysed the NGS of the whole transcriptome (RNAseq) of three sarcoma samples 
(55, 66 and 73) to identify genomic-encoded expressed mutations. 
6.1.4 Comparing the RNAseq to the DNAseq in CLC 
As described in the third chapter, the tumour RNA sequences were compared to the tumour DNA 
sequences of the same patient. The minimum coverage was set to 5 in the DNA and 1 in the RNA. 
This comparison results in a list of variants found in the tumour RNA and DNA. We then removed 
the germline variants found in the normal DNA of the same patient to get a list of expressed 





6.2 Results and discussion 
6.2.1 differentially expressed genes in the tumour and normal tissues of UPS samples 
6.2.1.1 Comparing RNAseq of the tumour tissue to the RNAseq of the matched normal tissue in 
patients 55, 66 and 73 
We have used the CLC Biomedical Genomics workbench to identify differentially expressed genes 
in the tumour and normal tissues of patients 55, 66 and 73. To run the ready-to-use workflow: 
Toolbox→ ready-to-use workflow→ whole transcriptome sequencing→ human→ identify and 
annotate differentially expressed genes and pathways. 
This analysis results in a list of genes that are overexpressed or suppressed in the tumour of each 
of the three patients, compared to the matched normal tissue. We then combined the lists of the 
three patients together into one list to get a mean expression of each gene in the three patients, 
in normal and tumour tissues. This produces a new list of genes in which 
overexpressed/suppressed genes in tumour tissues of the three patients are compared to that in 
their normal tissues. The volcano plot of these genes is shown in figure 6.1. 
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Figure 6.1. Volcano plot of genes that are overexpressed or suppressed in the tumours 55, 66, and 73 compared to 
the normal tissues of each patient. Each square represents a gene. The numbers on the X-axis show the log2 fold 
















6.2.1.2 Identification the pathways of overexpressed and suppressed genes in the tumour tissues 
compared to the normal tissues of patients 55, 66 and 73 
We have used the Gene Ontology enrichment analysis and visualization tool (http://cbl-
gorilla.cs.technion.ac.il/) to identify the cellular processes that involve the overexpressed and 
suppressed genes in the tumour tissues compared to the normal tissues. The processes of 
overexpressed genes in the tumour with ≥ 5 in fold change are shown in figure 6.2. The main 
processes include chromatin organization and silencing, nucleosome assembly and organization, 
protein-DNA complex assembly and regulation of gene expression.  
The processes involving the suppressed genes in the tumour (overproduced in the normal tissues), 
with ≥ 5 in fold change, are shown in figure 6.3. The main processes involve muscle contraction, 
muscle system processes, muscle cell development and actin-myosin filament sliding. The 
suppression of these genes may have played an important role in the development of the 








Figure 6.2. Diagram of the main cellular processes of the overexpressed genes detected in UPS by comparing the RNAseq of the tumour tissues of patients 55, 
66 and 73 compared to the RNAseq of their normal tissues. The cellular processes are shown in squares of different colours that represent different p-values, as 






Figure 6.3. Diagram of the main cellular processes of the suppressed genes in UPS by comparing the RNAseq of the tumour tissues of patients 55, 66 and 73 
compared to the RNAseq of their normal tissues. The cellular processes are shown in squares in different colours that represent different p-values as shown in 





6.2.2 Identification of expressed somatic mutations in RNAseq 
6.2.2.1 Number of somatic mutations detected in RNAseq 
To look for expressed mutations, we compared the variants between the tumour DNA and 
the RNA. The ‘compare variants in DNA and RNA’ ready-to-use workflow identifies variants in 
DNA and RNA, and studies the relationship between the identified genomic and 
transcriptomic variants. The important tracks generated were the variants found in both DNA 
and RNA track, all variants found in DNA or RNA track, and the Genome Browser View. 
A low percentage (8.75–17.44%) of somatic mutations detected in the DNA was found to be 
expressed in the RNA, as shown in table 6.1. Many of the mutated genes might not be 
expressed at the time that the tumour was obtained, as gene expression is known to be time, 
cell-type, and stimulus dependent [106]. When the sample is heterozygous for SNV, meaning 
that there are two different alleles in the same position in the DNA, this may lead to one of 
two alleles being highly transcribed into mRNA and the other allele being transcribed at either 
a low level, or not at all. This is known as allele-specific expression [106]. A low coverage or 
no coverage at the mutation site in the RNAseq is another reason for a detected DNA somatic 
mutation to be missed in the RNAseq. 
A previous study has compared the variants identified by high coverage whole-genome 
sequencing to those identified by high coverage RNAseq in the same individual, to explore 
the ability of RNAseq to identify human coding variants [107]. They found that only 40% of 
exonic variants identified by whole genome sequencing were captured in RNAseq, but this 
number rose to 81% when concentrating on genes known to be well-expressed in the source 
tissue. 
 
Sample Number of mutations 
detected in TDNA 
Number of expressed 
mutations 
Percentage of expressed 
mutations 
55 516 90 17.44% 
66 434 38 8.75% 
73 399 49 12.28% 
Table 6.1. Number of non-synonymous mutations detected in DNA and number of them detected in the RNA 





6.2.2.2 Types of expressed somatic mutations detected in RNAseq 
The detected somatic mutations in the RNAseq represent all types of mutations detected in 
the DNA (table 6.2). In patient 55 there were 74 SNVs, one replacement, 6 MNVs, one 
insertion and 8 deletions. All detected SNVs and MNVs led to amino acid substitutions, except 
for one SNV in the HIVEP3 gene that led to a truncation of the protein at amino acid 119. Five 
deletions and one replacement led to frame-shift mutations (one in MOV10 gene; one in 
FIP1L1 gene; two in HLA-DQA1 gene; two in HLA-DRB1 gene), and 3 deletions were in-frame 
deletions, each with one amino acid deleted, as shown in table 6.2.  
In patient number 66, 30 SNVs, 2 MNVs, 2 insertions and 4 deletions were detected. The SNVs 
and MNVs led to amino acid substitutions, except for one SNV and one MNV, which led to 
truncation mutations in the PCDH17 gene at amino acid 1095, and the CDC27 gene at amino 
acid 169 respectively (table 6.2). Two of the four deletions were in-frame and deleted one 
amino acid each, and the other two caused frame-shift mutations in KIAA0040 gene. 
In patient number 73, 30 SNVs, 11 MNVs, 5 insertions and 3 deletions were detected. The 27 
SNVs and all MNVs led to amino acid substitutions; 3 SNVs led to truncation mutations; two 
in the CDC27 gene and one in the MAN2C1 gene. Three of the insertions led to frame-shift 
mutations in CNOT6L, ATP8B3 and TMEM104 genes. The three deletions were in-frame 














6.2.2.3 Common genes with expressed somatic mutations in the UPS patients 
6.2.2.3.1 Common expressed genes in all three patients 
NBPF1 (neuroblastoma breakpoint family, member 1) and CTBP2 genes were mutated in all 
of the three samples. NBPF1 has different SNV mutations in each of the three patients, all of 
them leading to amino acid substitutions; one in patients 55, and 66, and two in patient 73. 
The normal control coverage is low (only 5) in patient number 55, and only 7 for one mutation 
in patient number 73 (table 6.2). These mutations with low control coverage need to be 
validated to make sure they are tumour specific and not false positive variants. When we 
looked at the detected somatic mutations in the tumour DNAseq, we found that NBPF1 was 
detected in all sarcoma samples except in two samples: 59 and 74. 
The CTBP2 gene also has different mutations in each of the three patients: one in 55 and 73, 
and two in patient 66. They all have low frequency mutations, but are expressed. The normal 
coverage is high in patient 55 and 66, but is only 12 in patient 73.  
NBPF1 is located on 1p36, and this region is frequently deleted in neuroblastoma and other 
cancer types, including those of neural, epithelial and hematopoietic origin, indicating that 
this gene may work as a tumour suppressor gene in a broad range of human cancers [108]. A 
study performed by [108] showed that forced expression of NBPF1 in the human HEK293T 
cell line resulted in a p53-dependent G1 cell cycle arrest that was accompanied by up-
regulation of CDKN1A.  
The CTBP2 gene was detected in 11 other sarcoma samples in the tumour DNAseq. This gene 
was discussed in chapter 4. 
6.2.2.3.2 Common expressed genes in patients 55 and 66 
The SLC7A5 gene was detected as being expressed in patients 55 and 66, with different SNV 
mutations in the coding region. Again the control coverage is low for both SNVs, with 5 and 8 
in patients 55 and 66 respectively. This gene was also detected in four other samples (94, 197, 








6.2.2.3.3 Common expressed genes in patients 55 and 73 
Three genes were detected in patients 55 and 73: MTCH2, TPSAB1 and HLA-DRB1. MTCH2 
had four SNVs in patient 55, and one MNV and one SNV in patient 73. All mutations had high 
coverage in the normal control. TPSAB1 had one SNV in 55 and one in 73, with high control 
coverage for both SNVs. HLA-DRB1 had 3 mutations in patient 55: MNV, replacement and a 
deletion; and one MNV in patient 73, all with high control coverage. 
MTCH2 (mitochondrial carrier homologue 2) was also detected in the DNA of patients 59, 84, 
94 and 343. The MTCH2 protein is conserved and belongs to the mitochondrial carrier protein 
family, which catalyses the exchange of solutes across the inner mitochondrial membrane 
[109]. It was reported that knockout of MTCH2 in embryonic stem cells and in mouse 
embryonic fibroblasts inhibited recruitment of tBID (belongs to the Bcl-2 protein family which 
consists of both pro-apoptotic and anti-apoptotic members) to the mitochondria, and 
resulted in reduced apoptosis [109]. 
MTCH2 mutations in patient 55 appear in several reads in tumour DNA, but only in one read 
in the RNAseq, as shown in figure 6.4A. We tried to validate these mutations in the cDNA of 
tumour 55 by Sanger sequencing, but failed to detect any of the mutations, as shown in figure 
6.4B. This may be due to their low frequency in the RNA. 
The TPSAB1 gene was also detected in the tumour DNA of patients 59, 66, 74, 84, 90, 97A, 
197 and 297. 
HLA-DRB1 was detected in many other sarcoma samples; 52, 59, 60, 74, 84, 94, 97, 197, 244, 
297, 343, 364, 430 and 496. HLA-DRB1 belongs to the HLA-class II antigens, which are key 
components of the immune response. They may affect inflammatory responses toward self-






Figure 6.4. Detection and validation of mutations in MTCH2 gene. A, the CLC detected different somatic 
mutations in the tumour DNA sequence in patient 55. These mutations were expressed, as they were detected in 
one read of the tumour RNA seq. Both the DNA and RNA sequences were compared to the normal Hg19 genome 
sequence. B, the cDNA of this region was amplified from the tumour sample of patient 55 and sequenced by 











6.2.2.3.4 Common genes in patients 66 and 73 
There were 5 genes detected with expressed somatic mutations in patients 66 and 73: CDC27, 
AHNAK2, CTDSP2, FRG1 and FAT3. 
CDC27 was also detected in the tumour DNA of the patients: 55 (not detected in the RNAseq), 
59, 60, 74, 84, 94, 97, 297, 364, 430 and 496. CDC27 is a cell cycle regulator, which participates 
in control of the mitotic checkpoint and surveys the mitotic spindle to maintain chromosomal 
integrity [111]. Therefore, mutations in this gene may disturb its function and influence the 
mitotic progression of cells. One study has shown that the expression of CDC27 was down-
regulated in breast cancer cell lines and postulated that it may act as a tumour suppressor 
[111]. 
AHNAK2 was also detected in patients 52, 55, 60, 84, 90, 343 and 378. CTDSP2 was detected 
in 59, 90, 97B, 197, 343 and 430. FRG1 was detected in patients 52, 97B, 258, 297, 343, 364, 
378 and 496. 
The FAT3 gene is only detected in patients 66 and 73 (fig 6.5). However, other FAT genes are 
detected with somatic mutations in the DNA in other patients: FAT4 in 52 and 378, FAT1 in 
90, FAT2 in 297. All of them have been reported to be mutated in several cancer types and 
believed to work as tumour suppressors [112].  
Figure 6.5. FAT3 RNA expressed somatic mutations in patients 66 and 73. The CLC browser of FAT3 mutations 
in the tumour DNA and tumour RNA of patients 66 and 73. The sequences are compared to the Hg19 sequence. 
FAT3 mutation in patient 73
G>A Gly to Asp
FAT3 mutation in patient 66




6.2.3 Individualised mass spectrometric (MS) proteomics using the patient specific 
mutant references databases to identify expressed tumour specific antigens 
6.2.3.1 Proteogenomics 
As stated above, the genome DNA sequence can be considered to be static. The expressed 
cancer genome (e.g. RNA and protein expression) more accurately describes the cancer 
samples at the time of presentation in the clinic. It would also be of interest to compare the 
mutated cancer genome with the expressed RNA landscape and the proteome to define how 
this information, in total, can be used to describe the cancer tissue in molecular terms. 
Improvements in mass spectrometry (MS)-based peptide sequencing provide new 
opportunities for determining whether or not a somatic mutation is translated. Detection of 
somatic mutations by NGS of cancer genomes and transcriptomes has demonstrated their 
enormous complexity, and it is often unclear which somatic mutations drive tumour biology 
and which are non-functional passenger mutations. Mutation detection at the peptide level 
clearly increases the confidence that any given variant is potential biological driver. Thus, 
integrated proteogenomic methods that combine the DNA/RNA sequences and proteomics 
are of particular importance for identifying novel peptides resulting from somatic mutations 
[113]. Determination of which DNA or RNA sequence level variants are expressed as proteins 
provides a basis for prioritizing mutations for further study of their contributions to cancer 
phenotypes [114]. 
In general, proteins extracted from each sample (tissue) are digested using enzymes with a 
high specificity for known cleavage sites, such as trypsin. Then, tandem mass spectra are 
generated for individual peptides using mass spectrometry. These peptide spectra can then 
be identified, by searching for matches in generalized human proteome databases [115]. 
6.2.3.2 Proteomics of patient 55 
Protein lysate from patient 55 (tumour vs normal tissue) was processed using MS to identify 
total proteins present in the tumour (performed as a collaboration between the Hupp 
laboratory and Dr Borek Vojtesek’s laboratory, Brno, Czech Republic). The proteins 
overproduced in the tumour vs normal adjacent tissue are shown in Figure 6.6 (scatter plot). 
 A recent study has carried out a proteome screen using tandem mass tag isobaric labelling 
on three high-grade UPS, one of which is the tumour 55, and has identified the commonly 




receptors, using immunohistochemistry (ICH), arising from two different population cohorts 
representing over 300 patients [116]. The study has shown that there were 749 proteins 
expressed in the three UPS biopsies, but it focused on dominant transmembrane receptors 
that might be suitable as targets for receptor inhibitors in the future, such as CD44 and CLIC1. 
The study showed that CD63, CD44, CLIC1 and CLIC4 were overexpressed in the three 
sarcomas, compared to the normal tissue 22 (Figure 6.7), and confirmed their elevated 
expression by qRT-PCR and ICH. CD44 is a cell-surface glycoprotein that is known to play roles 
in extracellular cell–cell contacts, cell adhesion and migration, and it has been shown that its 
absence prevents metastasis in osteosarcoma in mice [116]. CLIC1 was shown to work as a 
pro-metastatic factor in a set of cancer models [116]. Interestingly, CD44, CLIC1 and CLIC4 
were detected as overexpressed proteins in tumour 55, compared to normal tissue, with fold 
changes of 89.2, 73.02, and 56.04 respectively. CD44 and CLIC4 were also detected in the 
overexpressed genes in tumour 55 generated by RNAseq. This validates patient 55 tumour as 





Figure 6.6. Scatter plot of the differentially expressed proteins in the tumour 55 compared to the normal tissue 
generated by MS. Each blue dot represents a protein with specific p-value (Y-axis) and fold change (X-axis). Some 
of the highly produced proteins are named in the figure. 
 
 
Figure 6.7. Differential expression of CD44, CD63, CLIC1, and CLIC4 in three sarcoma patients. A, Summary of 
quantitative protein expression of the four proteins CD44, CD63, CLIC1, and CLIC4 expression in T22, T53, and 
T55, compared with each other and with N22, are shown with GAPDH included for comparison as a control. B, of 
these proteins, CLIC1 is the most novel pro-oncogenic target, and as such we determined whether standard 
immunoblotting could be used to confirm the TMT data. Lysates from all three cancers (T22, T53, and T55) and 
























6.2.3.3 Overexpressed genes/proteins in the RNAseq list and proteins list 
We compared the highly expressed proteins (≥ 1.5-fold change) in tumour 55 with the 
overexpressed genes detected by RNAseq in the three sarcoma patients to see if there are 
any common genes in the two lists. We found 163 proteins, which are overproduced in 
tumour 55, that are also detected in the overexpressed genes (≥ 5-fold change) by RNAseq. 
These genes are listed in table 6.3.  
 
Number Gene Name Number Gene Name Number Gene Name 
1 ACAN 60 FARP1 119 RAC1 
2 FBN2 61 PLOD1 120 IGF2BP2 
3 HIST1H1B 62 AGRN 121 RHOC 
4 POSTN 63 CTSB 122 RPS2 
5 CRABP1 64 PDXK 123 IL4I1 
6 TNC 65 CALD1 124 ALDH1A3 
7 IGFBP2 66 EIF4A1 125 GSN 
8 MDK 67 GLB1 126 FBLN1 
9 AEBP1 68 PLOD2 127 XPNPEP1 
10 PTK7 69 CLIC4 128 RPS3 
11 MFAP2 70 ANPEP 129 STARD5 
12 COL16A1 71 YARS 130 RECQL 
13 FN1 72 CTSA 131 FNDC3B 
14 MMP14 73 ANXA2 132 LGALS1 
15 CD276 74 GPX8 133 MRC2 
16 MEST 75 ITGB1 134 BAX 
17 ANO1 76 ISG15 135 TXNDC5 
18 COL6A3 77 SCRN1 136 COPA 
19 HIST1H1D 78 MCM4 137 NUP50 
20 TFRC 79 OLFML3 138 A2M 
21 IGF2 80 PALLD 139 IFI30 
22 TNMD 81 SEC24D 140 NID2 
23 TGFBI 82 MXRA5 141 VGLL4 
24 LEPRE1 83 PRDX4 142 COL4A2 
25 HIST1H4A 84 GMFG 143 TAGLN2 
26 COL18A1 85 THY1 144 AKAP2 
27 SPRY4 86 AKAP13 145 PDIA5 
28 HAPLN3 87 ARHGDIA 146 PPIA 
29 COL12A1 88 SCARB2 147 SERPINB9 
30 SERPINE2 89 SEC23A 148 SERPINA1 
31 GPNMB 90 VKORC1 149 UPF1 
32 CRABP2 91 LAMB1 150 ARPC1B 
33 ISLR 92 VCAN 151 LGALS3BP 
34 FSCN1 93 BASP1 152 LTBP4 
35 LOXL2 94 P4HB 153 SEC13 
36 HIST1H2BN 95 FKBP14 154 IFI16 
37 ZNF185 96 COL6A2 155 ENO1 
38 CDKN2A 97 GGH 156 PPP2R4 
39 SERPINH1 98 MX1 157 PDIA3 
40 TIMP1 99 ARMCX2 158 NCL 




42 CTNNB1 101 CSRP2 160 NDRG1 
43 LTBP1 102 MAN1B1 161 CD44 
44 GUSB 103 CADM1 162 GANAB 
45 HIST1H1A 104 S100A4 163 HDAC1 
46 COL5A1 105 PAFAH1B3   
47 GARS 106 RAB31   
48 PXDN 107 CASK   
49 PDGFRB 108 ANXA5   
50 HM13 109 FMOD   
51 CALU 110 SPARC   
52 FLNA 111 PRKCSH   
53 LEPREL2 112 GALE   
54 MFGE8 113 PHGDH   
55 PCOLCE 114 STMN1   
56 COL6A1 115 PPIB   
57 SEC31A 116 RCN3   
58 CNN3 117 POFUT2   
59 EMILIN1 118 ISYNA1   
Table 6.3. Shared overexpressed genes/proteins in the differentially expressed gene profiles generated by 
RNAseq, and the overproduced proteins detected by MS in patient 55. 
 
Some of these highly expressed proteins have been reported to be elevated in other cancers 
such as POSTN and FMOD. The periostin (POSTN) gene encodes the ligand for integrin, one of 
the key focal adhesion proteins contributing to the formation of a structural link between the 
extracellular matrix and integrins. High expression levels of the POSTN gene are correlated 
with numerous human malignancies [117]. It was reported that POSTN over-expression in 
colorectal cancer was positively correlated with tumour size, differentiation, lymph node 
metastasis, clinical stage and five-year survival rate [117]. FMOD (fibromodulin) was found 
overexpressed in virtually all patients with chronic lymphocytic leukaemia tested, and not 
detected in circulating B cells and other peripheral blood cells, which suggests its important 
role in tumourigenesis [118].  
6.2.3.4 Identification of mutant proteins using the genomic data 
In addition to total proteomic analysis to identify pathways elevated in tumours, emerging 
aims include identifying mutated proteins, which requires bespoke reference databases from 
patients’ tumours. These mutated proteins can be drivers, and may be used as potential 
vaccines via MHC Class I neoantigen presentation. To determine whether our genomics 
(DNAseq and RNAseq) can be used to detect mutated peptides, we formed a mutant 
reference database of over 300 potentially mutated proteins derived from the DNA and 




Specifically, to identify mutated peptides using MS, we cross-referenced >4,000 proteins 
detected in the tumour to the variants (indels and SNVs; patient 55) to create a list of possible 
mutated proteins. We then created an in silico tryptic library of mutated peptides based on 
the DNA variant list (data not shown). This library was used to search mass spectra files for 
tryptic peptides with a mutation. Using this approach, we could detect >25 mutant peptides 
in the tumour. As a specific validation to highlight, the PDCD6 gene was found mutated in the 
tumour, expressed RNA was detected with a mutation, and the mass spectra was able to 
identify the mutated tryptic peptide (V98I) (Fig 6.8). SWATH-MS also showed that PDCD6 was 
elevated. Together, these data highlight the workflow that can be used to identify expressed 
mutant peptides, based on DNAseq, RNAseq, and MS.  
 
 
Figure 6.8. Mutant peptide identification. A, the browser shows a PDCD6 mutation from cancer DNA using 
CLCbio software (top; “A” mutation). Orthogonal validation is achieved using RNAseq (bottom; “A” mutant 
mRNA). B, uploading over 100 mutant tryptic sequences into Bruker software allows identification of the mutant 
peptide with fragmentation shown. C, the mutant peptides thus identified can form a database from which a 






6.2.4 RNA editing  
6.2.4.1 Number of variants specific to RNAseq 
As stated above, software used to annotate RNA expression is in its infancy and there are no 
“gold standards” yet available for widespread use. Our collaborators at CLCbio have 
developed their software to be used as a tool for RNA editing events. When we compared the 
RNAseq to the DNAseq of each patient, the CLCbio software detected many variants in the 
RNAseq that are not detected in the matched DNA of the same patient. There were 4118, 
3112 and 3304 specific RNA variants detected in patients 55, 66 and 73 respectively that are 
not encoded by the DNA. This is suggestive of RNA editing.  
6.2.4.2 Main types of RNA editing 
RNA editing is the changing of nucleotide sequence of RNA transcripts relative to that of the 
encoding DNA [119]. There are two major types of RNA editing in mammals: adenosine to 
inosine (A to I), and cytidine to uracil (C to U). The A to I editing is catalysed by the ADAR 
(adenosine deaminase acting on RNA) class of enzymes that bind double-stranded RNA [120]. 
In fact, the base I is read as guanosine and it does not pair with U but instead with C [121]. 
The C to U editing is catalysed by a diverse family of 10 different cytidine deaminases, called 
APOBECs, that can target RNA and DNA. The effects of RNA editing by ADAR and APOBECs are 






Figure 6.9. Effects of RNA editing by ADAR and APOBEC enzymes. Base deamination is carried out by ADAR (A 
to I) and AID/APOBEC (C to U; C to T) protein families that result in extensive molecular effects such as ADAR: 
alternative splicing, protein sequence alteration, RNA stability, miRNA regulation and cell fate; APOBEC: RNA 
sequence modification, DNA mutation, 3′UTR modification and regulation of DNA methylation. Furthermore, 
editing changes have widespread effects but many affect processes that are related to cell proliferation and 
development, e g., ADAR: haematopoiesis, embryogenesis, brain development and pluripotency, APOBEC: muscle 
development, pluripotency, embryogenesis and genomic diversity [122]. 
 
6.2.4.3 RNA editing effects and its role in cancer 
RNA editing is believed to be regulated, possibly in response to cellular or extracellular stimuli, 
and can affect several steps during gene expression and regulation, such as splicing, RNA 
stability, localisation and translation [120]. 
A significant emerging consequence of abnormal editing is a strong connection to cancer 
biology. Associations with both solid tumours and blood cancers have been observed for 
multiple ADAR and APOBEC family members [122]. RNA editing can modulate the expression 
of oncogenes or tumour suppressor genes, for example by causing non-synonymous changes 




predictive markers for patient stratification [123]. The data from differential gene expression 
profiles generated from RNAseq of tumour and normal tissues show that there is elevated 
expression of different ADAR and APOBEC transcripts in the tumours of patients 55, 66 and 
73 (fig 6.10), which may explain the high rate of RNA editing in these tumours. 
Fig 6.10. Overexpression of ADAR and APOBEC transcripts in the tumours of patients 55, 66 and 73. The mean 
expression levels of ADAR and APOBEC transcripts in the tumour RNAseq (blue) and normal RNAseq (brown) in 
patients 55, 66 and 73 are shown.  
 
6.2.4.4 RNA editing in the MAP4K5 gene 
One example of the detected RNA editing is A to T in the second transcript of the gene 
MAP4K5, as shown in figure 6.11. The CLCbio has detected this edit in the RNAseq of patient 
73 with high frequency (69%). The edit was validated by Sanger sequence as shown in figure 
6.11C. The edit changes the amino acid valine at position 569 to glutamic acid. It is at the 
intron–exon junction and seems to be important for splicing. As shown in figure 6.11(A, C), 
the first transcript of the gene does not have the codon CTA that has the edit, and this 
transcript has the exon that has R1 primer in the figure 6.3A, whereas the second transcript, 




also confirmed to occur in the normal RNA with a lower frequency in all sarcomas tested (data 
not shown). 
In another experiment, the whole exome and transcriptome of the A375 cell line was 
sequenced and analysed in the same manner as the sarcoma samples, to validate the RNA-
editing software. We were able to recapitulate some of the RNA edits observed in clinical 
tumour tissue, such as the edit found in the MAP4K5 gene (performed by Giuse Grasso in the 
Hupp laboratory). This edit merits further studies to see if it has a role in tumourigenesis.  
In a recent study [124] the expression of MAP4K5 in pancreatic ductal adenocarcinoma (PDAC) 
was examined. It showed that MAP4K5 expression was decreased or lost in 77.1% of PDAC, 
but it was expressed at a high level in the normal pancreatic ductal cells in 100% of the 
matched non-neoplastic pancreas samples. It also showed that the loss of MAP4K5 expression 
was associated with reduced overall survival of pancreatic cancer patients. Thus, it is believed 







Figure 6.11. Detection of RNA editing (A>T) in MAP4K5 gene. (A)  Diagram shows two transcripts of the 
MAP4K5 gene. The edit location is shown in the 2nd transcript as A to T. the location of the primers used to 
amplify the regions are shown by F1, F2 and R. (B) The CLC browser shows the edit in the RNAseq of patient 
73 and the normal sequence in the tumour DNA match and Hg19. (C) The Sanger sequence validation of the 
1st and 2nd transcript amplified by the primers (F-R1) above and (F-R2) below. 
 
 
6.2.4.5 MAP4K5 RNA editing in different species 
When we looked at the human MAP4k5 protein in Ensembl; we found that there are three 
different transcripts in regards to the codon that has the RNA edit (fig 6.12 A). The first one 
has no edit in the codon GTA which codes for the Valine amino acid. The second transcript 
has the edit in the codon and becomes GAA which codes for the amino acid Glutamic acid. 
The third transcript has this codon deleted and the so the amino acid. Pan species has the 
same three transcripts to humans (fig 6.12 B). Murine species has the codon GCA, instead of 
GTA, in one transcript which codes for Alanine. The other two transcripts are similar to the 
second and third transcripts to humans with the edited codon GAA and with the deleted 
codon respectively (fig 6.12 C). the Danio species have two transcripts only; one with the 
edited codon GAA, and one with the deleted codon (fig 6.12 D). so this edit is conserved in 
many species and seems to be important for alternative splicing to produce different forms 





























Figure 6.12. RNA editing and different splice forms of MAP4K5 in four different species. A and B, there are three 
different transcripts: no edit in the GTA codon which codes for Valine, edited to become GAA which codes 
for Glutamic acid, and the codon is deleted in humans and pans respectively. C, Murine has GCA codon in 
one form which codes for Alanine, the other two forms are similar to the humans and pans 2nd and 3rd forms. 
D, Danio has only two forms: one with the edited codon GAA and one with the deleted codon. 
 
 
6.2.4.6 Expression of MAP4K5 in UPS 
We have performed PCR to amplify part of the 2nd transcript cDNA, with the primer locations 
shown in figure 6.3A, from different sarcoma samples and their matched normal samples. The 
PCR results indicate that there is more expression of the MAP4K5 transcript in the tumours 
T55, T73, T52 and T97 than the normal tissues. This appeared as larger bands in the agarose 
gel as shown in figure 6.13A. This is also supported by RNAseq data that shows overexpression 
of MAP4K5 gene transcripts in the tumour of patients 55, 66 and 73 compared to the tumour 






Figure 6.13. Overexpression of MAP4K5 gene in the tumour tissues. A, Gel electrophoresis image of the 
PCR results of the 2nd transcript of MAP4K5 gene shown in figure 5.3A. The F2-R primers were used to amplify 
the 260 bases of MAP4K5 gene from the cDNA which is made from the RNA from the tumour and normal 
tissues of the sarcoma patients 55, 74, 73, 52, 258 and 97. Beta actin primers were used as a control. B, 
Mean expression of MAP4K5 gene transcripts in the tumour (blue) and normal (brown) tissue, in the RNAseq 
of patients 55, 66 and 73. 
 
6.2.4.7 RNA editing specific to tumour RNA 
We found that some of the detected RNA editing variants were also present in the normal 
RNA, such as the edit in MAP4K5. Therefore, we followed the steps shown in figure 6.14 to 
restrict the detected variants to the exome regions of the tumour RNAseq. This results in 
many SNVs specific to tumour RNA and each variant has coverage of at least 5 in the DNAseq. 
There were 3397 variants detected in patient 55; 2194 of them were non-synonymous, 1463 
variants in patient 66; 1033 of them were non-synonymous, and 1367 variants in patient 73; 
















Figure 6.14. Steps to identify RNA editing variants specific to tumour RNAseq. A, firstly, the somatic mutations 
were identified in the tumour DNA and RNA. Then the germline variants found in normal RNA were removed from 
the somatic DNA list, and the germline DNA variants were removed from the somatic RNA list. Create one list 
and annotate with gene names. Then extract the variants to choose the coverage and to remove false positives 
and variants outside target region. B, shows the variant track parameters. They should have coverage in DNA 
and RNA. They must be SNVs only and detected in the RNA but not DNA. 
 
The mutation types of these editing SNVs are different in the three patients. In patient 55, 
C>T is the highest edit, then G>A (C>T in the other strand). In patient, 66T>C is the highest 
edit type and then A>G. In patient 73, T>C is the edit and then C>T (figure 6.15). All of these 






Figure 6.15. The mutation types of RNA editing SNVs in patients 55, 66 and 73. The plot shows the number of 




6.2.4.8 Validation some of the RNA edits in patient 55 by deep sequencing 
We chose 10 edits in patient 55 for further validation by deep sequencing (fig 6.16). We chose 
the primer sequencing around the edit site, and linked an adaptor sequence to these primers. 
We amplified the regions directly from the tumour RNA of patient 55 using the superscript 
one-step RT-PCR kit. We sent the PCR products to the laboratory in Brno to perform deep 
sequencing on the amplified regions.  
We analysed the results of the deep sequences using the CLC software and found many 
variants almost at each base of the amplified regions, with different frequencies, including 
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A>C A>G A>T C>A C>G C>T G>A G>C G>T T>A T>C T>G
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Figure 6.16. Choosing 10 RNA edits for validation. A, table shows the 10 RNA edits chosen for validation by deep 
sequencing. It shows the chromosomal number and the SNV region, the frequency of the mutation in the RNA 
(count/coverage) and the gene name. B, the CLC Browser of the edit in the tumour RNA sequence of the KMT2D 
gene compared to the tumour DNA sequence and Hg19. C, the sequence of the region of KMT2D gene where the 
edit is (red G) and the primers chosen to amplify the region (underlined). 
 
6.2.4.9 RNA editing in BLCAP gene 
We compared the genes with of non-synonymous edits in the three patients, and found 9 
genes in common: NBPF10, NBPF1, ASH1L, RUSC1, NBPF10, PLOD2, BLCAP, PSD3 and MEGF8. 
We took BLCAP (bladder cancer-associated protein) as an example because this gene was 
reported to be a novel candidate tumour suppressor gene identified in human bladder 
carcinoma [125]. It was shown that BLCAP overexpression could inhibit cell growth by 
inducing apoptosis in HeLa cells, which suggests that the alteration in BLCAP may play an 
important role in tumourigenesis [125].  
There were 6 non-synonymous mutations detected in the BLCAP gene in the three patients: 
one in patient 55, two in patient 66 and three in patient 73 (table 6.4). Tyr2Cys was detected 
in 66 and 73. Gln5Arg was detected in 55 and 73. Lys15Arg detected only in 66 and Pro19Thr 




previously as RNA editing in BLCAP pre-mRNA amplified from human bladder [121]. The same 
study found that these editing events occurred within the most highly conserved region of 
the protein, within the N-terminus (figure 6.17), and were driven by the ADAR enzymes [121]. 
Pro19Thr edit in patient 73 has not been reported before, and is different from the other edits, 
as the previous edits were all A>G, but this is a C>A. 
 
 
Figure 6.17. Structure of BLCAP gene and its conserved regions among species. A, schematic representation of 
the BLCAP pre-mRNA. Exon 1 encoding the 5ʹUTR is represented in light blue with grey bars followed by the intron 
that divides the 5ʹUTR in 2. Exon 2 encodes the remaining 5ʹUTR (light blue with grey bars), the coding sequence 
(red rectangle) and the 3ʹUTR (light blue). Red dots indicate the editing sites in BLCAP mRNA (5ʹUTR and coding 
sequences). Red lines indicate the editing sites identified within the intron. B, multiple alignments of BC10 
proteins. Initials correspond to hs, Homo sapiens; pt, Pan troglodytes; bt, Bos taurus; mm, Mus musculus; rn, 
Rattus norvegicus; md, Monodelphis domestica; gg, Gallus gallus; xt, Xenopus tropicalis; tn, Tetraodon 
nigroviridis; ga, Gasterosteus aculeatus; dr, Danio rerio; ag, Anopheles gambiae; dm, Drosophila melanogaster; 
ce, Caenorhabditis elegans. Identical amino acid conservation among species is indicated in black. Residues 
identical in most of the species analysed are indicated in grey. Amino acids found to be edited are Indicated in 
red. Black lines above the alignment indicate the hypothetical transmembrane domains (TM). Stars indicate the 












Although some of the edits have been reported to occur in normal tissues, there may be 
differences in percentage of the editing events in the tumour and normal tissues due to 
different expression of editing enzymes in the two tissues. A study that integrated RNAseq 
and DNAseq data derived from two pairs of hepatocellular carcinoma (HCC) tissues, found 
that BLCAP is a novel editing gene and has over-editing expression in 40.1% HHC tissues, 
compared to adjacent liver tissues [126]. The same study has shown that the RNA-edited 
BLCAP, when compared to the wild type, stably promotes cell proliferation (including cell 
growth, colony formation in vitro, and tumoringenicity in vivo). 
 
Sample Mutation Amino Acid change Frequency 
55 14A>G Gln5Arg 7.14 
66 5A>G Tyr2Cys 18.75 
44A>G Lys15Arg 10.71 
73 5A>G Tyr2Cys 35.29 
55C>A Pro19Thr 11.11 
14A>G Gln5Arg 11.11 
Table 6.4. RNA editing SNVs in BLCAP gene in three UPS patients. The table shows the type of mutations, 
which is A>G in all of them except one C>A in patient 73. The amino acid change and the frequency 






































1 16893721 SNV 4 16 25 5 T>G Phe931Cys 
NBPF
1 
55 1 155979344 SNV 16 44 36.36 16 70C>T Thr180Met SSR2 
55 






n 65 74 87.84 32 Del C Arg260fs 
MOV1
0 
55 1 32209833 SNV 62 71 87.32 39 C>T Arg350Trp BAI2 
55 
















n 81 91 89.01 20 del CTT Leu19del WDR6 
55 




































































551937 MNV 15 107 14.02 29 
Del TAC 


















ment 18 116 15.52 30 
Del GC 













609213 MNV 8 16 50 31 
Del CG 






609222 MNV 8 18 44.44 31 
Del GA 
















609228 MNV 10 19 52.63 32 
Del AG 
ins CA Ser75His 
HLA-
DQA1 
55 6 35280196 SNV 30 83 36.14 33 G>A Val89Ile DEF6 
55 








n 86 88 97.73 38 Del CAA Gln95del TBP 
55 6 56354402 SNV 102 118 86.44 38 T>A His6601Gln DST 
55 




























8 8234126 SNV 113 180 62.78 46 G>A Arg598Gln 
SGK2
23 
55 8 28588774 SNV 90 132 68.18 48 G>A Arg344Gln EXTL3 
55 










26683244 MNV 11 94 11.7 33 
Del GG 
ins CA Gly192Gln CTBP2 
55 
10 69571283 SNV 48 59 81.36 59 C>T Thr99Met 
DNAJ
C12 
55 11 65408583 SNV 34 39 87.18 11 C>T Thr64Met SIPA1 
55 
















11 47652591 SNV 10 67 14.93 22 A>T Tyr159Phe 
MTCH
2 
55 11 26463504 SNV 65 76 85.53 35 C>T Ser29Leu ANO3 
55 

















491581 MNV 24 27 88.89 11 
Del GC 




12 112605710 SNV 67 73 91.78 19 C>T Arg3902Cys 
HECT
D4 

























































17 63687 SNV 46 50 92 22 G>A Ala273Thr 
RPH3
AL 
55 17 7577538 SNV 72 75 96 23 G>A Arg248Gln TP53 
55 
17 18832245 SNV 62 69 89.86 27 G>A Arg309Gln 
PRPS
AP2 
55 17 8052583 SNV 34 107 31.78 46 G>A Arg300His PER1 
55 
17 72436616 SNV 125 139 89.93 53 G>A Arg279His 
GPRC
5C 
55 19 14552150 SNV 24 41 58.54 18 G>A Val85Ile PKN1 
55 
































































1 16907946 SNV 2 35 5.71 16 G>A Ala450Thr 
NBPF
1 










2 241991199 SNV 89 163 54.6 62 G>A Gly592Arg 
SNED
1 
66 3 195509515 SNV 7 19 36.84 6 A>T Asp2979Val MUC4 






n 24 139 17.27 40 
Ins 
CTTC Met1? FRG1 
66 




























385603 MNV 8 47 17.02 7 
Del GT 
ins AG Gly131Glu AQP7 
66 9 33385600 SNV 7 46 15.22 7 C>T Pro132Leu AQP7 
66 
10 96282182 SNV 6 22 27.27 5 C>G Leu658Val 
TBC1
D12 
66 10 126691583 SNV 17 144 11.81 45 G>A Val102Met CTBP2 
66 10 126691636 SNV 14 205 6.83 62 C>A Thr84Asn CTBP2 
66 11 125359559 SNV 52 158 32.91 42 G>A Glu39Lys FEZ1 
66 11 92624013 SNV 113 357 31.65 80 G>A Glu4352Lys FAT3 
66 12 6128898 SNV 3 42 7.14 6 T>G Val1229Gly VWF 
66 




12 58240184 SNV 7 103 6.8 30 G>T Arg12Met 
CTDSP
2 
66 12 7045924 SNV 46 173 26.59 76 G>T Gln498His ATN1 
66 













































234721 MNV 8 31 25.81 15 
Del AA 
































n 9 9 100 6 
Del 
GGCGG
C Ala12_Ala13del GPX1 
73 
3 127806598 SNV 56 121 46.28 22 G>A Arg357Gln 
RUVB
L1 














787673 MNV 32 421 7.6 67 
Del CAA 



























n 17 154 11.04 35 
Ins 




497962 MNV 9 45 20 16 
Del AAG 
ins GTT Lys14Val 
HLA-
DRB5 




557479 MNV 7 72 9.72 23 
Del CG 






238910 MNV 10 140 7.14 37 
Del AC 
ins CG Thr187Arg HLA-C 
73 








9 15422903 SNV 61 84 72.62 45 26C>G Pro9Arg 
SNAP
C3 
73 10 126682443 SNV 4 45 8.89 12 C>A His298Asn CTBP2 
73 






660335 MNV 13 164 7.93 39 
Del TG 















n 9 157 5.73 41 Del CTG Leu9del TSKU 
73 
11 117163801 SNV 40 162 24.69 56 A>T Asn226Ile 
BACE
1 




217422 MNV 10 123 8.13 34 
Del AC 






217815 MNV 12 133 9.02 65 
Del TT 






217804 MNV 19 168 11.31 71 
Del TT 
ins AC Cys192Arg 
CTDSP
2 
73 13 98641358 SNV 61 81 75.31 34 T>G Leu117Arg IPO5 
73 
14 105409196 SNV 14 129 10.85 16 G>A Asp4198Asn 
AHNA
K2 
73 15 23931508 SNV 25 67 37.31 14 A>G Asp286Gly NDN 
73 














































542291 MNV 10 22 45.45 8 
Del CT 





































Table 6.2. The expressed somatic mutations in the RNAseq of patients 55, 66 and 73. The table shows the 
chromosomal number and region of each mutation, the mutation type, count, coverage and frequency in the 





Cancer genome sequencing has revolutionized our understanding of the genetic basis of 
cancer, the classes of mutagenic events that drive cancer development, and the identification 
of genetic drivers. However, we do not yet know how this mutated code is translated into an 
expressed phenotype. Identifying the expressed cancer genome, using RNAseq and protein 
quantitation methods such as mass spectrometry, provides a more accurate view of the state 
of the cancer tissue at the time of presentation in the clinic. I was fortunate to have the 
opportunity to use a new software tool (in collaboration with CLCbio) that focused on the 
current state of the art in RNAseq mutation software that exploited cancer DNA sequencing. 
This enabled us to identify the dominant RNAs that were cancer genome encoded, and led us 
to highlight ~15% of mutated cancer genes are expressed at the time of surgery. I suggest that 
these mutated pathways or genes represent more realistic targets for therapeutics or 
diagnostics than conventional mutated cancer genes. For example, a mutant gene might have 
been required very early in the evolution of the cancer and might not even be expressed at 
the time of surgery. In addition to the expressed cancer-encoded genome, we also were able 
to use the novel software to identify mutations in RNA that are not genome encoded. This is 
suggestive of RNA editing. Some of these genes were validated by Sanger sequencing and by 
examining RNAseq in cell lines. For example, we find that MAP4K5 is indeed edited in cell lines, 
thus providing a model gene to dissect stages in RNA editing in the future. Currently, we do 
not know how many of the cancer genes that are mutated, the expressed RNA that is genome 
encoded or the RNA that is edited, are expressed at the protein level. I have shown one 
example where the mutated PDCD6 gene had detectable mutated RNA and mutated peptide 
using mass spectrometry. The full exploitation of mass spectrometry was beyond the scope 
of my PhD thesis, which was focused largely on DNA and RNA sequencing. It will nevertheless 
be interesting in future to determine how much of the potential mutation, whether coded 
from genome mutation or RNA editing, is translated into mutated protein. My current thesis 
data shows, using novel software designed for biologists and clinicians, that is it realistic to 








Studying the effects of the expression of 
wild-type and mutant ELMO1 in 
oesophageal adenocarcinoma cell lines 
7.1 Abstract 
Genomics and proteomics provide us with the tools with which to identify novel mutated 
genes and their associated proteins. The development of protocols to capture new signalling 
pathways driven by mutated genes and proteins will be valuable for exploiting genomic 
information. In this chapter, methods with which to explore functions of a novel mutated 
protein identified from genomic studies are set up. I would have aimed to develop this with 
mutations from UPS, but do to time constraints of the PhD training, I in parallel developed 
this method using mutations generated in OAC at the start of my PhD training. The mutated 
protein (ELMO1) was identified and chosen from OAC genomics, and the one chosen is a gain-
of-function oncogenic mutation. The mechanism whereby it operates as a gain-of-function 
mutant is not known and the interactomic methodologies set up in this chapter aim towards 
finding this out. OAC is characterized by an early invasion pathway that is linked to high 
frequency of gain-of-function mutations in the RAC signalling pathway that mediates 
metastasis. One of the key high frequency genetic mutations is in the DOCK–ELMO pathway, 
and the mechanisms describing its gain-of-function signalling are not well defined. We 
developed an SBP-tagged affinity purification method, in combination with label-free SWATH-
MS, to identify novel binding proteins of the gain-of-function mutant protein ELMO1, the 
product of a key metastatic gene. This method identified an elevated interaction with other 
oncogenic proteins encoded by the AGR2 and DCD genes and validates this proteomics 








7.2.1 mutant genes in OAC 
OAC has undergone a significant and rapid increase in incidence in the Western world. The 
reasons behind this increase are not completely understood. Because the disease is usually 
at an advanced stage at the time of diagnosis, the prognosis of OAC remains poor, with an 
overall five-year survival of ∼18% [127]. In 2013, a study analysed the mutation spectra from 
whole-exome sequencing of 149 OAC tumour–normal pairs, 15 of which were also subjected 
to whole-genome sequencing, a step expected to lead to identification of new therapeutic 
target for OAC [41]. By using MuTect and Indelocator to identify somatic mutations, the study 
found 26 genes to be significantly mutated, with two known tumour suppressors in OAC: TP53 
and CDKN2A being the most significant (fig 7.1). With the exception of ARID1A, PIK3CA and 
SMAD4, no other significantly mutated gene had previously been implicated in OAC, although 
several had been implicated in other cancers [41]. 
 
Figure 7.1. Significantly mutated genes in OAC as identified by whole-exome sequencing. Mutations in 
significantly mutated genes coloured by the type of coding mutation. Each column denotes an individual tumour, 
and each row represents a gene. Left, number and percentage of samples with mutations in a given gene. The 
grey bar represents the number of transversions at AA sites in a gene. Listed numbers within bars represent 
values exceeding the scale. Right, −log10 (q values) for the significance level of mutated genes shown for all genes 









7.2.2 Mutations in ELMO1 and DOCK2 in OAC samples 
Two of the significantly mutated genes are engulfment and cell motility 1 (ELMO1) and 
dedicator of cytokinesis 2 (DOCK2), which encode dimerization partners and intracellular 
mediators of the Rho family GTPase, RAC1. Although no RAC1 mutations were identified, 
either ELMO1 or DOCK2 was mutated in 25 OAC samples (17%), with two samples having 
mutations in both genes and two samples having two independent mutations in DOCK2 (fig 
7.2a, b). A single amino acid, Lys312 of ELMO1, was affected by mutation in three tumours 
(fig 7.2a), which suggests a gain-of-function mutation. Because aberrant RAC1 activation has 
been implicated in malignant transformation in other cancer types, mainly by enhancing 
cellular motility, recurrent mutations in these genes may be functionally important [41]. 
7.2.3 Gain of function mutations in ELMO1 
The mutations in ELMO1 were examined. Wild type (wt) and mutant ELMO1 constructs were 
generated and introduced into NIH/3T3 cells (mouse embryonic fibroblast cells). Compared 
to a green fluorescent protein (GFP) control, wt ELMO1 expression increased invasion by 
sevenfold (fig 7.2c). ELMO1 alterations (p.Phe59Leu, p.Lys312Glu, p.Lys312Thr, p.Lys349Arg 
and p.Thr421Asn) resulted in further significant increases (two to sevenfold) in invasion 
compared to wt ELMO1 (fig 7.2c). These results suggest that ELMO1 mutations can increase 





Figure 7.2. Recurrent somatic alterations in ELMO1, DOCK2 and other RAC1 GEFs. A, schematics of protein 
alterations in DOCK2 and ELMO1 detected by whole-exome sequencing. Coding alterations in OAC are coloured 
either in black (missense) or red (splice site or nonsense); silent mutations are depicted in grey. Conserved domain 
mapping is from UniProt; SH3, SRC homology 3; DHR, Dlg homologous region, ELMO, engulfment and cell motility; 
PH, Pleckstrin homology. B, sample mutational frequency of candidate ELMO1 and DOCK2 as well as other RAC1-
activating GEFs in 145 whole-exome sequenced OACs. C, wild-type or mutant ELMO1 proteins (or GFP control) 
were expressed in NIH/3T3 cells using retroviral transduction with the pBabe vector. Protein expression was 
confirmed by immunoblot analysis. Cells were plated in Matrigel invasion chambers with medium containing full 
serum in the lower chamber only, and invading cells from four fields were counted. The numbers of invading cells 
from three independent replicates are shown. Error bars, s.d. P values compare mutant ELMO1 to wild-type 









7.2.4 RAC activation by ELMO1-DOCK complex 
DOCK proteins are guanine nucleotide exchange factors (GEFs) controlling the activity of 
RAC1/CDC42 during migration, phagocytosis, and myoblast fusion. There are 11 mammalian 
members of the DOCK family: DOCK180 and DOCK2-11. They share the DOCK-homology 
regions (DHR1 and DHR2), which are known as Docker domains and lack the DbI homology 
(DH) and pleckstrin homology (PH) domains typically present in the mammalian Rho-family 
GEFs [128]. ELMO1 (75 KDa) is a cytoplasmic adaptor protein that physically associates with 
members of the DOCK family of RAC-GEFs, of which DOCK180 and DOCK2 are the best 
characterized. ELMO1 contains a PH domain for interaction with DOCK proteins [129]. Several 
studies have shown that ELMO1 binding enhances DOCK signalling by increasing its RAC-GEF 
activity, membrane localization, and protein stability [130]. It was reported that ELMO1 
modulated the RAC1 activation with Dock180 by at least three explicit mechanisms namely: 
helping DOCK180 stabilize RAC1 in its nucleotide-free transition state; protecting Dock180 
from ubiquitylation; and targeting Dock180 to the plasma membrane to get access to 
Rac1[131]. A study has developed a Transwell migration assay with LR73 cells (ovary cell line) 
to investigate the role of ELMO1 alone, DOCK180 alone, and co-expression of both genes, on 
cell migration [132]. The study found that co-expression of DOCK180 and ELMO1 strongly 
promoted migration compared with control cells, whereas expression of DOCK180 alone or 
ELMO1 alone did not promote migration, indicating a requirement for both proteins for this 
effect (fig 6.3). To prove this migration was RAC dependent, they co-transfected ELMO1 and 
DOCK180 with a dominant negative form of RAC (RacT17N), and found inhibition of migration 
increased (fig 7.3), which suggests that the enhancement of migration with DOCK180–ELMO1 






Figure 7.3. Dock180 and ELMO1 cooperate to promote RAC-dependent cell migration. LR73 cells were 
transiently transfected with the indicated plasmids plus a luciferase reporter construct. After 24 h, 1–105 cells 
were plated in duplicate on top of a 24-well Transwell chamber filter and allowed to migrate for 6 h. Equal 
numbers of cells were also plated in a separate chamber without a filter to estimate total luciferase activity for 
each condition. The percentage migration was calculated by dividing counts in the bottom chamber (migrated 
cells) by the total cell counts for each condition. Each point represents the mean percentage ± S.E. of two 
duplicate migration chambers. The luciferase alone control is set at 100%. Aliquots of cells from each transfection 
condition were lysed and immunoblotted with anti-FLAG to confirm expression of Dock180 and RacT17N and 












7.2.5 The role of RAC1 in cellular processes 
RAC1 is a member of the Rho GTPase family, which includes Rho, RAC1 and CDC42. These 
proteins classically regulate the machinery that controls the assembly and disassembly of 
cytoskeletal elements [133]. As a modulator of the cytoskeleton, RAC1 activity is critical for a 
number of normal cellular activities, including phagocytosis, mesenchymal-like migration and 
axonal growth. RAC1 also plays a major role in the moderation of other signalling pathways 
involved in cellular growth and cell cycle regulation. These RAC1-mediated activities appear 
central to the processes that underlie malignant transformation, including tumorigenesis, 
invasion, and metastasis [133]. The activation of RAC1 is through a GDP/GTP exchange 
mechanism catalysed by the GEFs resulting in an active, GTP-bound state [134]. The Rho 
GTPase GEFs are a large family of proteins that contain either a DH domain involved in 
nucleotide exchange or DHR domain that facilitates GEF function [134]. 
 
7.2.6 Structure of the ELMO1–DOCK complex 
7.2.6.1 ELMO1 
ELMO1 was previously identified as a mammalian orthologue of Caenorhabditis elegans CED-
12. It is functionally divided into N-terminal and C-terminal parts. The N-terminal region of 
ELMO1 is necessary for membrane targeting. The C-terminal region of ELMO1 interacts with 
proteins such as DOCK2 and is required for modulating downstream molecules [135]. 
Although ELMO1 has no intrinsic catalytic activity, it mediates several cellular functions by 
providing a scaffold for signalling proteins or by regulating the activity of other proteins via 
protein–protein interactions [135]. Among vertebrates, ELMO1 is an evolutionarily highly 
conserved protein that contains several armadillo repeats, a putative pleckstrin homology 




Figure 7.4. ELMO1 is a highly evolutionarily conserved protein. Multiple amino acid alignment of human 
(HELMO1), mouse (mELMO1), and zebrafish (zELMO1) ELMO1. Numbers indicate amino acid positions. Indicated 
are the predicted pleckstrin homology domain (black line), DOCK180 binding domain (red line), and the proline-
rich motif (double black line) [129]. 
 
 
7.2.6.2 binding regions of ELMO1 and DOCK2 
A study has identified the N-terminal 177-residue fragment and the C-terminal 196-residue 
fragment of human DOCK2 and ELMO1, respectively, as the mutual binding regions, and 
solved the structure of their complex at 2.1-A resolution (fig 7.5) [128]. The C-terminal Pro-
rich tail of ELMO1 winds around the Src-homology 3 domain of DOCK2, and an intermolecular 
five-helix bundle is formed. Overall, the entire regions of both DOCK2 and ELMO1 assemble 





Figure 7.5. Mutually interactive regions of DOCK2 and ELMO1. A, domain organizations of DOCK2 and ELMO1. 
Known protein interaction and functional regions are indicated. Blue and red bars indicate the DOCK2 and ELMO1 
regions included in the NMR construct. Green and yellow bars indicate the regions used for the crystal structure 
determination. ELMO1-interacting region (EIR) and DOCK2-interacting region (DIR) indicate the ELMO1-
interacting region and the DOCK2-interacting region, respectively. B, overviews of the crystal structure of the 
DOCK2–ELMO1 complex. Ribbon representations of the DOCK2–ELMO1 complex. DOCK2 is coloured green and 
ELMO1 is yellow. The six proline residues in the ELMO1 Pro-rich tail are coloured red. The two views are related 











7.2.6.3 An autoinhibitory mechanism in ELMO1 and DOCK2 
Both ELMO1 and DOCK2 proteins were shown to have autoinhibitory mechanisms. In ELMO1, 
the ELMO1 inhibitory domain (EID) binds to the ELMO1 autoregulatory domain (EAD) 
resulting in an autoinhibited form of the protein (fig 7.6), and in DOCK2 the SH3 domain 
interacts with catalytic DHR-2 domain, which may block RAC1 access to the DHR-2 domain 
and cause autoinhibition of DOCK2 (fig 7.6). Binding of ELMO1 to RhoG promotes relief of 
autoinhibition in ELMO1, and the binding of ELMO EAD domain to DOCK2 relieves DOCK2 
from autoinhibition, as shown in figure 7.6 [128, 136]. Double mutations in the EAD domain 
of ELMO1, Met692 and Glu693 to Ala, have been reported to disrupt the interaction between 
the EID and EAD, which leads to increased activity of ELMO1 [128]. 
 
Figure 7.6. Hypothetical model of the DOCK2–ELMO1 complex. Schematic model of the mutual relief of DOCK2 
and ELMO1 from their autoinhibited forms for RAC1 activation. EIR, ELMO1-interacting region; DIR, DOCK2-












7.2.7 ELMO1 binds to RhoG  
In addition to the DOCK proteins, other proteins are reported to bind to ELMO1 such as RhoG. 
RhoG is a member of the Rho family of small GTPases and is involved in cellular morphological 
processes such as neurite outgrowth in neuronal cells, which also requires the activation of 
RAC1. The GTP-bound form of RhoG, but not the inactive form, specifically binds to the N-
terminus of ELMO1. Thus ELMO1 is a mediator that links RhoG activation to RAC1 by 
interacting with both RhoG and DOCK [137, 138]. 
 
7.2.8 ELMO1 expression in cancer 
A study of human glioma cells detected high level of ELMO1 and DOCK180 expression in 
actively infiltrating cells within the invasive regions compared with the central tumour areas 
of primary human glioma specimens. They also reported that the inhibition of endogenously 
expressed ELMO1 and DOCK180 attenuated the invasive behaviour of glioma cell lines 
concomitant with a reduction in the activated RAC1. Conversely, exogenous expression of 
ELMO1 and DOCK180 in low-level expressing glioma cells increased their capacity to migrate 
and invade, both in vitro and in the brain, emphasizing the importance of these molecules in 
the invasive process of these malignant cells [134]. 
Previous studies in Rhabdomyosarcoma (RMS) have shown that the more metastatic RMS 
subtype, which has a worse prognosis, also expresses higher levels of ELMO1. The down 
regulation of ELMO1 in these cells has been shown to decrease the invasive nature of the cells 
[139]. This indicates that ELMO1 may be involved in the migration and subsequent metastasis 
of RMS cells and may be considered as a novel target for treatment. 
Another study aimed at identifying the role of ELMO1 in cell migration in ovarian cancer has 
reported that ELMO1 was mainly expressed in high-grade ovarian cancer tissues. Also, 
decreased colony formation and cell invasion were observed in ELMO1-RNAi cells, compared 
with the negative control, [131]. The study concluded that ELMO1 shows synergistic action in 
helping DOCK180 to activate RAC1 and promote cell motility, and thus promote untoward 




ELMO1 showed high expression in human breast cancer samples, and the expression 
correlates with lymph node metastasis and distant metastasis in breast cancer patient 
samples [140]. 
7.3 The aim and strategy of this study 
The ELMO1 gene and its gain of function mutations detected in OAC samples may play a role 
in OAC metastasis and can be a therapeutic target for OAC patients. This therefore forms a 
“model” for developing interactomic methods to identify new functions for a mutated protein 
defined by genomics, which I would have aimed to do in UPS if training time permitted. The 
aim of this research was to study the effect of wt and mutant ELMO1 (F59L) proteins in OAC 
cell lines and to identify the mode of action of the gain-of-function mutation, but it can also 
apply to mutated genes in UPS, such as IL11R mutation or the PDCD6 mutation described in 
the previous chapters.  
We tested the expression of ELMO1 in our key OAC cell lines: OE19, OE33 and FLO-1, and 
found that none of these cells express ELMO1. Therefore, we cloned ELMO1 cDNAs into 
human cell expression vectors and used them to develop artificial cell lines that express the 
wt and mutant ELMO1. We studied the effects of the wt and mutant ELMO1 on the growth 
of colonies in the transfected cell lines using a clonogenic assay. We have also developed an 
SBP-tagged affinity purification method, in combination with label-free SWATH MS, to 
identify novel binding proteins for the gain-of-function mutant ELMO1. This approach 
identified elevated interaction with other oncogenic proteins encoded by anterior gradient 
protein 2 (AGR2) and Dermcidin (DCD) genes. We further validated the interaction between 











7.4.1 Expression of ELMO1 in OAC cell lines 
We grew OAC cell lines OE19, OE33 and FLO-1 in specific media in a 37°C incubator. When 
they were approximately 100% confluent we lysed them in urea lysis buffer. We measured 
the protein concentrations in each lysate by Bradford assay and ran 20 µg of protein on 
sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS–PAGE) for Western blot 
analysis. Jurkat cell whole-cell lysate (sc-2204 Santa Cruz Biotechnology) was used as a 
positive control for ELMO1 expression because it has been reported that this cell line 
expresses ELMO1 and DOCK2 [141]. By using an ELMO1 specific antibody (Abcam ab2239 goat 
polyclonal) we could not detect ELMO1 expression in any of three OAC cell lines, whereas 
there is expression of ELMO1 in Jurkat cells (fig 7.7). This result was supported by our failure 
to amplify ELMO1 by PCR from the cDNA made from the whole RNA purified from each of the 
OAC cell lines (data not shown). This means that ELMO1 is not expressed in these three OAC 
cell lines. The expression of ELMO1 may be in different locations in the tumour, compared 
with the OAC cell lines examined. Indeed, it has been reported that immunohistochemistry 
(IHC) analysis of primary human glioma specimens showed high levels of ELMO1 in actively 
invading tumour cells in the invasive area, but not in the central regions of these tumours 
[134]. 
To study the effects of ELMO1 in the OAC cell lines we cloned ELMO1 into the human 







Figure 7.7. Western blot results of immunoblotting lysates of OAC cells and Jurkat cells with ELMO1 and β-
actin antibodies. OAC cell lines: OE19, OE33 and FLO-1 were lysed using urea lysis buffer. OAC protein lysates 
and whole Jurkat lysate (20µg) were run on a 12% gradient gel then transferred onto 0.2 μM nitrocellulose 
membrane. The membrane was incubated with goat polyclonal ELMO1 primary antibody at a dilution of 1/1000 
for one hour at room temperature (RT), and after washing it was incubated with rabbit anti-goat secondary 
antibody (1/1000). The membrane was also incubated with rabbit polyclonal to beta Actin (β-actin) as positive 
control because Actins are ubiquitously expressed in all eukaryotic cells. Antibody signal was detected using 
enhanced chemiluminescence (ECL). 
 
 
7.4.2 Cloning of ELMO1 in pEGFP-C1 and pEXPR-IBA105 vectors 
The Elmo1 gene was provided by Dr. Tilo (Heriot-Watt University) as a cloned gene in the 
pCR®-Blunt II-TOPO® vector. Elmo1 was amplified by PCR using the primers: 
ACCGGAATTCTATGCCGCCACCCGCGGAC and CGGTGGATCCTTAGTTACAGTCATAGACGAA with 
EcoR1 and BamH1 restriction sites respectively to clone it in the pEGFP-C1 vector, and 
GGGGGAATTCGATGCCGCCACCCGCGGACATCGTC and 
CCCCGGATCCTCAGTTACAGTCATAGACGAAGTC with EcoR1 and BamH1 restriction sites 
respectively to clone it in pEXPR-IBA105 Twin-Strep-tag vector (fig 7.8).  











Figure 7.8. Diagram of pEGFP-C1 and pEXPR-IBA105 vectors in which ELMO1 was cloned using EcoR1 and 
BamH1 restriction sites. Both vectors have neomycin resistance selectivity. 
 
The PCR product of Elmo1 and the two vectors (pEXPR-IBA105 and pEGFP-C1) were digested 
with EcoR1 and BamH1 restriction enzymes. After 3 h incubation at 37°C the digested DNA 
was run on a 1% agarose gel, specific bands were excised from the gel and DNA extraction 
was performed using a DNA extraction kit (Qiagen) followed by PCR purification. 
A ligation reaction was carried out to clone Elmo1 into the two vectors. 
DH5α cells were transformed with the ligation product and incubated at 37°C overnight. 
Colonies obtained were grown in LB media at 37°C overnight with shaking, and DNA mini-
preps were prepared the following day. Mini-preps were digested with EcoR1 and BamH1 and 
analysed on a gel to determine which clone contained Elmo1. Clones were sent for Sanger 
sequencing, which confirmed the presence of ELMO1 in both vectors.  
7.4.3 Making mutant ELMO1 (F59L) by PCR 
The next step was to make the F59L mutation in ELMO1. We generated the mutant ELMO1 
(F59L) by site directed mutagenesis, in which we designed a primer that has the mutant codon 
TTA that codes for leucine (L) instead of the wt codon TTC that codes for the phenylalanine at 
position 59 (F59). PCR reactions (2.5 μl) were transformed into DH5α competent cells and 
plated on LB agar plates. Colonies were selected and plasmid DNA obtained using the Qiagen 







Figure 7.9. Confirmation of the presence of C>A mutation in ELMO1 by Sanger sequencing. 
 
7.4.4 Transfection of wt and mutant ELMO1 in OAC cell lines 
We prepared large-scale plasmid DNA containing the wt and mutant ELMO1 using the 
HiSpeed Maxi-prep kit from Qiagen. We transfected FLO-1 and OE19 cell lines with 1 µg of 
GFP empty vector, GFP-wt ELMO1, GFP-F59L ELMO1, Strep-wt ELMO1, or strep-F59L ELMO1, 
using Attractene as a tranfection reagent. After 24 hours of incubation at 37°C, cells were 
lysed with 0.5% NP40 lysis buffer. Protein concentrations were measured by Bradford assay, 
and 10µg of proteins were loaded on SDS-PAGE and immunoblotted with GFP and ELMO1 
antibodies to test the expression of ELMO1. Wt and mutant ELMO1 were successfully 
expressed from both vectors in FLO-1 (fig 7.10) and OE19. 
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Figure 7.10. Western blot results of FLO-1 cell line transfected with wt and mutant ELMO1. FLO-1 was 
transfected with 1µg of GFP empty vector (1) as a control, GFP-wt ELMO1 (2), GFP-F59L ELMO1 (3), Strep-wt 
ELMO1 (4), and Strep-F59L ELMO1 (5). Attractene was used as a transfection reagent. Cells were lysed 24h after 
incubation at 37°C, with 0.5% NP40 lysis buffer. Proteins (10µg) were run on two 12% gradient gels and then 
transferred to 0.2 μM nitrocellulose membrane. A, the first membrane was blotted with rabbit anti-GFP primary 
antibody, and swine anti-rabbit secondary antibody. B, the second membrane was blotted with goat anti-ELMO1 
primary antibody and rabbit anti-goat secondary antibody. All antibodies were used at 1/1000 dilution and 
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7.4.5 Clonogenic assay  
The clonogenic assay has been established for more than 50 years. It enables an assessment 
of the differences in reproductive viability (capacity of cells to produce progeny) between 
control untreated cells and cells that have undergone various treatments such as exposure to 
ionising radiation, various chemical compounds or, in some cases, genetic manipulation [142]. 
Here we have used this assay to study the effect of wt and mutant ELMO1 on the viability and 
growth of FLO-1 cells by transfecting them with empty vectors (GFP and Streptactin), vectors 
with wt ELMO1, and vectors with mutant ELMO1 (F59L). After 24h of transfection, cells were 
trypsinized and re-cultured in medium containing neomycin for growth selection; both the 
GFP and strep vectors contain neomycin resistant gene, so only cells that have these vectors 
will survive. After a period of time (around 1 month) cells were washed and dyed with 
Leishman stain. There were more colonies in the plates containing wt ELMO1, compared to 
those containing empty vector (for both GFP and strep). Mutant F59L ELMO1 results in a 
higher number of colonies (similar to the mutant P53) compared to the wt ELMO1 (fig 7.11). 
This means that the exogenous expression of wt ELMO1 has increased the growth of FLO-1 
cells giving them advantageous growth compared with cells with no expression, and the F59L 
mutation increased the growth of cells even more than the wt ELMO1, meaning that it is a 
gain of function mutation. This is supported by another study, which shows that the silencing 
of ELMO1 or DOCK180 induced an appreciable inhibition of colony formation in SKOV3 
compared with wild type, non-targeting, and control cells, which indicates a role for ELMO1 
in cell growth (fig. 7.12 A, B) [131]. The same study investigated the roles of ELMO1 and 
DOCK180 on cell invasion by a Transwell Matrigel assay. As indicated in figure 6.12 C, D, 
ELMO1 or DOCK180 knockdown resulted in significant reduction of invasive cell number 
compared with control groups. 
To further investigate the pathways of ELMO1 and its interacting proteins, we developed an 
SBP-tagged affinity purification method, in combination with label-free SWATH MS, to 





Figure 7.11. Clonogenic assay of FLO-1 cells transfected with control empty vectors and vectors with wt and 
mutant (F59L) ELMO1. A, B FLO-1 cells transfected with GFP empty vector, GFP-wt ELMO1 or GFP-F59L ELMO1. 
C, D FLO-1 cells were transfected with Strep empty vector, Strep-wt ELMO1, Strep-F59L ELMO1 and Strep-mutant 
p53 gene (control). Cells were grown in media containing neomycin as selective drug. After one month of growth 

























Figure 7.12. Cell proliferation and invasion in vitro in each cell group. A and B, Dock180-RNAi and Elmo1-RNAi 
cells showed a significant reduction in their ability to form colonies as compared with NT control cells, empty 
vector control cells, and WT control cells. *P G 0.01. C, crystal violet stain of invading cells on the reverse side of 
the filter was shown (magnification, x 400). The bar analysis is shown in (D). Both cells silenced by Dock180 and 












7.4.6 SBP-tagged pull down experiment 
FLO-1 and OE19 cells were cultured in 10 cm plates and transfected with 5 µg of the Strep-
tag vector, empty, wt ELMO1 or F59L ELMO1, using Attractene transfection agent. After 24h 
of incubation at 37°C, cells were lysed with 500 µl of 0.5NP40 lysis buffer. Then, 15 µl of 
Streptavidin agarose beads were added to the lysate and incubated, shaking, at 4°C for 2 
hours. The beads were then washed 3X with 0.5NP40 buffer and bound proteins were 
separated SDS–PAGE. Silver staining, and immunoblotting with ELMO1 specific antibodies 
were carried out; both detected the presence of ELMO1 on the beads that were incubated 
with lysates of cells transfected with Strep-tagged ELMO1 (fig 7.13). In order to identify 
ELMO1 binding proteins, label-free SWATH-MS was performed, (in collaboration between the 
Hupp lab and Dr Borek Vojtesek’s lab, Brno, Czech Republic) to identify the total proteins 
bound to the beads, which in turn bound to wt ELMO1 and F59L ELMO1. 
Figure 7.13. SBP-tagged pull down experiment with wt and mutant ELMO1. FLO-1 and OE19 cells were 
transfected with Strep-tag vector (empty), Strep-tag wt ELMO1 or Strep-tag F59L ELMO1 and incubated for 24 
hours at 37°C. The cells were then lysed with 500µl of 0.5% NP40 lysis buffer and 15µl of streptavidin agarose 
beads were added to the lysate and rotated for 2 hours at 4°C. The beads were collected and washed three times 
with NP40 buffer. SDS–PAGE lysis buffer was added to beads and run on 12% gradient gels. Silver staining and 
Western blot were performed to confirm the presence of ELMO1. The beads were sent for SWATH-MS to identify 
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7.4.7 Detecting of ELMO1 binding proteins by SWATH-MS 
The SWATH-MS method identified many proteins in the pull-down samples containing wt and 
mutant ELMO1 in both FLO-1 and OE19 cells. ELMO1 is detected in all samples, which 
confirms the analysis method, but with a lower level of detection in the mutant ELMO1 
samples than in the wt ELMO1 samples (fig 7.14). The method identified previously known 
oncogenes as novel binding proteins of ELMO1, such as anterior gradient protein 2 (AGR2) 
and Dermcidin (DCD). When we compared the list of proteins detected in F59L ELMO1 to the 
list of the wt ELMO1, in both cell lines, it appears that the fold change of the binding of these 
two proteins is higher in mutant ELMO1 than in wt ELMO1 (fig 6.14). AGR2 has 2.93 of fold 
change in OE19 cells (table 7.1) and 3.07 in FLO-1. DCD has 6.94 in OE19 (table 7.1) and 3.29 
in FLO-1. This means that the F59L mutation in ELMO1 increases its binding to other oncogene 
proteins, which explains the increase in the number of colonies and invasion of mutant 





Figure 7.14. Scatter Blots of the fold change of proteins detected by SWATH-MS bound to the F59L ELMO1 over 
proteins detected with wt ELMO1 in FLO-1 (A) and OE19 (B). ELMO1 (green) was detected with lower fold 
change in F59L ELMO1 in both cell lines. AGR2 (red) and Dermcidin (yellow) have higher fold change in the mutant 




Number Group p-value Fold Change 
1 Plakophilin-1 GN=PKP1 0.00013 9.90911655020281 
2 Ig gamma-1 chain C region GN=IGHG1 5.3021e-6 9.66379234318151 
3 Cystatin-A GN=CSTA 0.00081 8.98575135827092 
4 Dermcidin GN=DCD 7.6267e-6 6.9409570409027 
5 60 KDa heat shock protein, 
mitochondrial OS=Homo sapiens 
GN=HSPD1 PE=1 SV=2 0.14099 6.72607337403442 
6 Calmodulin-like protein 5 GN=CALML5 0.00321 6.54839654019489 
7 Serum albumin GN=ALB 3.6991e-7 6.00598165464845 
8 Aldehyde dehydrogenase, dimeric 
NADP-preferring GN=ALDH3A1 0.00089 5.86928863718585 
9 Protein IGKV3-11 GN=IGKV3-11 1.9184e-5 4.98086211748401 
10 3-ketoacyl-CoA thiolase GN=HADHB 0.00725 3.58790506078299 
11 Filaggrin GN=FLG 0.00269 3.08113701964857 
12 Isoform 3 of Tropomyosin beta chain 
GN=TPM2 0.01746 3.03133882700613 
13 Eukaryotic translation initiation factor 4 
gamma 1 GN=EIF4G1 0.08196 24.1044053307855 
14 Corneodesmosin GN=CDSN 0.06600 2.96913023950455 
15 Anterior gradient protein 2 homolog 
GN=AGR2 4.6897e-5 2.9319572452782 
16 Isoform 2 of Mitochondrial import inner 
membrane translocase subunit TIM50 
GN=TIMM50 0.20079 2.80697042919826 
17 Zinc-alpha-2-glycoprotein GN=AZGP1 0.10022 2.79284140151035 
18 Immunoglobulin lambda-like 
polypeptide 5 GN=IGLL5 0.00082 2.68818046681556 
19 Arginase-1 GN=ARG1 0.00137 2.62664980897023 
20 Keratin, type II cytoskeletal 78 
GN=KRT78 0.00174 2.61137739849788 
21 Fatty acid-binding protein, epidermal 
GN=FABP5 5.4751e-5 2.51704420641723 
22 Junction plakoglobin GN=JUP 1.2009e-6 2.51530980971425 
23 Prelamin-A/C GN=LMNA 0.03584 2.43842717447525 
24 Tubulin beta-4B chain GN=TUBB4B 0.11432 2.40590529000604 
25 Desmoplakin GN=DSP 6.3563e-5 2.28217367853831 
26 Neuroblast differentiation-associated 
protein AHNAK GN=AHNAK 0.03380 2.24737343919498 
27 Protein-glutamine gamma-
glutamyltransferase E GN=TGM3 0.02862 2.20022119011577 
28 Protein UBBP4 OS=Homo sapiens 
GN=UBBP4 0.00334 2.19133636029379 
29 14-3-3 protein zeta/delta (Fragment) 
GN=YWHAZ 0.05568 2.13635213743807 
30 Keratin, type II cytoskeletal 1b  
GN=KRT77 0.13516 2.11011803323294 
31 Annexin A2 GN=ANXA2 0.01202 2.10609092114317 
32 UPF0568 protein C14orf166 




Table 7.1. Proteins that bound to the mutant ELMO1 (F59L) with >2-fold change compared to that in the wt 
ELMO1. P-value and fold change mutant/wt ELMO1 are shown. 
 
7.4.8 Validation of the ELMO1–AGR2 interaction 
We have carried out a proximity ligation assay (PLA) to validate the binding between ELMO1 
and AGR2 proteins in FLO-1 cell lines. As mentioned earlier, FLO-1 does not express ELMO1, 
and we could not detect AGR2 expression in FLO-1 by Western blotting (AGR2 expression may 
be low in these cell lines). Therefore, for the PLA we had to transfect FLO-1 cells with both 
genes. We transfected FLO-1 cells, grown on cover slips in 6 well plates, with 1µg of the Strep-
empty vector/Strep-ELMO1 (wt and mutant) with and without 1µg of pSF-CMV-AGR2 
(provided by Ayman Mohd in Prof. Ted Hupp’s group). PLA validated the binding between 
ELMO1 (both wt and mutant) and AGR2, as the fluorescent signals were only seen when both 
genes were expressed in FLO-1 cells (fig 7.15). 
Figure 7.15. Proximity ligation assay (PLA) results in FLO-1 cells showing Duolink immunospots of ELMO1 
(wt and mutant) with AGR2. FLO-1 cells were grown on cover slips and transfected with control (no 
transfection), or 1µg of the following: Strep-empty vector + pSF-CMV-AGR2; pSF-CMV-AGR2 only; Strep-wt 
ELMO1 only; Strep-wt ELMO1 + pSF-CMV-AGR2; Strep-F59L ELMO1 + pSF-CMV-AGR2. They were blotted 
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7.4.9 Co-expression of ELMO1 and AGR2 
FLO-1 cells were transfected with 1 µg of strep-empty vector + AGR2, strep-wt ELMO1 + AGR2, 
strep-F59L ELMO1 + AGR2, and AGR2 only (pSF-CMV-AGR2) in 6-well plate, in order to see if 
there is any different in the expression of AGR2 when expressed with wt and mutant ELMO1. 
24 hours after transfection, cells were lysed with urea lysis buffer. 15 µg of proteins were run 
on SDS-PAGE for Western Blot. The results of Western Blot show that there is no difference 
in the expression of AGR2 when expressed alone or with empty vector and when expressed 
with wt and mutant ELMO1 (fig 7.16). 
 
Figure 7.16. Western Blot results of co-expression of ELMO1 and AGR2 in FLO-1 cells. FLO-1 cells were 
transfected with 1 µg of AGR2 with and without 1 µg of wt and mutant ELMO1 using attractine. After 24 h 
cells were lysed with urea lysis buffer and 15 µg of proteins of each of the control and the transfected cells 
were run on two SDS-PAGE. The first membrane was blotted with goat polyclonal ELMO1 primary antibody 
and rabbit anti goat secondary antibody. The second membrane was blotted with rabbit polyclonal AGR2 
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3- Strep-wt ELMO1 + AGR2
4- Strep-F59L ELMO1 + AGR2
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7.4.10 OAC tissue microarray (TMA) of AGR2 and AGR2-induced FLO-1 tandem mass tag 
(TMT) 
A proteomics study was carried out on two OAC cases to identify high expression proteins in 
the tumour, compared to the normal tissue. AGR2 was one of the elevated proteins in the 
tumour tissues of both cases (fig 7.17A), and this was then confirmed by tissue microarray 
(TMA), which confirmed the high expression of AGR2 in OAC tissues (fig 7.17B). 
A further study was carried out to detect highly induced proteins in FLO-1 cells after the 
induction of AGR2. Tandem mass tag (TMT) was carried out on FLO-1 cells that were 
transfected with AGR2 or empty vector. The results showed that DCD was one of the proteins 
highly induced in the AGR2 positive cells but not in the negative control (data not shown), 
which suggests that AGR2 induces the expression of DCD.  
Both of these studies were performed in collaboration between the Hupp lab and Dr Borek 
Vojtesek’s lab, Brno, Czech Republic. 
 
 
Figure 7.17. High expression of AGR2 in the tumour tissues of OAC patients. A, AGR2 is detected among the 
highly expressed proteins in tumour tissues compared to the normal tissues of two OAC patients. B, TMA result 









7.5.1 ELMO1 interaction with AGR2 and DCD 
Here we report, for the first time, that ELMO1 protein binds to the oncogenic proteins AGR2 
and DCD, and their binding is greater to the mutant form of ELMO1 (F59L). It is still not known 
if this binding to ELMO1 is direct or via other protein(s). The F59L mutation is in the N-terminal 
of ELMO1 where active RhoG binds to ELMO1 and relieves ELMO1 from autoinhibition and 
transfers the ELMO1–DOCK complex from the cytoplasm to the cell membrane, where it 
activates RAC1. This mutation leads to more binding with AGR2 and DCD and shows increased 
cell growth and invasion, compared with wt ELMO1. Binding of AGR2 and DCD may help 
ELMO1 to increase binding to RhoG, stabilizing the complex to the cell membrane (fig 7.18), 
and thus increasing ELMO1 activity. The mutation may change the structure of ELMO1 protein 





Figure 7.18. Model of ELMO1 binding to AGR2 and DCD. AGR2 and DCD may help to stabilize the ELMO1–
DOCK complex to bind to the activated RhoG and activate RAC1. 
 
7.5.2 AGR2 production and function 
AGR2 is a 17 KDa protein that is highly conserved in vertebrates. In humans, enhanced AGR2 
expression was first described in breast cancer, which was followed by similar observations 
in most human adenocarcinomas, including those derived from oesophagus, pancreas, lung, 
ovary, and prostate. Both in vitro and in vivo studies demonstrated that AGR2 promotes 
tumour growth and metastasis [143]. AGR2 is classified as a member of the protein disulphide 
isomerase (PDI) family of proteins on the basis of amino acid sequence homology. It is 
localised to the endoplasmic reticulum (ER) as well as secreted. It has also been found in the 










oxidation/reduction reactions and isomerisation of disulphide bridges, thereby facilitating the 
maturation of proteins in the ER and ensuring correct folding and multimerisation of proteins 
targeted for the secretory pathway [144, 145]. AGR2 can be found outside cells, such as in the 
blood or the urine of cancer patients, which led some researchers to suggest that measuring 
the levels of AGR2 in body fluids may be a useful marker for detecting cancers [146]. It was 
reported that AGR2 makes cancer cells more aggressive, specifically when found outside cells 
[146]. Secretion of AGR2 was reported to correlate with metastasis and poor prognosis in 
breast cancer, and considered as a biomarker in prostate cancer. AGR2 upregulation was also 
detected in pancreatic carcinoma tissues. In gastric cancer tissues, higher expression in gastric 
cancer cells has previously been reported to be evident in the cytoplasm compared with non-
tumour cells. Notably, AGR2 can be used as a suitable candidate gene for the detection of 
circulating tumour cells, a novel resource for the identification of molecular markers in many 
types of cancer patients [147].  
 
7.5.3 AGR2 cellular mechanisms 
The cellular mechanism by which AGR2 promotes growth are poorly understood, but there 
have been a number of observations that are beginning to shed light on the role it plays in 
cell signalling networks. One pathway that AGR2 has been implicated in is the EGFR pathway. 
EGFR is a well-characterized receptor-tyrosine kinase that functions in development and 
serves a vital role in many human cancers. It was found that binding of EGFR to AGR2 in the 
ER is required for receptor delivery to the plasma membrane and thus EGFR signalling. AGR2 
was reported to induce expression of AREG, a growth promoting EGFR ligand. This study 
functionally linked AGR2 and AREG and supported a significant role for AGR2 in lung 
adenocarcinomas and the regulation of cell growth. As a result of AGR2 expression, AREG may 
stimulate the EGFR signalling pathway and may be responsible for the increased cell 
proliferation and anchorage-independent growth observed in transformed cells [148, 149]. 
AGR2 exhibits the basic features of a pro-oncogenic protein (fig 7.19). It was reported that 
AGR2 is upstream of, and stimulates, key cancer-signalling pathways, such as cyclin D1, c-Myc, 
p-Src and survivin, based on using both short interfering RNA and ectopic expression to 
manipulate AGR2 levels [148]. Genomic analysis of AGR2-stable cells by cDNA microarray 




proliferation, invasion and angiogenesis, which are very important for tumour progression 
and metastasis [148].  
 
7.5.4 AGR2 and p53 silencing 
In OAC there is an early selection pressure for p53 mutation during the replacement of 
squamous epithelium with metaplastic epithelium, which is called ‘Barrett’s oesophagus’. To 
identify potentially novel p53 inhibitors in this cancer ‘intermediate’, a clinical proteomics 
screen had been set up in a proliferative disease (Barrett’s epithelium) and identified AGR2, 
which was validated as a potent inhibitor of p53-dependent transcription and a growth-
promoting proto-oncogene, which suggests that AGR2 pathway might be a key mechanism to 
silence p53 signalling [148]. 
Both increased ELMO1 and AGR2 expression has shown an increase in the growth and 
metastasis of many cancer cell lines. The interaction between the two proteins (either direct 
or via another protein) may lead to further increase in tumour behaviour and metastasis. The 
effect of their interaction on cell growth and migration need to be further studied as their 





Figure 7.19. AGR2 biological pathways. AGR2 is presented as the central point of this picture (structure derived 
from ERP1831). Pathway intermediates known to regulate AGR2 expression are indicated in light grey ovals. 
AGR2-dependent functions are indicated in dark grey ovals. Potential (not experimentally demonstrated) 
intermediates are indicated as empty ovals. Physiological/pathophysiological inputs or outputs are represented 
as grey boxes. 
 
7.5.5 DCD production and function 
DCD is another oncogene that is found to bind ELMO1 in OAC cell lines. The DCD gene encodes 
for an 11 KDa protein, which in normal tissues displays a restricted expression pattern, with 
significant expression detected only in eccrine sweat glands of the skin, and in certain parts 
of the brain [150]. Overexpression of DCD was reported in multiple cancers such as melanoma, 
breast, prostate, pancreatic and hepatocellular carcinoma (HCC) [150]. DCD has diverse 
biological functions, such as acting as a growth and survival factor in breast cancer and in 
neural cells, displaying antibacterial activity, and inducing cancer associated cachexia in 




7.5.6 Binding of DCD and ELMO1 to Nck1 in hepatocellular carcinoma tissues 
A study on HCC has identified DCD as a novel binding protein of Nck1 by performing GST pull-
down assays using the SH2 domain of Nck1 as bait. The Nck family adaptor proteins couple 
tyrosine phosphorylation signals to actin cytoskeletal reorganization that leads to cell motility 
[151]. This study has reported that the binding of DCD to the SH2 domain of Nck1 was only 
detected in the tumour tissues and moreover that DCD expression was restricted to tumour 
tissues. They reported that the overexpression of wild type DCD resulted in a remarkable 
increase in the activation of both RAC1 and CDC42 compared with control cells, which 
supports a role of DCD in tumour metastasis. Interestingly, when we examined the list of the 
other proteins (table 7.2) that were detected to bind to the Nck1, we found that ELMO1 is 
one of these proteins and also that it is only detected in the tumour tissues, similar to DCD. It 
was reported that phosphotyrosine residues at position 18, 216, 395, and 511 of ELMO1 
mediate binding to the SH2 domain of NcK1. The association of Nck1 with ELMO1 facilitated 
the binding of ELMO1 to active RhoG, and thus promoted the GEF activity of ELMO1–
DOCK180 complex [152]. So, both ELMO1 and DCD bind the same domain of Nck1, or 
alternatively these two proteins may bind to each other and one of them binds to Nck1. We 
do not have Nck1 in the SWATH-MS list of ELMO1 binding proteins in OAC cells, so DCD may 
bind to ELMO1 even in the absence of Nck1. This binding may be direct or through a third 




















1 Q9NTJ3 Structural maintenance of 
chromosomes protein 4 
4 >2 
2 P16152 Carbonyl reductase [NADPH] 1 4 >2 
3 Q86YZ3 Hornerin 5 >2 
4 P60660 Myosin light polypeptide 6 1 >2 
5 Q969J3 Loss of heterozygosity 12 
chromosomal region 1 
3 >2 
6 P62736 Actin, aortic smooth muscle 2 >2 
7 Q99943 1-acyl-sn-glycerol-3-phosphate 
acyltransferase alpha 
1 nd N 
8 Q6T4R5 Nance-Horan syndrome protein 2 nd N 
9 Q86YZ3 Hornerin 12 nd N 
10 Q99583 Max-binding protein MNT 2 nd N 
11 P60709 Actin, cytoplasmic 1 10 nd N 
12 P81605 Dermcidin 2 nd N 
13 Q92556 Engulfment and cell motility 
protein 1 
1 nd N 
14 P60059 Protein transport protein Sec61 
subunit gamma 
4 nd N 

















Methods were devised to begin to rapidly and quantitatively discover new functions of 
“orphan” mutated proteins in cancer. Steps in the method include: (i) clonogenic assay; (ii) 
SBP-pull down; and (iii) proximity ligation assays to validate the interaction in vivo. I suggest 
that many of the mutated proteins I discuss in my thesis, such MAP4K5, could also be 
processed using this workflow. In this case study, mutated ELMO was chosen as the model. 
Exogenous expression of ELMO1 was shown to increase the number of colonies of the OAC 
cell lines OE19 and FLO-1. This number was increased more with expression of the F59L 
mutation of ELMO1 that was detected by whole exome sequencing of OAC tissues, suggesting 
this is a gain-of-function mutation. The SWATH-MS of pull-downs of SBP-tagged wt and 
mutant ELMO1 has shown that ELMO1 binds to the oncogenic proteins AGR2 and DCD, and 
this binding is greater to the mutant form of ELMO1. This interaction between ELMO1 and 
the two proteins AGR2 and DCD needs to be further studied to investigate its effects on 


















CONCLUSION AND FUTURE WORK 
8.1 Detection of mutations using CLC-bio software 
We have used a novel software algorithm, CLC-bio to analyse the cancer genome by DNAseq 
and expressed cancer genome arising from transcription by RNAseq to define dominant 
sources of potentially expressed tumour-specific mutations and oncogenic targets. We 
focused primarily on the rare human pleomorphic sarcoma as a disease of high unmet clinical 
need but used a range of cancer models to accelerate the development of the pipeline.  
8.1.1 Analysing the whole exomes sequences of patients with head and neck tumour 
First, we applied next generation sequencing of whole exomes of tumour tissues and two 
matched normal tissues (blood and “normal” tumour adjacent tissue) from a small set of 
patients with head and neck cancer to define parameters for use of the new software. The 
approaches identified significant mutations in tumour relative to germline DNA, but also in 
normal adjacent tissue, relative to normal germline, consistent with known field cancerization. 
The analysis results showed that there were two different genetic groups in the five patients, 
independent of the age of the patients. The first group has mutations in the p53 and have 
more CNVs, which is seen in the old patients 119 and 137, and in the young patient 82. The 
other group does not have mutations in p53 and has very few CNVs. 
8.1.2 Analysing the whole exomes of twenty cancer pleomorphic sarcoma cancer 
patients 
For setting up the larger sequencing screen in the subsequent set of twenty cancer 
pleomorphic sarcoma cancer patients, whole exome sequencing was performed on tumour 
tissues and their matched normal adjacent tissues, rather than germline blood derived DNA, 
to define truly tumour-specific mutations. This approach provided sets of recurrent non-
synonymous mutations in tumour tissue such as a transmembrane protease and suggests 







8.1.3 CLC-Bio and MuTect 
We have shown that the CLC-bio software has detected higher number of variants in each 
sarcoma patients compared to MuTect software which might be due to the different 
parameters applied by the two softweres. These detected variants need to be further 
validated by Sanger sequences to make sure that they are real somatic variants. 
8.1.4 Cancer heterogeneity  
Two biopsies taken from different regions of one sarcoma tumour have shown different 
somatic mutations when compared to the normal adjacent tissue of the same patient, which 
is an evidence of intratumour heterogeneity. However, the two different lists of genes share 
several pathways such as RAS pathway and Wnt signalling pathway. 
8.1.5 Expressed somatic mutations in the RNA 
Identifying the expressed cancer genome, using RNAseq and protein quantitation methods 
such as mass spectrometry, provides a more accurate view of the state of the cancer tissue 
at the time of presentation in the clinic. The CLC-Bio software has enabled us to identify the 
dominant RNAs that were cancer genome encoded, and led us to highlight ~15% of mutated 
cancer genes are expressed at the time of surgery. I suggest that these mutated pathways or 
genes represent more realistic targets for therapeutics or diagnostics than conventional 
mutated cancer genes. For example, a mutant gene might have been required very early in 
the evolution of the cancer and might not even be expressed at the time of surgery. In 
addition to the expressed cancer-encoded genome, we also were able to use the novel 
software to identify mutations in RNA that are not genome encoded. This is suggestive of RNA 
editing. Some of these genes were validated by Sanger sequencing and by examining RNAseq 
in cell lines. For example, we found that MAP4K5 is indeed edited in cell lines, thus providing 









8.1.6 expression of somatic mutations at the protein level 
 Currently, we do not know how many of the cancer genes that are mutated, the expressed 
RNA that is genome encoded or the RNA that is edited, are expressed at the protein level. I 
have shown one example where the mutated PDCD6 gene had detectable mutated RNA and 
mutated peptide using mass spectrometry. The full exploitation of mass spectrometry was 
beyond the scope of my PhD thesis, which was focused largely on DNA and RNA sequencing. 
It will nevertheless be interesting in future to determine how much of the potential mutation, 
whether coded from genome mutation or RNA editing, is translated into mutated protein. My 
current thesis data shows, using novel software designed for biologists and clinicians, that is 
it realistic to routinely define this expressed genome at the nucleic acid level to support future 
proteomics studies.  
8.1.7 Conclusion 
In conclusion, we have applied and validated newly emerging software to begin to interrogate 
cancer tissue from patients of unmet clinical need in order to define new mechanisms of 
cancer progression and to define possibly new or better drug targets for new therapies. The 
data identified highly recurrent genome encoded mutations in human pleomorphic sarcoma 
and a potentially novel, targetable landscape represented by RNA editing driven mutant 
protein production.  This will provide a foundation for future work on making better choices 
to advance our ability to improve patient management in human pleomorphic sarcoma.  
8.2 Applied methods to study the effects of wt and mutant ELMO1 
Lastly, novel or orphan mutant proteins observed in human cancers, whether from DNA 
encoded mutant proteins or from RNA-edited driven mutant protein synthesis require new 
tools and technologies to discover new oncogenic signalling mechanisms. Methods were 
devised to begin to rapidly and quantitatively discover new functions of “orphan” mutated 
proteins in cancer. Steps in the method include: (i) clonogenic assay; (ii) SBP-pull down; and 
(iii) proximity ligation assays to validate the interaction in vivo. I suggest that many of the 
mutated proteins I discussed in my thesis, such MAP4K5 and PDCD6, could also be processed 
using this workflow. In this case study, mutated ELMO was chosen as the model. Exogenous 
expression of ELMO1 was shown to increase the number of colonies of the OAC cell lines OE19 
and FLO-1. This number was increased more with expression of the F59L mutation of ELMO1 




function mutation. The SWATH-MS of pull-downs of SBP-tagged wt and mutant ELMO1 has 
shown that ELMO1 binds to the oncogenic proteins AGR2 and DCD, and this binding is greater 
to the mutant form of ELMO1. This interaction between ELMO1 and the two proteins AGR2 
and DCD needs to be further studied to investigate its effects on proliferation and migration 
of cancer cells, and it may work as a therapeutic target in OAC and other cancers. 
8.3 Summary for future work 
- Study the effects of the detected somatic mutations in key genes such as PDCD6 on 
cells growth and invasion by the methods used in the study; clonogenic assay 
- From the mass-spectrometry data; detect which mutated genes have higher 
expression in the tumour compared to the normal adjacent tissues, and look if the 
mutation has been translated into the peptide 
- Detection of the list of proteins that bind to the mutated gene by using the SWATH-
MS of pull-downs of SBP-tagged of the wild type and mutant forms of the gene 
- Validation the RNA editing events, and study their effects on splicing and on cells 
growth and number of colony formation 
- Perform tumour microarray of ELMO1 and DCD in OAC tissues to detect the expression 
of ELMO1 and DCD and find out if there is an overlap between the expression of 
ELMO1, DCD and AGR2 
- Study the effects of binding of ELMO1 to AGR2 and DCD on cells proliferation and 
migration 
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